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ABSTRACT

As critical mediators of cell-to-cell communication, gap junctions (GJs) are comprised of
membrane channels that directly link the cytoplasm of adjacent coupled cells thereby allowing for
the passage of ions, small metabolites, and secondary messengers. Each channel is formed by
the apposition of two connexons from adjacent cells, each composed of six connexin (Cx) proteins.
Each GJ channel functions to promote signal propagation and synchronization of cells and tissues
in organs. Furthermore, GJs are essential for proper propagation of cardiac action potentials from
one cell to the next, leading to the coordinated contraction and relaxation of heart muscle powering
circulation. In diseased human hearts, the organization and expression of Cxs in the working
myocardium is remodeled leading to impaired impulse propagation and risk of lethal arrhythmias.
Diverse post-translational modifications (e.g., phosphorylation) and protein partner interactions, the
majority of which involve the carboxyl-terminal (CT) domain, serve to regulate Cx function.
The CxCT domain serves a critical role in the regulation of all aspects of the Cx life cycle
including trafficking, assembly, channel open states, as well as internalization and degradation.
Importantly, the CT domain is the site at which the greatest degree of sequence divergence is
observed between family members. A number of studies have highlighted that little conservation of
regulatory mechanisms contained within the CT domain exists between family members.
Furthermore, a clear understanding of the molecular determinants that influence different Cx
channel properties between family members is lacking. Thus, investigation into the specific

ii

mechanisms that regulate each family member is essential to develop a complete picture of Cx
biology and to develop novel therapeutics with which to modulate Cx function.
Previous work from our laboratory identified a novel feature of the Cx45CT domain, highaffinity (KD ~ 100 nM) dimerization. Here using a combination of biophysical, biochemical, and
cell/molecular biology approaches we demonstrate that dimerization is essential for proper Cx45
turnover, localization, phosphorylation, and function. Additionally, we demonstrate that
phosphorylation by three kinases that are dysregulated in heart disease alter the function of Cx45
to promote cell coupling and consequently may contribute to the pathogenic phenotype.
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1. Gap Junction Overview
At the heart of physiological function within an organism is a diverse network of coordinated
cellular actions. This coordination is achieved by many diverse mechanisms, from the binding of
ligand to a receptor, to changes in membrane potential elicited from the release or uptake of ions.
These mechanisms categorized into four groups include endocrine, paracrine, juxtacrine, and
autocrine signaling; defined as long distance, short distance, juxtaposed (contact dependent), and
self-acting signals, respectively. Paracrine, juxtacrine, and autocrine signaling are mediated, in
part, by the activity of the connexin (Cx) family of GJ proteins.
GJs are composed of tetraspan integral membrane proteins that contain four
transmembrane (TM1-4) domains, two extracellular loops (EL1 and EL2), a cytoplasmic loop (CL),
amino-terminus (NT), and carboxyl-terminus (CT) [1-5]. Six Cx proteins (homomeric or
heteromeric) oligomerize into connexons (hemichannels) that can further dock (homotypic or
heterotypic) with connexons apposed from adjacent cells. Six conserved cysteines are present in
the ELs (three in each) that are essential for proper docking and GJ formation [1-5]. GJs are semicrystalline arrays of 100s-1000s of individual GJ channels [6, 7]. Figure 1.1 illustrates this hierarchy.
GJs consisting of Cx proteins are found only in vertebrates. Invertebrates possess a homologous
family of GJ proteins known as the innexins (Inxs) [8, 9]. The homology between Cxs and Inxs is
limited to topological and functional homology as they contain no sequence homology [8, 9]. In
humans, there are 21 Cx proteins, while in mice there are only 20 (19 can be paired as orthologues)
(reviewed in [10-12]). Two major nomenclature classifications for Cxs exist. The most commonly
used system names Cx proteins for their apparent molecular weight (e.g., Cx45 is a Cx protein of
45 kDa) [13]. The second system, based on evolutionary homology, names the Cx genes based
on the extent of sequence similarity and the length of the CL domain [13]. This nomenclature based
on homology, segregates Cxs into three major (α, β, or γ) and two minor (δ, or ε) classes and the
names begin with Gj (for gap junction) and ends numerically for the order in which the specific
family member was discovered [13]. For example, the gene for Cx43 is Gja1 as it was the first αCx described.
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Figure 1.1. Topology and organization of connexin proteins.
A) Membrane topology of a Cx protein, having four transmembrane (TM) domains, two extracellular loops
(EL1 and EL2), and a cytoplasmic loop (CL) as well as cytoplasmic amino- and carboxyl-termini (NT and
CT respectively). B) Oligomerization of six Cx proteins into a connexon (hemichannel), each barrel shape
represents a single Cx protein. C) Organization and docking of Cxs from two adjacent cells forms a single
channel, channels cluster in semicrystalline arrays to form gap junctions, which can be of four distinct
types (I-homomeric/homotypic, II-homomeric/heterotypic, III-heteromeric/homotypic, and IVheteromeric/heterotypic). Solid black lines represent the plasma membrane.
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In general, GJs serve to allow the passage of small (≤1000 Da) cytoplasmic constituents
including ions, small metabolites, and second messengers (e.g., cAMP) between the cytoplasm of
coupled cells or with the extracellular space, thereby propagating and amplifying signals
transduced from various initiating events [14]. The initiating stimuli can be in the form of growth
factor receptor signaling, kinase cascades, ion release, cytokine stimulation, or mechanical stretch
[15-30]. Each Cx isoform contributes a unique set of channel properties when homomeric
homotypic channels are considered, for heteromeric and heterotypic channels there is often the
development of novel channel properties not seen in either family member when homomeric
(reviewed in [31]). This high degree of variability coincides with a high degree of differential Cx
family member expression among different tissues and organs [32]. Furthermore, the Cx
expression patterns for a given organ or tissue are regulated spatiotemporally [32]. Cxs are found
in most tissues and organ systems in the adult under normal conditions with the exception of
skeletal muscle and some mobile cells (e.g., sperm and red blood cells) [32]. Importantly, a given
cell type can express multiple Cx family members simultaneously creating the possibility for the
formation of heteromeric and/or heterotypic GJs (Fig. 1.1). This variable diversity allows Cxs to
perform a number of highly specialized roles in various tissues and cell types.
With widespread distribution and the high degree of interplay between family members, it
follows that dysregulation or loss of function for a particular family member may pose deleterious
for the host. Indeed, a number of pathologies have been attributed to dysregulation or loss of a
particular Cx family member. For example, loss of Cx45 (genetic ablation or loss of function) results
in death on approximately embryonic day 10 in mice due to a cushion defect in cardiogenesis [33].
Cx43 null mice survive throughout fetal development but suffer from perinatal lethality due to
pulmonary outflow defects in the heart, and also exhibit anomalous lens development and germ
line deficiency in both sexes [34-37]. Additionally, mutations within the Cx43 protein sequence
cause oculodentodigital dysplasia (ODDD) [38-45]. Other Cxs have also been attributed to human
maladies including Cx32 which is shown to be causal to X-Linked Charcot-Marie-Tooth disease
(CMTX), or Cx26 for which a subset of mutations lead to non-syndromic hearing loss in humans
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while homozygous null mice die around embryonic day 11 [46-55]. Furthermore, mutations in Cx46
and Cx50, the dominant lens Cxs, have been associated with cataracts (reviewed in [56]).
In the heart, GJs play a critical role in the propagation and amplification of impulses
originating in the sinoatrial (SA) node [57]. There are specifically four Cxs known to function in the
heart. In decreasing order of relative expression level, the four cardiac Cxs are: Cx43, Cx40, Cx45,
and Cx30.2 [57-60]. The bulk of impulse propagation in the working myocardium is handled by
Cx43 (atria and ventricles) and Cx40 (atria) [60-64]. Although Cx40 is of significant interest in the
atria, it will not be discussed in detail. In the human heart Cx45 is the first Cx expressed during
embryogenesis, but by the time of birth has been limited to the cells of the specialized conductance
and pace making system [65]. Here the unique properties of Cx45 channels serve to prevent reentrant arrhythmia by slowing conduction velocity between the ventricles and atria thereby ensuring
sequential contraction [66, 67]. Cx30.2 is expressed in the mouse heart in a similar localization
pattern to Cx45, and its expression is stabilized by Cx45, however, in humans the orthologue
Cx31.9 has not been detected in the heart [68-70]. Cx30.2 therefore likely plays a mouse specific
role in the fine-tuning of impulse propagation in the special conductance system and for the
purposes of this dissertation will not be discussed further [68, 69]. In diseased hearts Cx expression
is altered. A number of studies have demonstrated a primary effect of cardiac remodeling
subsequent to ischemic events or during end stage heart failure is loss of Cx43 expression at the
intercalated disc (ID) (reviewed in [67, 71]). This loss of Cx43 is preceded by lateralization of Cx43
away from the ID where internalization processes have been suggested to reduce overall Cx43
expression and limit cell connectivity [72]. In addition to remodeling of Cx43, Cx40 and Cx45 are
also remodeled [67, 71, 73-78]. Ischemic heart disease was shown to increase overall Cx40
expression in the ventricles, where under healthy conditions its expression is absent, specifically
localizing in a band of working myocytes adjacent to the conduction system [71, 79, 80]. It has been
suggested that this may be a compensatory mechanism to the loss of Cx43 coupling in the ventricle
[79, 80]. In the atria where Cx40 is the primary Cx, its expression was shown to increase in heart
disease, leading to increased incidence of atrial fibrillation [81]. Cx45 similar to Cx40 is not
appreciably expressed in the healthy adult ventricular myocardium and has been demonstrated to
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be upregulated in various heart disease states [65, 82, 83]. In end stage heart failure, work from
Yamada et al. have demonstrated upregulation of Cx45 localizing to the ID in ventricular myocytes
[82]. This was observed in conjunction with the typical lateralization and downregulation of Cx43
[82, 84]. Importantly, Yamada et al. also demonstrated Cx45 and Cx43 colocalized at the ID,
suggesting the possibility for heteromeric channels to form [82, 83]. Channel properties of the
primary cardiac Cxs differ such that they serve specific functions with little overlap. It therefore
stands to reason that remodeling (alterations in localization, size, or composition of the GJ plaques)
can have significant effects on conduction properties of the heart. This is especially the case for
the formation of heteromeric channels (e.g., Cx43/Cx45) because the properties of these channels
can be dominated by the properties of one of the family members, or they can take on new
properties either intermediate or novel to either homomeric counterpart [83, 85, 86]. Indeed, using
cell and molecular biology techniques a number of groups have substantiated the existence of
Cx43/Cx45 heteromeric channels [86, 87]. Furthermore, studies have also shown Cx45 exerts a
dominant negative effect on Cx43/Cx45 heteromeric channels such that channel properties are
more similar to homomeric Cx45 channels than those of homomeric Cx43 channels; altering dye
permeability, conductance, open probability, and plaque size [83, 86, 88]. In the heart, this is
thought to be a potential substrate for lethal arrhythmias [82, 83, 86, 88]. Therefore, the formation
and regulation of heteromeric channels is of significant clinical interest to the therapeutic and GJ
community alike.
2. Gap Junction Regulation
With the diverse set of physiological functions carried out by GJs (e.g., cell-to-cell
communication, hemichannel functions, etc.) it is essential that they are tightly regulated. The
regulation of GJs occurs at a number of hierarchical levels. First, Cxs are regulated
spatiotemporally. Not every Cx family member is expressed by all cell types, and in cell types where
multiple family members are expressed they are not always expressed simultaneously. Several
layers of regulatory mechanisms exist to ensure proper spatial (tissue type or subcellular
localization) and temporal (developmental stage, cell cycle stage, or stimulus response) regulation
of GJs including transcriptional, translational, trafficking, post-translational, assembly, or turnover
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mechanisms. This is especially true for functional regulation of GJ intercellular communication
(GJIC). GJ functions are regulated at the plaque by various factors including but not limited to:
phosphorylation, voltage, Ca2+, pH, and association with binding partners. Here, we will discuss the
various regulators of Cx proteins and GJs.
2.1 Transcriptional Regulation of Cxs
Typical Cx gene structure involves two (or more) exons. The first exon normally includes a
5’-untranslated region (UTR) which is separated from the second exon by an intron of variable
length [89, 90]. The second exon for most Cxs includes the entire protein coding sequence and the
3’-UTR (reviewed in [91, 92]). Deviations from this scheme have been described, including
alternative/consecutive splicing of the 5’-UTR thought to function in alternate promoter usage,
leading to changes in mRNA stability, or altered translation efficacy (reviewed in [91, 92]).
Furthermore, the protein coding region of the second exon can be punctuated with one or more
introns (e.g., mCx36, hCx36, mCx39, hCx40.1) leading to alternative splice variants.
The gene structure for Cx43 (Gja1) in mice was originally thought to only contain the two
canonical Cx exons, however, it was more recently shown that the gene for Gja1 contains four
additional exons totaling six overall [93, 94]. Five of the six Gja1 exons are dedicated 5’-UTR
regions (Exons 1A-1E) and the sixth (Exon 2) includes the remaining portion of the 5’-UTR, all of
the Cx43 coding sequence, and the 3’-UTR [93, 94]. Additionally, the Gja1 gene in mice has been
shown to have three promoters, two of which are downstream of the originally discovered Gja1
promoter (P1). The first, P2, is located in Exon 1A, and P3 is located in the intron that precedes
Exon 1C. Through combinations of differential promoter usage and intron splicing this leads to nine
different Cx43 transcripts in mice [93].
Similar to Cx43 in mice, Cx45 (Gja7; Gjc1), exceeds the traditional two exons with five total
exons (1A-C, 2, and 3) [90, 95]. Contrary to Cx43, however, Exons 1A-C and 2 include only 5’UTR, while Exon 3 contains the remaining 5’-UTR, the Cx45 protein coding sequence, and the 3’UTR [90]. Cx45 transcripts observed in mice suggest that Exons 1A-C splice independently to E2E3, or alternatively a second transcription start site exists in Exon 2, resulting in four total mouse
Cx45 transcripts [90, 95]. The transcripts produced have been found to be tissue specific.
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Transcripts containing Exon 1A are present in nearly all cell types where Cx45 is expressed,
however, expression of Exon 1B and 1C transcripts are less widespread. Exon 1B transcripts are
found only in trace amounts in the colon, and Exon 1C transcripts are found in the heart, skeletal
muscle, lung, bladder, colon, and ovary [90, 95]. Conservation of Exon 2 and 3 sequences was
shown between mouse and human for Gja7 [96].
Promoter analysis for many Cxs has revealed the presence of multiple promoters
(reviewed in [91]). For most Cx proteins P1 (the basal level promoter) is contained approximately
300 base pairs upstream of the transcription start site contained in Exon 1 and includes the binding
site for numerous ubiquitous and cell/stimulus dependent transcription factors (reviewed in [91]). In
the following paragraphs, we will highlight a number of the transcription factors and the conditions
(if applicable) that lead to the activation of the gene.
Transcription factor specificity protein 1 (Sp1) is a zinc-finger transcription factor that binds
GC rich regions of promoters. Sp1 drives basal transcription for several Cxs including Cx26, Cx32,
Cx40, and Cx43 (reviewed in [91]). Specifically, for Cx43 analysis revealed four potential Sp1
binding sites that contributed to Cx43 promoter activity [96]. Another study found that disruption of
histone deacetylases by trichostatin A (TSA) induced expression of Cx43 in a Creb binding protein
dependent manner [97]. For Cx40, ablation of the Sp1 binding sites in the promoter region by
mutation severely impaired promoter activity [96]. Another basal transcription factor found to
activate Cx transcription is the AP-1 complex (reviewed in [91]). The AP-1 complex consists of
heterodimers of the c-Fos, c-Jun, activating transcription factor (ATF), and Jun dimerization protein
(JDP) protein families and binds to the consensus sequence [TGAC (T/G) TCA] [98]. In the
proximal promoter for Cx43 there have been two identified AP-1 binding sites in rat while only one
site has been identified in human and mouse [99]. Activation of AP-1 mediated transcription of
Cx43 was stimulated by transforming growth factor β (TGF-β), mitogen activated kinase 4 (MKK4),
and Erk1/2 signaling [100] [101] [102]. In addition to Sp1 and AP-1, Wnt signaling and cAMP
mediated transcription have also been shown to regulate at least Cx43 transcription (reviewed in
[91]).

8

More critical to expression of GJs in the heart and cardiac pathology are the cell/stimulus
dependent transcription factors. Tissue specific promoter usage occurs in virtually all organs and
tissues of the body [103]. Despite the occurrence of GJs in the majority of organ systems and
tissues, this section will focus solely on the cardiac specific transcription factors and some of the
functions they serve. Regular development of the cardiac tissues requires the symphonious
function of several transcription factors including Nkx2.5, Shox2, Homeodomain-only protein (Hop),
Iroquois homeobox 3 (Irx3), T-box transcription factors (Tbx), and GATA family transcription factors
(reviewed in [91]). Nkx2.5 is a transcription factor that is essential for proper cardiac development
[104]. Indeed, mutations in Nkx2.5 interfering with its DNA binding function promote cardiac
maladies such as conduction block [105]. Importantly, binding sites for Nkx2.5 have been detected
in the promoters of Cx40, Cx43, and Cx45 [99, 106, 107]. Interestingly, while several studies have
concluded that Nkx2.5 acts as a transcriptional activator for both Cx43 and Cx40, at least one study
has identified a repressive role of Nkx2.5 for Cx43 expression [108, 109]. Specifically, exogenous
expression of a constitutively active version of Nkx2.5 showed downregulation of Cx43 expression
within 16 hr of transduction, suggesting that subsequent heart failure was not a contributing factor
[109]. Dupays et al. demonstrated that day E9.2 Nkx2.5 null mouse embryos lacked significant
expression of Cx43 in the heart as the result of poorly developed ventricular trabeculae as well as
substantially reduced gene expression of Cx45 [106]. The same study concluded that mouse
embryos heterozygous for Nkx2.5 developed normally [106]. Furthermore, ventricular loss of
Nkx2.5 in mice resulted in no overt structural cardiac abnormality, however, slowed progressive
atrioventricular conduction was observed [110]. The same study also showed that while mutant
mice perinatally expressed Cx40 in the conduction system, its expression was essentially absent
in the adult mutants, suggesting a Nkx2.5 was not essential for perinatal expression of Cx40 but
was required for age related continuity [110].
Shox2, another homeobox type transcription factor is also essential for cardiac
development. Mice null for Shox2 display lethality at embryonic days E11.5-13.5 and die from heart
defects such as abnormally slow beating rhythm, and underdeveloped sino-atrial node and valves
[111, 112]. Interestingly, Shox2 functions upstream of a number of the important cardiac
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transcription factors including Nkx2.5 and Tbx factors [112]. For Nkx2.5, Shox2 appears to be a
transcriptional repressor ensuring genes activated by Nkx2.5 (Cx43 and Cx40) remain repressed
in the area of the sino-atrial node [112]. Conversely, and consistent with known expression patterns
of Cx45, Shox2 appears to activate Cx45 gene expression to facilitate differentiation of the pacemaking system [67, 71, 75, 113].
Similar to Nkx2.5 and Shox2, the Hop, Irx, Tbx, and GATA families of transcription factors
function to regulate the expression of the cardiac Cxs. Hop for example, which is expressed in the
developing heart, is essential to development of the mature conduction system (reviewed in [91]).
Homozygous loss of Hop results in loss of Cx40 expression throughout the heart when
homozygous, while heterozygous knock-out of Hop reduces Cx40 expression in the atrioventricular node and associated conduction system [114]. Furthermore, overexpression of Hop
reduced expression of Cx40 in the atria in models of ventricular hypertrophy that was restored by
the addition of the HDAC inhibitor TSA [115]. The Irx family transcription factor Irx3 functions to
repress Cx43 and induce expression of Cx40 [116]. The Tbx family of transcription factors, namely
Tbx2, Tbx3, Tbx5, Tbx18 also function to regulate the expression of Cxs in the heart (reviewed in
[91]). Cx43 and Cx40, for example, are repressed transcriptionally by both Tbx2 and Tbx3 [117,
118]. Interestingly, the expression of Cx45 does not seem to be affected by either Tbx2 or Tbx3
[117]. Similar to Tbx2 and Tbx3, Tbx18 suppressed the expression of Cx43, however, unlike Tbx2
and Tbx3 it does not appear to downregulate Cx40 or Cx45 [119]. In contrast to the other Tbx
transcription factors noted here, Tbx5 appears to be the only transcriptional activator, activating the
expression of Cx40 in a dose dependent manner [120]. Finally, of the GATA family of transcription
factors, GATA4 has been observed to regulate both Cx40 and Cx30.2 in mice [107, 121].
In addition to regulation by transcription factors, Cx gene expression can be regulated
epigenetically. Similar to all genes, histone modification (and modulation thereof) affects the
expression of Cx transcripts (reviewed in [122]). Two other mechanisms described also fine tune
the expression of Cxs: DNA methylation and the expression of microRNAs that target Cx transcripts
(reviewed in [122]). Although these mechanisms are important for the regulation of Cxs, discussion
of their specific nature (beyond noting they occur) is beyond the scope of this dissertation.
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2.2 Connexin Life Cycle
Temporally, all functional Cx family members follow a similar expression scheme that can
be referred to as the Cx life cycle. The Cx life cycle is closely tied to both cell cycle as well as
extracellular stimuli (e.g., cell surface receptor activation) and begins with transcription and ends
with turnover/recycling. A number of factors contribute to the regulation of the Cx life cycle including
transcription factors, the interactions with protein partners, and post-translational modifications
((PTMs); e.g., phosphorylation). This section provides an overview of the Cx life cycle and explores
some of the factors that regulate it. Since the control of Cx expression by transcription was
addressed in Section 2.1 it will not be addressed in detail in this section. Additionally, since the vast
majority of studies illustrating stages of the Cx life cycle focus on Cx43, the discussion in this section
will have a similar primary focus.
2.2.1 Connexin Biosynthesis
Biosynthesis of Cxs begins in the nucleus of the cell with transcription of a Cx gene by
transcription factors. The degree to which the gene is transcribed is a function of the combinations
of various transcription factors present. For example, one mechanism by which Cx43 transcription
is initiated in cell culture is activation of Wnt signaling from cell-cell contact. This leads to the
inhibition of GSK-3β, leading to stabilization of β-catenin which translocates to the nucleus where
it promotes transcription of a number of genes including Gja1 (Cx43; [123-125]). There are a
number of general and tissue specific conditions and transcription factors (e.g., general - SP1,
cardiac specific - Nkx2.5) that regulate the transcription of GJ genes (reviewed in [91, 92]). To
further increase the diversity of Cx family member expression as well as tissue specific levels of
expression, not all Cx genes contain the same promoters (reviewed in [91, 92]). Once transcribed
Cx mRNAs are exported from the nucleus to the endoplasmic reticulum (ER) for protein translation.
Cx protein translation, like that of all integral membrane proteins, occurs on ribosomes
studding the surface of the rough ER. However, in contrast to most proteins, the mRNA structure
of Cx transcripts (abnormally long 5’-UTR) favors cap-independent translation [90, 126]. In capindependent translation, specific sequences contained in the 5’-UTR promote ribosomal entry and
translation initiation [127, 128]. This is important for the Cx family proteins because it allows their
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expression to bypass cellular stress responses that impact cap-dependent translation thereby
maintaining cell coupling [127, 128]. As integral membrane proteins Cx polypeptide chains are cotranslationally inserted into the membrane of the rough ER. This is accomplished by the translation
of hydrophobic domains (likely the TM1) which are recognized and bound by the signal recognition
particle (SRP), halting translation. The Cx peptide/ribosome/SRP complex then docks with ER
translocons where translation proceeds [129]. The nascent polypeptide chain is retained in the
lumen of the translocon until translation completes and the complete protein is inserted into the ER
membrane (secretory proteins are released into the ER lumen) [130-134]. For Cx43 integration into
the ER membrane and folding of the general topological features (i.e., four TM domains with
cytoplasmic NT and CT domains) occurs simultaneously [135]. Additionally, studies have begun to
demonstrate the importance of ER resident protein partners (chaperone proteins) in Cx synthesis
(reviewed in [136]). One example is ER resident protein 29 (Erp29) which was shown to stabilize
Cx43 as a monomer in the ER to prevent early oligomerization of Cx43 connexons [137]. An
important caveat revealed by the Das et al. study was the saturable nature Erp29 and thus extreme
overexpression systems may drive early channel oligomerization [137]. In addition to Erp29, the
ER-associated cytosolic protein—Connexin interacting protein of 75 kDa (CIP75)—regulates
expression and trafficking of Cxs [138-142]. For Cx43, CIP75 binds Cx43 over a large region of the
CT domain (K264-Q317) where it mediates ejection from the ER lumen and transport of misfolded
Cx43 to the proteasome via ER associated degradation (ERAD) [139-142]. It has been suggested
that this is a mechanism of both quality control and fine tuning of expression levels [141].
Supporting CIP75’s role in Cx quality control, treatment of cells with denaturing compounds
increases the association of CIP75 with Cx43, and suggests that only Cx43 that is not bound by
CIP75 escapes the ER and continues into the secretory pathway [141].
2.2.2 Trafficking and Assembly of Gap Junctions
Following successful translation of monomeric Cx protein, oligomerization of six Cx
proteins into a connexon (hemichannel) and trafficking to the plasma membrane is essential for
proper Cx function. The oligomerization of Cx channels has been described for Cx43, Cx46, Cx32,
and Cx26 by several studies [129, 143-146]. In the studies characterizing Cx32 and Cx26,
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oligomerization of both family members was observed to occur in ER membranes; however, an
important caveat to the studies was the use of cell-free expression systems [129, 145, 146]. In
contrast, Cx43 and Cx46 were demonstrated to oligomerize in the trans-Golgi network (TGN) using
numerous methods [137, 143, 144]. In one study, a large panel of secretory pathway inhibitors
were used to demonstrate that Cx43 requires export from the ER to successfully form connexons
[144]. Another study examining the oligomerization of Cx43 and Cx46 in rat osteosarcoma (ROS)
cells also used secretory pathway inhibitors and sucrose gradient density centrifugation to
determine that Cx43 and Cx46 were both retained in the ER as well as cis-Golgi in a monomeric
form [143]. A follow up study then used Cxs (Cx43 and Cx32) expressed with C-terminal retention
tags for either ER and ER-Golgi intermediate compartment (ERGIC) retention (HKKSL or AKKFF,
respectively) [147]. The results of that study confirmed that Cx43 indeed oligomerizes in the TGN,
while it offered support to the work of Falk et al., as Cx32 was observed to oligomerize even when
retained in the ER [129, 145-147]. Importantly, the study also demonstrated that Cx43 and Cx46
could form heteromeric channels and this occurred in the TGN, as co-expression of tagged Cx43
and untagged Cx46 led to Cx43 immunoreactivity present at the plasma membrane in structures
consistent with GJ plaques [147].
In addition to connexon oligomerization a critical step in the Cx life cycle is trafficking from
the ER and/or Golgi to the plasma membrane. Interestingly, a study demonstrated an early
phosphorylation event closely following translation for Cx43 using Brefeldin A ((BFA); blocks ER to
Golgi transport in the ERGIC) and is likely essential for subsequent maturation steps [148]. Upon
exiting the TGN Cx43 is contained in vesicles that are trafficked along the microtubule network to
be delivered to the plasma membrane [149-152]. A number of phosphorylation events occur during
trafficking that regulate the vast number and types of protein interactions that are critical for efficient
transport to the plasma membrane and subsequent membrane insertion (reviewed in [153]). These
phosphorylation events will be discussed in greater detail in a later section dedicated to regulation
of Cxs by phosphorylation. Of note, delivery (and insertion) of connexon containing vesicles to the
plasma membrane appears to be random (i.e., not targeted) [135, 154]. Although, further
characterization is required to clearly define the mechanism by which Cxs are incorporated into the
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plasma membrane, recent studies have begun to implicate roles for the cAMP-dependent protein
kinase A (PKA)- and actin-binding protein Ezrin as well as 14-3-3 protein in the capture and
insertion of Cx43 containing vesicles into the plasma membrane [155-164]. Once in the plasma
membrane, lateral diffusion processes seem to direct the connexons to the periphery of the GJ
plaque (perinexus) [154, 165, 166]. Conversely, an alternative mechanism has been suggested in
cardiomyocytes where trafficking via microtubules target Cx43 containing vesicles directly to the
adherens junctions in the ID [152, 167].
The final step of GJ assembly is the docking of connexons (via the ELs) and incorporation
into the GJ proper. As Cx43 connexons from apposed cells are retained in the perinexus, they are
generally bound by interactions with ZO-1, and release from ZO-1 coincides with docking [166]. In
addition to ZO-1, Ca2+-dependent cell adhesion proteins such as E- and N-cadherin are important
for GJ formation, however, further investigation is required to clearly delineate the role as studies
have produced conflicting results [168, 169]. In one study knock-down of N-cadherin was shown
to reduce GJ formation in NIH3T3 cells and thereby impaired GJIC [170]. Conversely, another study
using mouse L cells concluded that loss of cadherin increased GJ formation when stimulated with
forskolin, while cells expressing cadherins showed decreased overall Cx43 expression [171]. A
third study investigating the role of cadherins on Cx43 expression in hepatocytes demonstrated
that expression of E-cadherin correlated with increased GJ assembly, while N-cadherin expression
resulted in GJ disassembly [172]. Although, the exact roles for cadherins in GJ assembly remain
unclear, it is clear that cadherins influence GJ assembly. Additionally, catenins (cadherinassociated intracellular proteins) also influence GJ formation. Colocalization of α-catenin with Cx32
and Cx26 in hepatocytes as well as Cx43 in cardiomyocytes has been demonstrated [173, 174].
This was also observed for β-catenin in cardiomyocytes, and authors subsequently demonstrated
the association of β-catenin with Cx43 was essential to GJ formation [174]. Additionally, recently
our laboratory took an NMR approach and demonstrated a direct interaction between the CT
domain of Cx43 and β-catenin that can be modulated by phosphorylation of Cx43 residues (Y265
and Y313) via Src [175]
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2.2.3 Internalization and Gap Junction Turnover
Completion of the Cx life cycle requires internalization and subsequent turnover (or
alternatively recycling) of GJs. A process that is mediated by a number of normal and pathological
cellular stimuli, including but not limited to cell division, response to growth factors, differentiation,
apoptosis, wound healing, depletion of cellular metabolites, and preventing the spread of toxic
factors (preventing the by-stander effect) (reviewed in [176, 177]). Similar to the diverse stimuli that
promote GJ turnover, a diverse set of protein interactions are required for proper turnover of GJ
channels.
Although Cxs are membrane proteins they uniquely have relatively short half-lives (1-5 hr)
[178, 179]. This is somewhat variable depending on the tissue and cell type, for example in the lens
of the eye the predominant Cxs (Cx45.6 and Cx56) seem to be more static with half-lives
approaching 90 hr under organ culture conditions [31]. However, in the same study when primary
cells were isolated and cultured in vitro the stability was lost, and half-lives were more consistent
with studies of other family members [31]. Although the molecular determinants resulting in this
stability were not identified, the authors did observe differential phosphorylation of Cx56 between
the organ and primary cultures [31]. Consistent with observations of relatively short half-lives, Cx26,
Cx32, Cx37, Cx43, and Cx45 have all been shown to have half-lives ranging from 1-5 hr [148, 180197]. This was even true for Cx43 in isolated perfused hearts suggesting the difference seen with
lens Cxs is likely tissue specific or as the authors suggested may have been the consequence of
large non-synchronized pools of Cx45.6 and Cx56 in the lens [31, 188].
Degradation of GJs has been shown to occur by multiple mechanisms. The primarily
described mechanism is through the generation of annular GJs, which are double membrane
vesicles containing intact GJ plaques that are internalized by one of the adjoined cells [198]. It is
generally accepted that the EL interactions between docked connexons are of sufficient strength
that separating them into connexons is not possible [66, 86, 199, 200]. This is supported by
evidence from immunogold labeled electron microscopy studies [66, 86, 199, 200]. Despite the
general acceptance of this model of internalization, other groups have suggested mechanisms by
which the GJ are disassembled into pools of connexons and then internalized by endocytic
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mechanisms. In one study, hepatic GJs immunogold labeled appeared to disaggregate and the
authors speculated this may represent undocking and internalization, however, were unable to
provide concrete evidence [173]. More recent studies have provided evidence that Cx43 GJs
partially turnover by through internalization of central connexons as new connexons are integrated
into the GJ at the periphery [154, 201]. Exactly how this occurs remains to be determined.
Degradation of Cx43 has been shown to involve both proteasomal and lysosomal
pathways. In their study of perfused rat hearts Beardslee et al. used inhibitors of proteasomal and
lysosomal degradation and determined that in both circumstances Cx43 expression levels were
increased [188]. Interestingly, they showed that phosphorylation of Cx43 may be a critical
determinant of which pathway was utilized. They observed increased Cx43 phosphorylation when
lysosomal degradation was inhibited and conversely accumulation of non-phosphorylated Cx43
when the proteasomal pathway was inhibited [188]. This was in contrast to a previous study
demonstrating both increased Cx43 phosphorylation and GJIC following blockade of proteasomal
degradation, suggesting the existence of cell type specific mechanisms [202].
Additionally, Cx ubiquitination has been suggested as a contributor to GJ turnover. For
Cx43, specific phosphorylation events have been linked to increased ubiquitination and turnover.
Specifically, phosphorylation of key Ser residues (addressed in detail in the section on
phosphorylation) creates a high affinity binding site for the E3 ubiquitin ligase neuronal expressed
developmentally downregulated protein 4 (Nedd4) [203, 204]. Ubiquitination of Cx43 by Nedd4
recruits adapter protein 2 (AP2) and clathrin to mediate internalization and transport to the
lysosome (reviewed in [205]). In addition to AP2 and clathrin, 14-3-3 has been shown to play a role
in the internalization and degradation of Cx43 [164, 206].
2.3 Channel Gating
Cell-cell communication via GJs is controlled by various mechanisms in the cell. A primary
control mechanism for coupling is expression and turnover as described in the previous section.
Additional mechanisms include phosphorylation and channel gating, the latter being an important
control of when and to what degree channels are open. This is important as communication must
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be regulated for proper tissue synchronization and to control the spread of ions and metabolites. In
this section, the three major types of channel gating will be discussed in detail.
2.3.1 Voltage Gating
One of the three major types of GJ channel gating is voltage gating. Voltage gating works
to modulate channel openness by translating changes in electrical potential surrounding the GJ
channel into a conformational change which leads to channel closure [207]. Similar to other voltage
regulated channel proteins, GJ proteins contain a series of charged amino acid residues that
constitute a “voltage sensor” [208-210]. In vertebrate GJs, voltage gating can be derived from either
the transjunctional voltage (Vj; ubiquitous, albeit to variable degrees) or transmembrane voltage
(Vm; less common) [211].
In vertebrates, all GJ family members to a degree are gated by changes in Vj indicated by
the ability of generating junctional conductance (gj) by either hyperpolarizing or depolarizing one
cell of the coupled pair [207]. Furthermore, early studies indicating the presence of two types of Vj
dependent gating, fast-gating and slow-gating [212]. All three of the intracellular domains are
involved to some degree in voltage gating. The NT domain was shown to contribute to Vj
dependence using mutational approaches abolishing key charged residues on Cx26 and Cx32
channels [208-210]. Studies on Cx43 and Cx32 revealed a role for the CT domain in fast Vj-gating.
Where truncation of Cx32 at residue 222, or Cx43 at residue 257 resulted in a disruption of fast
conductance, and led to voltage gating mostly of the slow-gating type [213]. Based on the studies
investigating the mechanisms of fast-gating the current model (“ball-and-chain”) posits the CT
domain physically moves into proximity of the channel pore sterically blocking the conductance
[207].
In contrast to Vj dependent gating, Vm dependent gating is much less common amongst
Cx family members. Three Cxs that are gated in a Vm dependent manner are Cx43, Cx45, and
Cx57 [214-216]. Interestingly, for Cx45 channels it was shown that Vm dependence was the result
of two separate gates, one in each hemichannel [214]. It is suggested that Vm dependence is likely
cell type or species specific, as Cx43 channels exhibit strong Vm dependence in oocyte expression
systems, but rather limited Vm dependence in HeLa cells [216, 217]. It has been speculated that
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Vm dependent gating may serve to prevent the spread of excess charge from damaged cells to
healthy neighboring cells.
2.3.2 pH Gating
In addition to voltage gating, GJ channels are also gated by changes in pH. Specifically,
intracellular acidification, such as what occurs during ischemia, has been identified as a mechanism
by which GJ channels close [218-221]. Similar to voltage gating during membrane depolarization
this may be a protective mechanism by which cells suppress the by-stander affect [222].
Additionally, like the “ball-and-chain” model proposed for voltage gating one proposed model
describing how intracellular acidification leads to channel closure is a “particle receptor” model,
again involving CT-CL interactions [223, 224]. Several electrophysiological studies support the
notion that a CT-CL interaction mediates pH gating [225-228]. For pH gating in Cx43 there is a
clear dependence of the CT domain, as truncation of the CT domain rendered Cx43 channels pH
insensitive and co-expression of a soluble Cx43CT domain restored pH sensitivity of the truncated
Cx43 channels [223]. Furthermore, soluble Cx43CT increased the pH sensitivity Cx32 channels
when co-expressed [223]. Although a similar effect was also shown for Cx40, the model may not
apply to all Cx family members as similar truncations of Cx26 and Cx45 failed to prevent pH
mediated channel closure suggesting alternative mechanisms may also be involved [229].
Interestingly, for Cx45 homotypic and Cx45/Cx43-enhanced green fluorescent protein (eGFP)
heterotypic channels a relationship between voltage gating and pH gating has been observed [230].
Specifically, it was observed that as pH increased, open probability and the gj-Vj dependence
increased, while acidification conversely had the opposite effect resulting in more channel closure
and a decreased gj-Vj dependence [230]. In addition to the “particle receptor” interactions, a
number of studies have shown that pH dependent changes in Cx CT domain structure occur, which
may lead to altered affinity for the CL or other protein partners [204, 231]. For Cx43, a decrease in
pH from 7.5 to 5.8, as would occur in ischemia, results in an increase in helical content from
essentially 0% at pH 7.5 to 7% at pH 5.8 [231]. Increasing helical content was also detected for the
CT domains of Cx32 and Cx45 under acidic conditions [204]. Cx hemichannels also appear to be
pH gated as reported by a number of studies [232-235]. Trexler et al. suggested that the pH sensor
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for Cxs is likely contained on a domain near the pore as a result of two observations [234]. First,
intracellular application of acidic solution led to rapid long-term channel closure, while extracellular
application resulted in closure that rapidly returned to the open state [234]. Second, extracellular
application of weak membrane permeable acids prevented hemichannel openings under positive
membrane potentials, while strong acids (membrane impermeable) had little effect on opening, but
rapidly closed open hemichannels [234].
2.3.3 Ca2+ Gating
Another form of GJ channel gating is Ca2+ dependent gating. Ca2+ dependent gating is an
important effect of cellular Ca2+ signaling, and likely plays an important role in cardiac tissue where
Ca2+ signaling is critical for proper myocyte function [236]. Ca2+ dependent gating has been
suggested to occur via two primary mechanisms, directly via Ca2+ ion binding to Cx hemichannels
and indirectly through the action of the Ca2+ binding protein Calmodulin (CaM) [237, 238]. The
direct mechanism of Ca2+ ion binding is a mediator of Cx hemichannel closure [237]. In this
mechanism Ca2+ ions bind to charged residues disrupting a salt bridge between the hemichannel
subunits in the extracellular portion of the pore resulting in a conformational change [237]. CaM
mediated Ca2+ gating serves to close GJ channels through Ca2+ dependent interaction of CaM with
the cytoplasmic domains of Cx family members [238]. Ca2+ regulation has been reported for several
Cxs including Cx32, Cx36, Cx43, Cx44, Cx45, and Cx50 [239-245]. In this mechanism increased
levels of intracellular Ca2+ enhance the affinity of CaM for the cytoplasmic domains and the binding
of CaM has been observed to alter secondary structure [243]. Specifically, for Cx43 CaM has been
shown to interact with both the CL and CT domains, and induces significant helical structure in the
Cx43CL domain [246, 247]. The induction of secondary structure may occlude the pore to ions
[243, 246]. A similar increase in helical content was observed for the Cx32CT, however, unlike
Cx43, Cx32 also has a CaM binding domain present on the NT where W3 has been shown to be
critical for the interaction [248-250]. CaM was recently shown to interact directly with Cx45 via the
CL domain, mediating channel closure [251]. Interestingly, when interacting with the Cx45CL, CaM
was not observed to adopt a more compact structure in contrast to what was observed for Cx50
[245, 251]. This was noted to be similar to the binding of CaM to non-Ca2+ dependent targets like
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myosin, however, similar to other Cxs the binding of CaM to the Cx45CL was greatly enhanced by
Ca2+ [251, 252]. In addition to the CL, CaM was also recently shown to interact with the CT domain
of Cx45, albeit the functional implications were not explored [247]. This significance of this
observation remains to be determined.
2.4 Importance of the CT Domain
The CT domain of Cx proteins has long been understood as an important regulatory
domain. It is a hub for protein-protein interactions, and a plethora of PTMs. Importantly, although
significant homology of the extracellular and transmembrane domains of Cxs exist, the cytoplasmic
domains have a large degree of divergence between family members. The CT domain containing
the highest degree of divergence amongst the three cytoplasmic domains, and thus has long been
hypothesized to be a determinant of differences in channel properties and regulation between Cx
family members. In this section, we will highlight the importance of the CT to Cx function and
regulation.
2.4.1 Intrinsically Disordered Proteins
The majority of expressed proteins are folded into well-structured arrangements to carry
out specific functions and can often be categorized by their folding. Kinases for example contain a
conserved kinase fold domain where the side chains of specific key residues are oriented in a
manner which supports the catalytic activity required to attach a phosphate to a target (reviewed in
[253, 254]). For many biochemical reactions or protein interactions, a specific 3D conformation is
essential, and often loss of 3D structure correlates with decreased or abolished function (reviewed
in [253, 254]). For proteins that contain stretches of contiguous residues (30 or more) that do not
adopt structure, known as intrinsically disordered proteins, the regions of disorder are often
essential to function (reviewed in [255]). Intrinsically disordered regions of proteins are now well
understood to be good substrates for promiscuous protein-protein interactions. Intrinsically
disordered regions of proteins tend to adopt secondary structure as a function of protein partner
binding or PTM, allow for overlapping protein partner binding motifs, and provide large surface area
for interactions to occur (reviewed in [255]). Combined these features allow intrinsically disordered
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proteins to be highly dynamic. For Cxs, the cytoplasmic domains often adopt an intrinsically
disordered arrangement (reviewed in [256]).
2.4.2 Connexin Cytoplasmic Domains
The cytoplasmic domains of Cxs consist of the NT, CL, and CT domains and are important
for channel gating, channel formation, and regulating channel function. These domains contain
sites for the interactions with protein partners as well as PTMs. While the cytoplasmic domains are
less homologous between family members than the transmembrane and extracellular domains, the
degree of divergence between family members is greatest for the CT domain.
The NT domain of Cxs is the most well conserved intracellular domain between family
members in size (reviewed in [257, 258]). For the α-type Cxs the NT is 22 residues in length, while
for the β-type Cxs the NT is 23 residues long (reviewed in [1, 258]). Two exceptions to this are
Cx36 and Cx47, which have 24 and 25 NT residues, respectively [259]. Despite similarity in length,
the NT domains of different family members have been shown to adopt differing secondary
structure [258]. The structure of the NT domains of Cx32 and Cx26 were solved by solution NMR,
and Cx32NT was determined to be disordered, however, the Cx26NT was observed as helical in
structure [260, 261]. Importantly, for the Cx26NT a critical bend was detected at residues 11 and
12 which allow the first 10 residues to swing into the pore [210]. Indeed, crystallographic studies
modeling Cx26 similarly observed the NT domain lining the vestibule of the pore where it
contributes to ion selectivity and voltage gating [262]. Furthermore, the high-resolution crystal
structure presented by the Maeda et al. study was that of the open Cx26 channel, and it provided
evidence for the notion that interactions between the NT and the transmembrane helices maintain
the open pore [262]. Specifically, a ring of hydrogen bonds formed between residues D2 and T5 of
adjacent protomers at the narrowest point of the pore, and hydrophobic contact between W3 and
a hydrophobic patch of TM1 on the adjacent protomer [262]. Importantly, studies investigating
mutations in the NT domain have illustrated its importance in plaque formation, and proper channel
function (reviewed in [258]). Furthermore, NT domain mutations of many family members have
been linked to diseases (Cx26, Cx30, Cx30.2/Cx31.3, Cx31, Cx32, Cx43, Cx46, and Cx50)
(reviewed in [258]). Interestingly, the effects of these mutations are diverse with some mutations
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causing impaired trafficking and plaque assembly, others rendered channels nonfunctional, while
still others induced cell death when exogenously expressed [168, 263-273]. Using mass
spectrometry (MS), PTMs of the NT domain have been detected; among those are phosphorylation,
acetylation, and hydroxylation, the functional effects of which will be addressed in more detail in
Section 3.2 [274, 275].
In contrast to the NT domain, the CL domain of Cxs has a larger degree of size variability.
Family members can be clustered into 3 groups by the length of the CL domain (and total sequence
homology): small (30-35 residues; α; e.g., Cx43, Cx40), medium (50-55 residues; β; e.g., Cx26,
Cx32), and large (80-105 residues; γ; e.g., Cx45, Cx47) [12]. Similar to the NT domain, the CL also
plays a role channel formation and gating [212]. Unfortunately, due to the dynamic and disordered
nature of the CL domain, crystallographic studies have been unable to resolve the CL domain [262,
276]. Meaningful structural studies have therefore been limited to the use of solution NMR and
circular dichroism (CD) and suggest the domain is primarily disordered with a tendency to adopt
helical character [277]. For the Cx43CL, the structure was solved in solution by NMR and revealed
the presence of two small α-helical regions that are induced by acidification or the interaction with
CaM [246, 277]. Analysis of CL domain peptides of Cx43, Cx32, and Cx36 using CD spectroscopy
revealed the CL of all three family members had a tendency to form α-helices when samples were
supplemented with the secondary structure stabilizer trifluoroethanol (TFE) [278]. Notably, this was
attributed to the distal half of the loop (where CaM binds), the proximal portion of the loop yielded
complex results that were difficult to interpret [278]. Despite the lack of a crystal structure of the CL
domain, truncation studies have demonstrated the importance of the CL domain in Cx trafficking
and channel formation [279, 280]. Cx43 synthetic mutants harboring deletion of CL residues were
shown to be non-functional suggesting a critical role for the CL in channel function [279, 280].
Interestingly, while both the Cx43 Δ130-134 and Cx43 Δ130-137 were non-functional, only the
Cx43 Δ130-134 properly trafficked to the plasma membrane [279, 280]. This finding suggested that
a portion of the CL domain may also be critical for trafficking [279, 280]. Deletion of a similar region
of the Cx32CL impaired GJIC measured by dye transfer suggesting the importance of the CL to
channel function is a general feature of Cxs [281]. The CL domain is an important factor of gating
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in both the “ball-and-chain” and “particle receptor” models of voltage and pH gating respectively,
as well as Ca2+ gating. Critical to the function of the CL in gating, is interactions with other proteins
(or domains; see section 2.3). The Cx43CL for example functions as the receptor in the “ball-andchain” and “particle receptor” models of channel gating [207, 223, 224]. Similarly, the CL of several
Cx family members serve as a target for CaM in Ca 2+ gating (reviewed in [282]). The CL domain,
like the NT, has been detected to be post-translationally modified by phosphorylation and
carboxylation [274, 275, 283]. The importance of these modifications will be discussed in greater
detail in Sections 3.1 and 3.2.
The CT domain of Cxs is the most variable domain between family members in both length
and primary sequence [1]. Cx26 for example has a CT containing only 10 residues while the CT of
Cx62 is 310 residues in length [1]. Like the NT and CL domains, the CT domain is important for
trafficking, channel gating, and regulation, and similarly to the CL domain the CT is dynamic and
unstructured, thus not amenable to crystallographic studies [1, 262, 276]. Solution NMR and CD
studies have revealed the CT domain of several Cxs as primarily disordered [231, 247, 284-286].
While they are primarily disordered, structural studies of the CT domains of Cx43 and Cx45
revealed they contain α-helical regions [247, 286]. The helical domains of the Cx43CT are involved
in the dimerization of Cx43CT domains and are important for the CT-CL interaction in pH dependent
gating [277, 286]. Interestingly, the NMR structure of transmembrane tethered Cx43CT protein
(TM4-Cx43CT) suggested that a total of 7 helical domains were present [287]. Of the 7 helical
domains, the two detected when the CT domain is expressed without TM4 were contained within
slightly longer helical domains when tethered [287]. For the Cx45CT, the helical region (A331N361) mediates high affinity (KD ~100 nM) homodimerization and will be covered in greater detail
in the next section [247]. The functional implications of the Cx45CT α-helical domain are a key
portion of this dissertation and will be discussed in Chapter Two. In addition to Cx43 and Cx45,
helical propensity was also reported for the CT domains of Cx32 and Cx36 [278]. Worth noting in
the case of Cx32 and Cx36, the secondary structure had to be stabilized by the addition of TFE
[278].
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2.4.3 Connexin CT Dimerization
An additional feature that has been attributed to the CT domains of Cxs is homo- and
heterodimerization [231, 247, 286]. To date, the phenomenon has been reported for Cx43 and
Cx45 [247, 286]. For Cx43, dimerization between the two CT domains was revealed by a
combination of NMR, in vitro crosslinking, and analytical ultracentrifugation (AUC) sedimentation
equilibrium experiments [286]. Crosslinking of recombinant Cx43CT at various pH values
suggested formation of a pH-dependent dimer when analyzed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) [286]. Western blot of the same SDS-PAGE gel
suggested the presence of even higher order oligomers [286]. Further analysis of the recombinant
protein by AUC sedimentation equilibrium suggested that at physiological pH only 12% of the total
Cx43CT was in dimer conformation, however, acidification to pH 6.5 and 5.8 yielded 84% and 86%
dimer conformations, confirming the pH dependence suggested by the crosslinking experiments
[286]. Use of NMR revealed the residues likely involved in the dimerization to be M281–N295,
R299–Q304, S314–I327, and Q342–A348 [286]. Although dimerization of the Cx43CT was
revealed, the affinity of the interaction was not determined [286]. Based on previous reports, our
laboratory examined the ability of the CT domain of other primary cardiac Cxs (Cx40 and Cx45) to
dimerize [231, 247, 286]. For the Cx40CT AUC sedimentation equilibrium suggested that very little
Cx40CT was present as a dimer conformation regardless of pH (pH 6.0 – 5.2% and pH 7.4 – 2.3%)
[231]. Interestingly, for the Cx45CT dimerization was detected at both physiological and ischemic
pH [247]. Furthermore, the calculated affinity of the interaction (KD) at both physiological and
ischemic pH were comparable, albeit slightly weaker at ischemic pH (141 nM at pH 5.8 and 97 nM
at pH 7.5) [247]. Interestingly, this observation is in contrast to the effect of pH on the dimerization
of the Cx43CT [247, 286]. NMR analysis revealed a number of resonance peaks that broadened
beyond detection when 15N-labeled Cx45CT was titrated with unlabeled Cx45CT suggesting a selfinteraction [247]. Assignment of the Cx45CT resonances, identified the peaks that broadened
beyond detection as residues A333-N361 [247]. Subsequently, residues A333-N361 were
expressed alone and characterized by AUC sedimentation equilibrium and CD spectroscopy to 1)
confirm these residues mediate Cx45CT dimerization and 2) determine if a structural component
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was present [247]. AUC analysis of the A333-N361 peptide indicated it sedimented with a mass of
approximately 13 kDa, suggesting a tetrameric complex and the calculated KD for the dimer species
was 74 pM confirming the identity of A333-N361 as the dimerization domain of the Cx45CT [247].
Structural analysis of both the full length Cx45CT and Cx45CT A333-N361 were done using CD
spectroscopy. For the full length Cx45CT the spectra revealed, similar to several other Cxs, a
predominance of disorder, however, a small contribution of helical character was also detected
[247]. Interestingly, the CD spectra of Cx45CT A333-N361 suggested the peptide was nearly
entirely helical in structure, indicating it was the region contributing the helical character to full
length Cx45CT [247]. The study also suggested that the Cx45CT dimerization was mediated by
hydrophobic contacts between the two helices [247]. Several lines of evidence supported this: first
molecular modeling of the energy conformers predicted the greatest number of intermolecular
contacts to be between key hydrophobic residues along one of the α-helical faces [247]; second, a
large buffer screen was conducted to test buffer conditions that would either disrupt hydrophobic
or electrostatic interactions, and only buffer conditions that disrupted hydrophobic interactions also
inhibited dimerization [247]. Confirming the hydrophobic nature of the interaction, replacement of
the predicted key hydrophobic residues with charged residues resulted in a Cx45CT mutant that
was dimerization incompetent [247].
In addition to homodimerization between CxCT domains, the propensity to form
heteromeric channels suggests an opportunity for heterodimerization between CT domains of
different Cxs. Indeed, these interactions have been described for Cx40CT-Cx43CT as well as for
Cx43CT-Cx45CT [231, 247]. Although these interactions have been detected in vitro, whether or
not they occur in the context of a GJ as well as their functional significance remain to be determined.
Furthermore, recent unpublished work in our laboratory has suggested the detected interaction
between the Cx45CT and Cx43CT was the result of pH differences between samples, and not likely
a true representation of heterodimerization. However, this does not preclude the possibility the
interaction occurs in the context of a GJ and will require further investigation.
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3. Post-Translational Regulation of Connexins
Like many proteins, GJ proteins are regulated post-translationally by a number of detected
modifications. Those described in the literature to date include phosphorylation, acetylation,
hydroxylation, γ-carboxylation, palmitoylation, ubiquitination, SUMOylation, and nitrosylation. The
effects of the PTMs are diverse and complex, and often specific to not only the modification but
also the Cx family member. In this section, currently known PTMs of Cx proteins and their functional
impacts are reviewed.
3.1 Connexin Phosphorylation
The most common and well-studied PTM of Cx proteins is phosphorylation. To date
phosphorylation has been detected on the majority of the Cx family members including Cxs 26, 32,
36, 37, 43, 45, 46, 50, and 56 (reviewed in [288]). The Cx domain most commonly reported to be
modified by phosphorylation has been the CT domain; however, for Cx36 and Cx56 CL
phosphorylation has been detected, and Cx26 expressed in HeLa cells NT phosphorylation was
also detected [274, 283, 289, 290]. Notably, Cx26NT phosphorylation has not yet been detected
from endogenous expression systems [182, 274, 289]. The lack of detectable phosphorylation of
Cx26 and the short nature of its CT domain has been suggested as evidence that phosphorylation
of Cxs is not essential for channel formation (reviewed in [291]). Therefore, it is suggested that
phosphorylation of Cxs serves to modify Cx function, either by enhancing or impairing some aspect
of Cx regulation. Indeed, phosphorylation of Cx proteins has been linked to the regulation of virtually
every stage of the Cx life cycle, as well as altering channel properties such as selectivity or
conductance states (reviewed in [288, 292]).
3.1.1 Introduction to Connexin Phosphorylation
Landmark studies identifying Cxs as phosphoproteins were carried out in the 1980’s and
have laid the foundation for countless studies [293, 294]. Since those early studies, many Cx
phosphorylation sites have been identified and characterized (e.g., 23 sites for Cx43 alone
(reviewed in [288, 295]). A predominance of identified phosphorylation sites for Cxs are Ser/Thr
residues. Congruent with this observation many Ser/Thr kinases have been identified that
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phosphorylate Cx proteins (see Section 3.1.3). In addition to Ser/Thr residues phosphorylation of
Tyr residues has also been detected for Cx proteins (reviewed in [288]). Although, a number of
phosphorylated Tyr residues have been identified for Cxs, the number of kinases identified is rather
low (reviewed in [288]). To date the only confirmed Tyr kinases that phosphorylate Cxs are Src,
Fps, and epidermal growth factor receptor (EGFR) [296-298]. In the following subsections, we will
review the methods that have been used to study phosphorylation of Cxs, the functional impacts of
phosphorylation and identified kinases, the relationship of Src and Cx43, the significance of
phosphorylation sites that overlap binding motifs, and finally phosphorylation of other Cx45.
3.1.2 Methods for Studying Connexin Phosphorylation
Early studies investigating phosphorylation of Cxs relied on the use of radiolabeled [32P]
orthophosphate to label proteins. Since the standard 20 amino acids do not contain phosphorus
atoms, any protein labeled with [32P] orthophosphate, consequently must be phosphorylated. A
drawback to this approach for identifying phosphoproteins is the requirement for highly specific
(preferentially monoclonal) antibodies that were competent for immunoprecipitation (IP).
Successful IP of Cx proteins from [32P] labeled cells can then be resolved by SDS-PAGE and
detected by autoradiography [299]. While this method is useful for identifying phosphoproteins, it
does not identify the number of phosphorylated residues nor their identity (type [pSer vs. pThr vs.
pTyr] or specific residue). A similar approach has been used to approximate the number of
phosphorylated residues and detect changes in phosphorylation of a Cx protein between basal
conditions and some stimulus yielding a “phosphorylation fingerprint” for the condition, called
phosphopeptide analysis. The major difference between this approach and the previous is use of
tryptic digests of the [32P] labeled proteins captured by IP, followed by 2D electrophoresis on thin
layer cellulose [299]. A caveat of this method, is the potential for partial digests, and thus
interpretation of the data should be conservative [299]. Finally, the classical method for determining
the identity (pSer vs. pThr vs. pTyr) and the relative percentages of phosphorylated residues is
phosphoamino analysis and follows a similar scheme as phosphopeptide analysis [299]. The main
difference in these two techniques is the method of fragmentation and size of fragments, for
phosphopeptide analysis tryptic digests are used to produce peptides of variable size, while for
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phosphoamino analysis acid hydrolysis is utilized to generate free amino acids [299]. Following
acid hydrolysis, the sample is resolved by 2D electrophoresis, and detected by autoradiography.
Another difference between the phosphopeptide analysis and phosphoamino analysis are the
conditions used in the 2D electrophoresis [299]. Major drawbacks to all of the classical methods of
detecting Cx phosphorylation are the need for large amounts of starting material and the inability
to identify residue specific phosphorylation and then associate that site with a specific functional
outcome. Initial methods to identify site specific phosphorylation of Cxs were site-directed
mutagenesis and Edman degradation (e.g., Cx43 pS368 and pS255/279/282) [300-302]. A
drawback to Edman degradation is the limitation of “read length”. One benefit of the classical
methods of detecting phosphorylation is the assays are amenable to using recombinant CxCT
domains that are in vitro phosphorylated to ensure enough starting material is available. This has
also reduced the need for excessive amounts of radioactive waste.
Some Cx proteins show patterns of banding consistent with slower electrophoretic mobility
that collapse (or disappear) upon phosphatase treatment [291]. Multiple migratory bands have been
observed for Cx32, Cx40, Cx43, Cx45, Cx46, and Cx50 [248, 303-307]. For Cx32, this consisted
of a doublet of bands that were reactive to both general pTyr and pSer antibodies that collapsed
into a single band of immunoreactivity only to antibodies against Cx32 [248]. Cx40 and Cx45 were
similarly observed as a doublet when extracted from atrial tissue and HeLa cells, respectively [304,
306]. Cx50 was also shown to migrate as a doublet, with a phosphatase sensitive slower migrating
band extracted from mouse or mink seminiferous tubules [305]. A second study which used in vitro
phosphorylation of GST-Cx50CT by PKA similarly observed the appearance of a slower migrating
band after incubation with PKA, however, activation of PKA in cells did not result in the appearance
of a second slower migrating band [307]. The study by Pelletier et al. also showed Cx46 was
detectable as a pair of migratory bands, however, upon phosphatase treatment both bands
decreased in intensity [305]. The authors speculated this was an indicator that Cx46, when nonphosphorylated, was rapidly degraded although they did not explore this further [305]. Unlike the
previous examples, Cx43 resolves into several electrophoretic bands ranging in number from three
to five depending on the study and conditions of phosphorylation, however three are most often
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observed (reviewed in ([308, 309]). These bands are referred to as the P0 (slow migrating;
~42kDa), P1 (slow migrating; ~44kDa), and P2 (slower migrating; ~46kDa) bands [310]. Notably,
Musil and Goodenough demonstrated the P2 form was present in communication competent
normal rat kidney (NRK) cells, primarily in a detergent insoluble fraction corresponding to GJ
plaques [144]. Furthermore, in two communication deficient cell lines (S180 and L929) neither
insoluble Cx43 nor the P2 isoform were detected [144]. This study was the first to connect a
potential functional role to one of the Cx43 migratory forms. Subsequently, work from our group
and others focused on determining the identities of the Cx43 contained within each migratory band
[311, 312]. The work of Cooper et al. demonstrated that phosphorylation of Cx43 by Casein kinase
1 (CK1) corresponds to the P2 isoform and requires residues S325/328/330 [311]. Grosely et al.
used a biophysical in vitro approach with phosphomimetic mutants of several known kinase
phosphorylation sites of the Cx43CT [312]. Confirming the work of Cooper et al., the soluble and
TM-tethered CK1 phosphomimetic (S325,328,330D) Cx43CT mutants both resulted in slowed
electrophoretic mobility similar to what was observed for the P2 isoform [311, 312].
Phosphomimetic mutants corresponding to PKA, PKC, Mitogen activated protein kinase (MAPK),
Src, and cyclin-dependent kinase 1 (CDK1, also cdc2) phosphorylated Cx43CT were also analyzed
and only PKA and MAPK were found to result in the P1 slower migrating form [312]. Importantly,
single substitution of only one of the residues targeted (regardless of which) for kinases that
phosphorylate multiple sites, failed to induce an electrophoretic mobility shift [312]. The slower
migration of phosphorylated proteins compared to their non-phosphorylated counterparts has been
attributed to disruption of the sodium dodecyl sulfate (SDS) to protein binding ratio from the
negatively charged phosphate as well as structural changes (kinks) induced by phosphorylation
sites adjacent to proline residues [313, 314].
To begin to unravel the functional effects of phosphorylation, site specific methods of
identification are essential. Two modern methods have begun to help discern the effects of site
specific phosphorylation of Cxs: MS and the development of quality phosphorylation specific
antibodies. The current gold standard for the identification of site specific phosphorylation of
proteins is MS. The benefits of which are the ability to reliably detect quantities of phosphoprotein
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in the femtomole range, as well as the lack of need for radiolabeled samples [315]. Furthermore,
MS samples can be processed and analyzed rapidly with relatively low cost. Studies using MS to
pinpoint the locations of site specific phosphorylations have relied on instruments capable of
tandem MS/MS (reviewed in [316]). Although this has been relatively successful, several factors
complicate analysis. These are the relative abundance of phosphorylated protein compared to the
non-phosphorylated form, phosphopeptides generally produce lower signal that the nonphosphorylated peptides, observed MS/MS properties of phosphopeptides generated by collision
induced decay can be difficult to analyze (reviewed in [316]). As a result, enrichment of the
phosphospecies is usually to the advantage of the investigator. Several recent technological and
chemical advancements have been aimed at doing just this. The simplest method of enrichment
has proven to be IP of phosphopeptides using general pTyr, pSer, or pThr antibodies [317]. While
a number good antibodies exist for the enrichment of pTyr containing peptides, quality IP competent
pSer and pThr antibodies are lacking [317]. A more reliable form of enrichment commonly used is
immobilized metal affinity chromatography (IMAC) [318]. In IMAC, a solid phase utilizing various
immobilized metal ions separates proteins to variable degree based on affinity for the metal ions,
a classical example being the use of Ni2+ to bind His-Tag containing proteins [318, 319].
Specifically, phosphopeptides have noted affinity for Fe 3+, and thus columns with chelated Fe3+ are
most commonly used for enrichment of phosphopeptides [318]. Notably, acidic residues have also
been noted to bind to Fe3+ leading to some non-phosphorylated background, however, this can be
overcome with the conversion of the carboxylic acid moieties to their corresponding methyl esters
(reviewed in [316]). In addition to column based enrichment, chemical alteration of the phosphate
group to stable thiol by β-elimination and Michael addition allows for the capture of the thiol by
column chromatography (reviewed in [316]). A final method of enrichment follows a similar work
flow, where, after β-elimination, the resulting residue is converted to an aminoethylcysteine that
can be recognized by Lys targeting proteases such as trypsin (reviewed in [316]). The latter method
improves analysis of the peptides because it places the phosphorylated residue at the CT, creating
a unique y1 ion (reviewed in [316]). Technological advances in instrumentation such as the
employment of matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) have
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improved the detection limit of phosphopeptides and helped to simplify analysis and offer a
quantitative method of detecting phosphorylation [320]. The high sensitivity and overall reliability of
the technique have yielded dividends in the identification of specific phosphoresidues of Cxs
(reviewed in [288, 316]). Indeed, a number of studies on Cx proteins have successfully used MS to
pinpoint site specific phosphorylations from both in vitro and in vivo samples [274, 321-323].
In addition to MS, the development and use of phosphospecific antibodies has been crucial
in the identification of site specific functions of phosphorylation (reviewed in [308, 309]). A number
of studies since the mid-2000s have described the development of phosphospecific Cx antibodies
and used them to characterize site specific functions both in vitro and in vivo [312, 324, 325]. Use
of phosphospecific Cx43 antibodies have helped reveal (partially) the identity of the multiple
electrophoretic bands, specifically phosphorylation of residues S325/328/330 (understood to be
phosphorylated by CK1) contributes to the P2 form [311, 324]. Although the use of phosphospecific
antibodies has helped to define the source of the multiple electrophoretic bands observed for Cx43,
the picture is not as clear as one would expect. Tyr phosphorylation of Cx43 (pY265 and pY247),
for example, was observed in the P0, P1, and P2 bands of Cx43, suggesting the nature of the
altered mobility by phosphorylation is complex [325].

A current drawback to the use of

phosphospecific antibodies is the lack of commercial availability for family members other than
Cx43. Although, labs have developed phosphospecific antibodies to other family members (e.g.,
Cx37, Burt laboratory unpublished data) the efficacy and applications of use have yet to be
determined. Important to the studies contained herein, no phosphospecific Cx45 antibodies have
been developed to date.
3.1.3 Serine/Threonine Phosphorylation
Phosphorylation of Cx proteins is an important regulatory feature. Currently, the Cx protein
that is most well characterized in terms of the regulation by phosphorylation is Cx43, although
phosphorylation of other family members is beginning to be unraveled (reviewed in [288, 308, 309]).
As mentioned in the introduction for this section to date Cx31, Cx32, Cx36, Cx37, Cx40, Cx43,
Cx45, Cx46, Cx50, and Cx56 have all been demonstrated to be phosphoproteins, through direct
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[32P] incorporation, MS, or phosphatase sensitive electrophoretic mobility shifts (reviewed in [288,
309]). However, since Cx43 is the best characterized it will be the primary focus of this section.
The primary sequence of Cx43 contains a total of 39 residues that can be phosphorylated
(intracellular, 23 Ser/7 Thr/9 Tyr). Of those 39 sites, at least 22 of the residues have been detected
as phosphorylated by one or another detection method, including 19 Ser residues, Thr residues,
and 3 Tyr residues [295, 308, 326-328]. Although, Thr phosphorylation of several residues has
been detected in a human, rat, and mouse Cx43, the studies were not focused on Cx43 specifically,
utilized shotgun approach MS, and the functional effects were not explored [329-336]. Therefore,
Thr phosphorylation will not be discussed in further detail, and the importance of Tyr
phosphorylation will be discussed in Section 3.1.4.
Ser phosphorylation of Cx43 has been well described with respect to the phosphorylated
residues, the functional effect of phosphorylation, and in many cases the kinase for the site(s) has
been identified (reviewed in [288, 309]). Functional outcomes of Ser phosphorylation ranges from
channel forward trafficking, channel opening and closure, and priming for internalization; ultimately
leading to changes in cell-cell coupling [288, 308, 309]. A current list of Ser phosphorylation sites
and their functional effects on GJIC, and the kinase (if known) are summarized in Table 1. Generally
speaking, early phosphorylation by kinases such as PKA, Protein Kinase B (PKB/Akt), and CK1
are associated with forward trafficking, GJ assembly, and channel opening [153, 311, 337, 338].
While mid- and late-stage phosphorylation by kinases including MAPK, PKC, Akt, Ca2+/Calmodulindependent kinase II (CaMKII), and CDK1 promote GJ channel closure and prime Cx43 for
internalization [153, 288, 301, 323, 339, 340]. A study by Laird et al. detected phosphorylation on
newly synthesized Cx43 when it was blocked in the ERGIC by BFA, however the specific site and
kinase involved were not identified [148]. The authors did note that a number of casein proteins are
phosphorylated in the Golgi, which may suggest CK1 as the potential kinase involved [148]. Indeed,
work from Cooper and Lampe, characterized CK1 phosphorylation of Cx43 and demonstrated
phosphorylation of three key Ser residues (S325/328/330) regulated GJ assembly and were
associated with fully open channels [311]. Two other Ser residues that promote forward trafficking
of Cx43 are S373 and S364/365, phosphorylated by Akt and PKA, respectively [157, 160, 341,
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342]. Specifically, in the perimembrane region an interaction of Cx43 with Ezrin promotes the
phosphorylation of Cx43 S365 and S364 (and S369) by PKA, and likely primes Cx43 to interact
with ZO-1 [343]. The interaction with ZO-1 is thought to hold Cx43 at the perinexus of the GJ where
it can be quickly incorporated into the GJ proper when needed [166]. Interestingly, phosphorylation
of S365 and S369 does not affect the binding of either Ezrin or ZO-1 to Cx43 [160, 343]. Importantly,
phosphorylation of S365 is reported as a “gate keeper” site, when phosphorylated it maintains
channels in the open state by preventing PKC phosphorylation of S368 [344]. Capture of Cx43
containing vesicles at the plasma membrane has been reported to be facilitated by 14-3-3 [161].
Notably, phosphorylation of Cx43 S373 by Akt modulates the affinity of 14-3-3 and ZO-1 for Cx43.
Specifically, it promotes dissociation of ZO-1 and association of 14-3-3, which likely coordinates
incorporation into the GJ proper [158, 159, 164]. Once incorporated into the GJ, several protein
interactions serve to stabilize GJs, these will be covered in detail in Section 3.1.4 focusing on Tyr
phosphorylation. Finally, another set of Ser phosphorylation events regulate the closure and
priming for internalization of Cx43.
Priming of Cx43 GJ junctions for internalization begins with activation of Src kinase (will be
addressed in Section 3.1.4.1) and downstream effectors [153]. Mid stage activation of MAPK
(downstream of Src) leads to increasing phosphorylation of S255/262/279/282 [292, 309, 312, 345348]. Phosphorylation of S279/282 results in partial channel closure and the recruitment of Nedd4,
the E3 ubiquitin ligase for Cx43, which ultimately leads to recruitment of the clathrin machinery
[203, 349, 350]. Around the same time, loss of phosphorylation at S365 allows PKC access to
S368, and phosphorylation of S368 leads to subcondunctance states of Cx43 and contributes to
channel closure [344, 351]. From a structural standpoint, the study by Solan et al. suggested that
phosphorylation of S365 by PKA, induced a structural change in the Cx43CT that restricted the
access of PKC to the S368 site using a S365D phosphomimetic [344]. Complete channel closure
requires S262 phosphorylation by MAPK and likely occurs simultaneously to PKC phosphorylation
of S368 [153]. In one study, phosphorylation of Cx43 S255/262/279/282 were observed to occur at
the same time as S368 phosphorylation when cells were treated with vascular endothelial growth
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Ser Phosphorylation of Cx43
Kinase

Effect on GJIC

Residue(s) Phosphorylated

PKA

Promote (forward trafficking)

S364/365/369/373

PKB
(AKT)

Promote (forward trafficking)/Impair
(Internalization)

S369/S373

PKC

Impair (Channel closure/subconductance)

S368

CaMKII

S306 Promote

S244/255/257/296/306/314/325/328/330
/364/365/369/372/373

CK1

Promote

S325/328/330

CDK1

Impair (Closure/Internalization)

S255/262/279/282

MAPK

Impair (Closure/Internalization)

S255/262/279/282

Table 1. Kinases that phosphorylate Cx43 Ser residues and their effect on GJIC.
Table derived from Sorgen et al. (2018)[153].
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factor (VEGF) [345].

Surprisingly, when cells were treated with a PKC inhibitor, decreased

phosphorylation was observed for the MAPK sites (S255/262/279/282) and the PKC site (S368)
suggesting that PKC phosphorylation may precede MAPK phosphorylation, at least in the context
of VEGF stimulated cells [345]. A number of other studies reported similar results in other kinase
programs [352-354]. Similar to forward trafficking and assembly, phosphorylation of Cx43 by Akt
and an interaction with 14-3-3 also occurs during turnover to promote ubiquitination and
internalization [164]. Two other kinases also phosphorylate Cx43 during the late stage of its life
cycle, these are CDK1 and CaMKII [355-357]. CDK1 is likely a mediator of GJ turnover in response
to cell cycle, and like MAPK phosphorylates S255/262 [355, 356]. The role of CaMKII in the
regulation of Cx43 is unclear and the sites phosphorylated slightly ambiguous (15 Ser detected as
phosphorylated) [357]. Prediction software only identifies four canonical CaMKII consensus
sequences [153, 358]. Interestingly, experimental evidence of one CaMKII site (S306) has been
shown, however, S306 phosphorylation correlated with increased cell-cell coupling [359].
To this point our description of Cx43 phosphorylation has been over simplified as an all-ornone type situation to focus on the functional outcome of a specific site. In cell and tissues,
however, the situation is much more complex as both the kinases involved and the Cxs are
regulated spatiotemporally [338, 349]. Furthermore, it is unlikely that single phosphorylation events
exist in isolation, almost certainly the functional outcome is a combinatorial effect of several
phosphorylation events [338, 349]. An important caveat to this notion is that until we are able to
follow a single connexon and resolve the contributions of each Cx subunit we must derive our
observations from a pool of Cx proteins that may be in different stages of the life cycle or
accomplishing different tasks. In the study by Solan and Lampe, a chronological approach to
detecting phosphorylation events was taken. Using the PKC activating phorbol ester phorbol
myristate acetate (also 12-tetra-decanoyl phorbol acetate; PMA) to stimulate cells they observed
phosphorylation by Akt (S373) ranging from 5-30 min, which peaked at 5 min following addition of
PMA and then tapered off. Phosphorylation by MAPK (S279/282) was the next phosphorylation
site to be detected, and began to rise after 10 min and peaked around 30 min, but was detectable
out to 60 min. Phosphorylation of S368 (PKC) began to rise gradually at around 10 min and had
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not begun to taper off by the 60 min. They also monitored phosphorylation of the well described
Src site Y247 which followed a trend similar to S368 [338]. Since Akt phosphorylation has been
attributed to increased GJ plaque size stemming from enhanced forward trafficking, its seems
counterintuitive that phosphorylation of S373 has been observed as a precursor to GJ turnover via
internalization of annular GJs, however, the authors suggest this may be the result of two
mechanisms (that are not likely mutually exclusive). First the enhanced forward trafficking may
deplete the cells of intracellular Cx43 pools, and second the rapidly increasing GJ size may result
in lower energetic requirements of internalization of the annular GJ due to reduced need for
membrane invagination [338]. Although treatment of cells with PMA offers a good model for
observing the effects of a specific kinase program on Cx43 turnover, the question is: How reflective
of a physiological process is it? As it turns out, treatment with PMA closely reflects the process of
Cx43 GJ shutdown and turnover as occurs in wound healing [338, 360]. Notably, in studies
investigating wound healing, Cx43 phosphorylation was observed to follow the same trends; S373
(Akt) at 5-30 min, S279/282 (MAPK) and S368 (PKC) at 15-60 min, and Y247 (Src) 30 min to 24
hr [158, 361-363].
Despite the breadth of knowledge we have obtained regarding the regulation of Cx43 by
Ser phosphorylation, we have only begun to scratch the surface and a number of questions remain
to be answered. First, and perhaps most important: How are other Cx family members regulated
by Ser phosphorylation? It is tempting to use Cx43 as the model Cx due to its near ubiquitous
expression and the degree to which it is characterized with respect to phosphorylation, however,
as noted in the coming section on Cx45 phosphorylation a number of opposite effects have been
observed between Cx43 and Cx45 (see Section 3.1.5 on Cx45 phosphorylation). Furthermore,
several notable differences have been seen between Cx43 and other family members also,
including Cx32 (see chapter 6), Cx37 [364], and Cx36 [290]. This leads to a second important
question: When multiple Cxs are expressed and heteromeric channels are present what happens
to the regulation of these channels by phosphorylation? An example is in the working myocytes of
the ventricle when Cx45 is expressed in the failing heart [82]. Since both Cx43 and Cx45 are
expressed in the same cell and exposed to the same kinase programs, what determinants maintain
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Cx45 containing (homomeric and Cx45/Cx43 heteromeric) connexons at the ID? The latter
question is one of the focuses of this dissertation.
3.1.4 Tyrosine Phosphorylation
Tyr phosphorylation of Cxs is of significant current interest. While Ser phosphorylation has
been very well characterized for Cx43, Tyr phosphorylation has not. Interestingly, Tyr
phosphorylation appears to have a more dominant effect on channel function than Ser [288, 309].
Only a small number of Tyr kinases have been identified that modulate Cx43 function (Src, EGFR,
Tyk2, Ephrin receptors B1 and B4) [296-298, 323, 365, 366]. In this subsection, we will discuss the
importance of Tyr phosphorylation to Cx43 highlighting the special case of Src kinase.
3.1.4.1 Role of Src with Cx43
One of the most notable (and well-described mechanistically) kinases that phosphorylates
Cx43 is pp60-Src (Src) [293, 367, 368]. The Src family of kinases, are segregated into 3
subfamilies: SrcA (Src, Yes, Fyn, and Fgr), SrcB (Lck, Hck, Blk, and Lyn), and Frk in its own
subfamily [369]. Structurally the Src family of kinases consist of a highly conserved NT region that
contains residues which are modified by lipid moieties (myristoylation - all members; palmitoylation
- subset) which confer plasma membrane anchoring [369]. Additionally, they all contain SH2, SH3,
Tyr kinase, and C-terminal domains [370]. For the canonical member, c-Src, activation of the kinase
requires phosphorylation of a key Tyr residue (Y416) and loss of autoinhibitory phosphorylation of
another Tyr residue (Y527) [370]. Constitutively active Src (v-Src) lacks the autoinhibitory Y527
and thus does not require dephosphorylation for activity and consequently has been a tool
frequently used to study the regulation of Cx43 by Src [325, 371]. To date phosphorylation of three
key Tyr residues of Cx43 by Src have been identified (Y247, Y265, and Y313) [295, 325]. The
mechanism by which Src phosphorylates Cx43 has been well described [72, 372-374]. The general
scheme is once active, Src associates with the Cx43CT on its proline rich region (P274-P284,
containing a PXXP motif), through the Src SH3 domain facilitating phosphorylation of Cx43 Y265,
this in turn creates an SH2 binding site [372-374]. Subsequent binding of the Src SH2 domain to
pY265 then allows for the phosphorylation of Y247 and Y313 [295, 373, 374]. Notably, a Cx43
mutant (Y265F) drastically reduced Y247 phosphorylation and failed to co-immunoprecipitate (co37

IP) v-Src when cotransfected into HEK293 cells, experimentally demonstrating the importance of
Y265 phosphorylation to phosphorylation of Y247 [372]. Recent work from our laboratory confirmed
these results using co-transfection of v-Src and Cx43 (Y265F) into HeLa cells, and additionally
demonstrated a similar effect on Y313 phosphorylation [295].
Several studies investigating the relationship of Src and Cx43 (in numerous systems) have
come to the same conclusion: Src phosphorylation of Cx43 disrupts GJIC by promoting GJ turnover
[295, 325, 340, 375]. Recent studies have demonstrated indirect effects on GJIC mediated by
activation of Src including increased phosphorylation by MAPK and PKC, as well as decreased
phosphorylation by PKA [325, 373, 374]. When Lin et al. studied the effect of site specific mutations
of Cx43 on GJIC in a Cx43-KO mouse cell line, they observed Cx43 mutants Y247F, Y265F, and
Y247F/Y265F to be resistant to effects of v-Src co-transfection [373, 374]. Similarly, work from our
laboratory noted resistance to v-Src mediated GJ disassembly in HeLa cells expressing mutants of
Cx43 (Y247F, Y265F, Y313F, Y247F/Y265F, and Y247F/Y265F/Y313F), however contrary to the
Lin study, only the triple mutant was completely resistant to the effects of Src [295, 373, 374].
Contrary to both of these studies, in oocytes, injection of v-Src was still capable of downregulating
gj for the Cx43 Y247F, Y265F, and Y247F/Y265F mutants [376]. Whether this reflects the effect of
Src on activating the MAPK and PKC pathways, or the requirement of phosphorylation on Y313
was not determined. Based on the studies by Zheng et al. and Solan and Lampe it is likely a
combination of these [295, 325].
The phosphorylation of Cx43 by Src has both direct and indirect effects on GJIC. The
indirect effects as mentioned above, include the activation of parallel pathways (MAPK and PKC)
that lead to GJ closure and turnover [328]. The direct effects of Src are mediated specifically by the
phosphorylation of Y247, Y265, and Y313 (reviewed in [153]). Although, this will be covered in
detail in the following section a brief synopsis is: Src phosphorylation sites (Y247, Y265, and Y313)
occur in the binding motifs for proteins understood to stabilize GJ plaques (β-Tubulin and
Developmentally regulated brain protein 1 (Drebrin)) [295, 377, 378]. Furthermore, Src directly
titrates ZO-1 binding away from Cx43 [72, 286].
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3.1.4.2 Phosphorylation in Binding Motifs
Regulation of Cx43 by phosphorylation can be the result of a number of mechanisms: the
addition of the negative charge can alter secondary structure, influence pore size and selectivity,
or alter the affinity of protein partners. In this section, our focus is on describing the role of
phosphorylation in various binding motifs on the Cx43CT. A number of phosphorylation sites on
the Cx43CT overlap with the binding motifs of protein partners and thus could be expected to (at
least in part) influence the binding of the protein partner (see Figs. 1.2 and 1.3) [153]. This section
will be broken up into two primary focuses where phosphorylation sites overlap binding motif: 1)
interactions involved in forward trafficking and GJ assembly, and 2) interactions involved in
disassembly, internalization, and turnover of GJs.
During forward trafficking phosphorylation influences a number of key interactions. First
phosphorylation of S373 by Akt (or PKA) disrupts the binding of ZO-1 to the far CT of Cx43 and
promotes the binding of 14-3-3 [158, 159, 341, 343]. In a nearby region of Cx43, the minimal binding
motif for Ezrin (enhances PKA mediated phosphorylation of S373) was identified by using a peptide
scanning approach (366RASSR370), notably this contains S368 (PKC) and S369 (PKA) and S365
(PKA) directly precedes the sequence [160, 309, 341]. Surprisingly, however, phosphorylation of
these sites did not affect the binding of Ezrin to Cx43 [160]. Similarly to Ezrin, ZO-1 which binds
over S364-I382 was not affected by the phosphorylation of either S364 or S369 [341]. Whether
S368 affects the binding of ZO-1 remains to be determined.
In GJ disassembly and turnover, the influence of both Ser phosphorylation and Tyr
phosphorylation has been noted [153]. A number of important interactions with cytoskeletal
anchoring proteins (β-Tubulin, Drebrin, and ZO-1) are all required to stabilize GJ plaques [153]. A
commonality between these interactions is the ability of all three to be modulated by the activity of
Src. For β-Tubulin, which interacts with Cx43 in a region covering Y247, use of non- and
phosphorylated (Y247) Cx43 peptide (K234–D259) via NMR demonstrated that phosphorylation of
this site directly inhibited the binding of β-Tubulin to Cx43 [377]. Similarly, Drebrin which interacts
with three regions of the Cx43CT (K264-T275; S282-T290; and R299-G321; over Y265 and Y313)
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Figure 1.2. Protein partners that directly interact with the Cx43CT domain to promote intercellular
communication.
The black line represents Cx43CT domain residues 234-382. Provided for each Cx43CT protein partner (circle) is its diameter (in
Å) as estimated from their molecular weight, and number of amino acids (aa), and the Cx43CT residues affected as a result of the
interaction (lines). If the protein partner is a kinase or phosphatase, the Cx43CT residues affected are labeled on the Cx43CT
(circle or triangle). Abbreviations are as follows: β-tubulin (β-tub), T-cell protein Tyr phosphatase (TC-PTP), Connexin interacting
protein 75 kDa (CIP75), Ubiquitin-associating domain (UBA), Casein kinase 1 (CK1), Protein kinase A (PKA), Zonula Occludens
1 (ZO-1), and Protein kinase B (AKT). Kinases have been highlighted (shaded circle). Reprinted from Sorgen et al., (2018).
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Figure 1.3. Protein partners that directly interact with the Cx43CT and Cx43CL domains to impede intercellular
communication.
The black lines represents Cx43CT domain residues 234–382 and Cx43CL domain residues 100–158. Provided for each Cx43 CT
and CL protein partner (circle) is its diameter (in Å) as estimated from their molecular weight, and number of amino acids (aa), and
the Cx43CT residues affected as a result of the interaction (lines). If the protein partner is a kinase, the Cx43CT residues affected
are labeled on the Cx43CT (circle). Abbreviations are as follows: Calmodulin (CaM), Src homology 3 domain (SH3), Tyr kinase 2
(Tyk2), Mitogen-activated protein kinase (MAPK), Neural precursor cell expressed developmentally down-regulated protein 4
(Nedd4), Cyclin-dependent kinase 1 (CDK1), Tumor susceptibility gene 101 protein (Tsg101), Ubiquitin E2 variant domain (UEV),
Protein kinase B (AKT), Protein kinase C (PKC), matrix metalloproteinase-7 (MMP7), and Ca2+/calmodulin-dependent protein
kinase II (CaMKII). Kinases have been highlighted (shaded circle). Reprinted from Sorgen et al., (2018)
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is inhibited by phosphorylation of these residues [295, 378]. The initial study by Ambrosi et al.
reported phosphorylation of Y265 (through the use of a Y265D mutant) was sufficient to disrupt
Drebrin binding, however, recent work from our

laboratory suggests complementary

phosphorylation of Y313 is also required [295, 378]. Notably, when Drebrin is depleted in cells,
Cx43 is internalized and degraded resulting in impaired cell-cell coupling [379]. In addition to
phosphorylation by Src, MAPK phosphorylation of S279/S282 occurs in the binding motifs for both
AP2 (of the clathrin complex) and the E3 ligase Nedd4 [153]. Nedd4 primarily interacts with Cx43
residues P283-Y286 (PPXY motif) via its WW2 domain and phosphorylation of the nearby MAPK
sites (S279/S282) was demonstrated to increase the affinity of Nedd4 for the Cx43CT by
approximately two-fold (KD pS279/S282 = 585 µM vs. npS279/S282 = 1064 µM) in two independent
studies [203, 204]. In addition to Nedd4, both AP2 and Tumor-susceptibility gene 101 (TSG101)
interact with the Cx43CT nearby the PPXY motif and are important for the internalization of Cx43
[380, 381]. Interestingly, the Cx43 PPXY motif includes Y286, a site that has been identified to be
phosphorylated by both MS and low through-put methods (Sorgen Laboratory, unpublished data;
[382, 383]). Although a connection to the binding of protein partners was not investigated, the
possibility exists that phosphorylation of this site may modulate the affinities of one or more protein
partners. Another noted outcome of phosphorylation by MAPK is the priming for phosphorylation
of S368 by PKC although an exact mechanism was not determined [325]. Speculatively, the
phosphorylation of S279/S282 (or other sites by Src) may recruit a phosphatase which
dephosphorylates S365, to allow PKC to phosphorylate S368. Finally, the association of AP2 with
Cx43 is mediated by Tyr-based sorting motifs, of which Cx43 contains three (S1-230YVFF233, S2265YAYF268,

and S3-286YKLV289) [196, 381]. The proximity of S1 to the plasma membrane makes

this site unfavorable for protein interactions. Notably, S2 overlaps the PPXY motif recognized by
the WW2 domain of Nedd4, suggesting that both Nedd4 and AP2 likely cannot interact at the same
time, suggesting that clathrin mediated endocytosis and ubiquitin mediated degradation may be
alternate pathways for Cx43 internalization [196]. Whether S2 and S3 both function as AP2 binding
sites remains unclear, however, a recent study demonstrated using the yeast two-hybrid system,
that a Cx43CT mutant with a YA mutation in S3 (Y286A) no longer functioned as bait for AP2
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[354]. Similar to the speculative note above, it is likely that phosphorylation of either Cx43 Y265 or
Y286 would inhibit the interaction with AP2, as Tyr phosphorylation of other proteins within Yxxψ
tyrosine-based sorting motifs inhibits the binding of AP2 [384]. Since Src phosphorylates Cx43 on
Y265 it is likely, Src modulates the association of Cx43 and AP2.
3.1.5 Phosphorylation of Cx45
Despite how well phosphorylation of Cx43 is described, information regarding the
phosphorylation of Cx45 is quite limited. Early phosphoamino analysis of Cx45 revealed
phosphorylation of Ser, Thr, and Tyr residues, although the bulk of the phosphorylation was
attributed to Ser residues [189]. It was suspected that Ser phosphorylation was contributed heavily
by the enrichment of Ser residues in the far Cx45CT domain, experimentally this was supported by
the observation that either deletion of the last 26 residues or mutation of the 9 most C-terminal Ser
residues reduced the detectable phosphorylation by 90% [189]. The remaining phosphorylation,
however, was independent of the presence of the 9 Ser residues in the last 26 residues of the CT
[189]. This was supported by an earlier study, which identified several phosphorylation sites for
chicken Cx45 present in both the CL and CT domains [385]. While mutation of the Ser residues did
not impair GJ assembly or dye transfer by neurobiotin (NB) injection, deletion of the last 26 residues
impaired both [189]. Furthermore, loss of the Ser residues correlated with decreased stability as
indicated by pulse chase experiments measuring the half-life of Cx45 and mutants, however, the
truncation mutant did not have significant decreases in its half-life [189]. Interestingly, mutation of
certain Ser residues (e.g., Cx45 3Ser mutant; Cx45 S374A/S376A/S378P, Cx45 Ser381,382
mutant; Cx45 S381G/S382A) reduced the overall Ser phosphorylation to a greater degree than
would be expected (3Ser - 33% remaining; S381,382 – 22% remaining), suggesting that these sites
are prerequisites for other phosphorylation sites [189].
Another study focusing on the effect of Cx45 phosphorylation on the electric properties of
the channel noted conductance was modulated by phosphorylation [306]. Activation of PKC by the
addition of PMA resulted in an increase in the gj of Cx45 HeLa cell pairs from 2.0 to 4.9 nS while
the biologically inactive analogue 4α-Phorbol 12,13-didecanoate (4α-PDD) had no effect on gj
[306]. Conversely, activation of the cAMP dependent kinase, PKA, by addition of cAMP reduced gj
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from 27.3 nS to 18.2 nS, while addition of cGMP had no effect [306]. Similarly, treatment with
pervanadate, which increases Tyr phosphorylation indirectly by inhibiting Tyr phosphatases,
reduced gj from 10.5 nS to 4.5 nS [306]. Interestingly, none of the treatments significantly altered
single channel conductance states, suggesting that phosphorylation was impacting open
probability [306]. Contrary to the results of the van Veen et al. study, a study by Martinez et al.
reported treatment of HeLa cells expressing Cx45 by PMA reduced gj to approximately 30% of
control [86, 306]. However, in the same study the authors observed no change in the transfer of
microinjected NB dye after PMA, suggesting activation of PKC alters the permselectivity of Cx45
channels, although this remains to be determined [86]. Finally, a recent study from our laboratory
using NMR observed a direct interaction between the Cx45CT and the SH3 domain of c-Src,
suggesting that c-Src may regulate Cx45, although this was not validated nor were the functional
effects explored [247]. Investigating these aspects is the focus of Chapter Four.
3.2 Other Connexin Post-translational Modifications
In addition to phosphorylation, a number of other PTMs modulate Cx protein function
through a number of mechanisms. These modifications include the addition of carbon moieties,
ubiquitin, small ubiquitin modifier (SUMO) protein, and reactive nitrogen species. In the current
section, these PTMs and their effect on Cx proteins are summarized.
3.2.1 Connexin Carbon-based Modifications
Primary PTMs involving carbon-based moieties include methylation, acetylation, and
glycosylation among others. For Cxs, the primary relevant carbon based modifications are
methylation, acetylation, and γ-carboxylation [326]. While methylation and acetylation of histones
(and DNA methylation) play critical roles in the epigenetic control of gene expression they also can
directly modify proteins besides histones [326].
Cxs have been shown to be modified post-translationally by methylation, acetylation, γcarboxylation, and in one case palmitoylation [326]. Cx26 and Cx32 were among the first identified
by MS to be modified post-translationally by carbon-based moieties [274, 289]. For Cx26
methylation was found on five sites. Of note one of the five methylation sites R75 when mutated
(R75W or R75Q) results in non-syndromic deafness suggesting the methylation of this site may be
44

important to Cx26 function [289]. Other studies characterizing the R75W mutant have indicated
that although it suffers no trafficking problems, the channels are non-functional and exert a
dominant negative effect on wild type Cx26 and the co-expressed Cx30 [49, 52, 265, 386-388].
Acetylation of Cx26 was identified on six residues, two of which, K15 and K102, are
deafness mutations (K15T, K102del). Each of these two mutations abolishes a positive charge from
the lysine side chain. K15 is in the hinge region of the NT where it flips into the pore to aide in
formation of the voltage gate [262, 389]. In Cx32 this residue is an Arg and a R15Q mutation—also
abolishing positive charge—causes peripheral neuropathy, and although functional, the channels
have altered voltage sensitivity [268, 390]. It is possible that a similar mechanism leads to the
deafness seen in Cx26 K15T mutants. K102 in Cx26 is present in the CL which functions in pH
gating and is a site for protein partner interactions [391, 392]. Similarly, to K15, the residue
corresponding to Cx26 K102 in Cx32 is also charged (Glu in this case) that when mutated to Gly,
abolishing the charge, results in changes in Cx32 pH sensitivity and mild neuropathy [391]. Colussi
et al. described a functional role for Cx43 acetylation [393]. In the Duchenne muscular dystrophy
mdx mouse model it was demonstrated that Cx43 was acetylated and improperly localized and
mutants mimicking acetylation at the three predicted sites (K9, K234, and K264) phenocopied the
improper localization seen in mdx mice [393].
Glutamate γ-carboxylation is a vitamin K dependent PTM carried out by γ-glutamyl
carboxylase and was originally discovered in coagulation proteins and converts the sidechain of
Glu residues to a dicarboxylic acid [394-397]. Importantly, γ-carboxylation creates a high affinity
Ca2+ coordination site [396, 398]. To date, γ-carboxylation has been demonstrated on Cx26 and
Cx32 by MS [274, 289]. Glutamate γ-carboxylation was identified on E42 and E47 in the EL1 of
Cx26 as well as E114 of the CL [289]. Both of the EL1 Glu residues when mutated cause deafness
and E114 is a site involved in the Ca2+ dependent loop gating mechanism which maintains
undocked connexons in the closed state [387, 399-402]. Interestingly, E114 in the CL of Cx26 is
conserved in Cx32 where it was also determined to be γ-carboxylated [274]. With the Ca2+
coordinating function of γ-carboxylglutamate it is possible that γ-carboxylation of E114 of Cx26 and
E110 of Cx32 is involved in imparting Ca2+ sensitivity [274, 289]. Furthermore, with potential roles
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in Ca2+ sensitivity it is likely that other Cx family members (e.g., Cx43) regulated by intracellular
Ca2+ may also be γ-carboxylated.
3.2.2 Connexin Ubiquitination
Ubiquitin, a 76-residue polypeptide that is found ubiquitously, is a key PTM for protein
degradation and turnover [326]. Ubiquitination is an enzymatic process that requires the transfer of
ubiquitin in a cascade manner. Ubiquitin is initially bound to the ubiquitin activating enzyme (E1
family of ubiquitin ligases) then shuttled to a ubiquitin carrier (E2 family of ubiquitin ligases) which
associates with a final ubiquitin ligase (E3 family of ubiquitin ligases). The E3 family of ubiquitin
ligases provide substrate specificity and transfer the ubiquitin covalently via an isopeptide bond
from G76 of the ubiquitin to Lys residues on the target protein [403]. Further ubiquitination of the
target can occur via ubiquitin-to-ubiquitin linkages. These linkages can be on any Lys residue in
the ubiquitin, however, K48 polyubiquitination chains destine the target for proteasomal
degradation [403]. Cxs are substrates for ubiquitination [404].
Ubiquitination is an important quality control mechanism that couples with ERAD (with the
assistance of CIP75). For Cx43 and Cx32 as much as 40% of newly synthesized protein undergoes
ERAD, a feature that is correlated with levels of cellular stress. Interestingly, a mutation in Cx32
conferring CMTX results in nearly 100% of Cx32 being destined for ERAD. Cellular stress
counteracts the ERAD, reducing the degree of polyubiquitination allowing improperly folded Cx32
to accumulate in the ER and oligomerizes with the remaining wild type Cx32 altering function and
contributing to the disease phenotype [194, 405]. Once incorporated into the GJ plaque, Cxs are
ubiquitinated by Nedd4, promoting internalization through endocytosis and trafficking to the
lysosome for degradation [406].
3.2.3 Connexin SUMOylation
In addition to ubiquitin a small family of structurally and functional similar proteins known
as SUMO proteins exist. In humans, the family is made up of three members (SUMO1-3) [407].
Despite structural similarity to ubiquitin little sequence conservation between the two exist. Like
ubiquitin, SUMO proteins are conjugated to Lys residues in ψKX(D/E) motifs, where ψ is a bulky
hydrophobic residue (F, L, I, W) and X is any residue [408]. Similar to ubiquitin, the conjugation of
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SUMO moieties to targets is achieved in a cascade manner [409]. First cleavage of a C-terminal
peptide from SUMO results in the exposure of a di-glycine motif. SUMO then associates with the
E1 (SUMO activating enzyme) and is passed to the E2 which can directly conjugate the SUMO to
proteins with a canonical SUMO acceptor motif. For a subset of targets without the canonical motif
SUMO can be shuttled to one of several E3 that, similar to ubiquitin, serve the role of target ligase
[409]. Additionally, SUMO conjugates are removed, similar to the process of dephosphorylation
and deubiquitination, by sentrin-specific proteases [409]. Differing from ubiquitination SUMOylation
does not lead to target degradation, but is involved in various housekeeping processes such as
regulation of transcription, stabilizing targets, stress response, and cell cycle progression [410].
Cx43 is the only Cx to date demonstrated to be SUMOylated [411]. However, the
SUMOylated Lys residues detected, K144 and K237, are evolutionarily conserved among many
mammalian species, and K144 is conserved among several of the Cx family members including
Cx26 and Cx32 [411]. This suggests other Cx family members may be SUMOylated as well.
SUMOylation of Cx43 is by any of the three human SUMO proteins. SUMO1 and SUMO2 were
found on Cx43 only as mono-SUMOylation modifications, while SUMO3 was found as both monoand poly-SUMOylation (both multisite mono-SUMOylation and chains of poly-SUMOylation).
SUMOylation of Cx43 appears to regulate Cx43 expression levels, as when SUMO1 or SUMO2
were cotransfected into HeLa cells with Cx43, the Cx43 levels doubled. Additionally, co-expression
of SUMO3 with Cx43 in HeLa cells resulted in increased GJIC, suggesting that SUMOylation plays
a role in modifying Cx43 function as well [411]. Interestingly, the bulk of SUMOylated Cx43 was
found in the Triton X-100 (TX-100) soluble fraction, suggesting it was not incorporated into
functional plaques [411, 412]. However, it has been shown that plaques become soluble just prior
to internalization, and inhibition of degradation pathways (both lysosomal and proteasomal) in
myocytes resulted in both an increase in soluble Cx43 and communication [413, 414]. Additionally,
K144R, K237R mutations in Cx43 reduced expression levels and plaque formation, suggesting that
SUMOylation may play a vital role for proper GJ maintenance [411].
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3.2.4 Connexin S-nitrosylation
S-Nitrosylation is a reversible covalent medication to Cys residues of proteins where nitric
oxide (NO) is added to the thiol group [415, 416]. Nitrosylation is carried out and regulated by the
activity of nitrosylases and denitrosylases [417]. Despite most targets of nitrosylation containing
multiple accessible Cys residues, only a subset are detected as nitrosylated suggesting there is
likely a recognition motif [417]. Nitrosylation of proteins alone can alter protein function, or
alternatively can influence other PTMs on the target thereby indirectly affecting function [417].
Nitrosylation is an important regulator of vascular functions [418].
Studies providing clear evidence of a functional effect of nitrosylation on Cxs are limited.
However, Cx43 was found to be constitutively nitrosylated in the myoendothelial junctions where
endothelial cells are coupled to vascular smooth muscle cells [419]. Additionally, it was determined
that when treated with phenylephrine, which activates denitrosylases, Cx43 GJ permeability to IP3
was reduced and correlated with a reduced degree of nitrosylation on Cx43 residue C271 [419].
Addition of NO donors resulted in decreased permeability to small molecules in vascular endothelial
cells and reduced coupling of Cx37 channels [420, 421]. Nitrosylation also likely plays a regulatory
role for Cx hemichannels. In astrocytes hypoxia and ischemia, which are associated with increased
NO generation, also increased hemichannel permeability of the astrocytic GJ proteins, Cx43 and
Cx46 [422]. This effect was reproduced by addition of S-nitrosoglutathione and reversed by
subsequent treatment with reducing agents. Additionally, mutants of Cx46 abolishing the Cys
residues in the CT domain prevented increased hemichannel permeability by NO donors [423].
4. Objective
Regulation of GJ function is achieved through alterations in phosphorylation and
modulation of protein partner interactions within the CT domain of individual Cx proteins. Although
a significant body of work exists characterizing these features for Cx43, little information exists
about other Cx family members.
The objective of this dissertation is to identify the functional significance of protein
interactions and phosphorylation of the Cx45CT domain. Chapter Two includes studies focused on
determining how Cx45CT domain dimerization affects channel properties including expression,
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localization, plaque formation, channel function (GJIC and hemichannel), basal phosphorylation,
and interactions with protein partners. In Chapter Three, we use chimeric Cx45 proteins to further
support our studies in Chapter Two, namely the importance of sequence specific regulatory roles
of the Cx45CT dimerization domain (A333-N361). For Chapter Four, we change focus to delineate
the regulation of Cx45 function by three kinases (PKC, Pyk2, and Src) that are active downstream
of the Angiotensin II (AngII) type 1 receptor (AT1R) and identify key Cx45 residues phosphorylated
by these kinases. Chapter Five, follows up on Chapter Four by investigating cross-regulation of
Cx43 and Cx45 in both acute and chronic activation of the kinases from Chapter Four. Chapter Six
contains a study on another Cx family member (Cx32) and its regulation by Ephrin receptor kinases
and TC-PTP. Finally, Chapter Seven is a summary all of my projects and I propose future directions
for the continuation of these studies.
The importance of GJs and intercellular communication to the homeostasis of humans
makes Cxs attractive potential therapeutic targets. A clear understanding of the molecular
determinants (protein partners, PTMs, etc.) that make each family member unique is essential for
a solid foundation from which to develop novel therapeutic interventions.
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CHAPTER TWO

Identifying the Physiological
Role of Cx45 CT Domain
Dimerization
The bulk of data presented in this Chapter is published Trease et al.

(2017), Journal of Molecular and Cellular Cardiology [424]
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5. Introduction
GJs are plaques comprised of tens of 1,000s of passive membrane channels that directly
adjoin the cytoplasm of neighboring cells. The channels allow for the direct exchange of ions,
metabolites, and second messengers (cAMP, ATP, IP3, etc.) [14]. The resulting electrical and
metabolic coupling is essential to several physiological processes including: organization and
synchronization of cells in organs and tissues, development, and impulse propagation in some
excitable tissues [14]. Each channel is formed from the apposition of two connexon hemichannels,
one contributed from each coupled cell. The connexon contributed from each cell is composed of
six Cx proteins. Cx nomenclature is derived based on the molecular weight of the given family
member (e.g., 45 kDa isoform is Cx45; Cx45), of which there are 21 human family members. Cxs
family members share common structure from primary to tertiary. In terms of membrane topology,
all Cx proteins contain four transmembrane domains, two extracellular loops (EL), a cytoplasmic
loop (CL), and cytoplasmic N- and C-terminal domains (NT and CT respectively). Between Cx
family members the transmembrane and extracellular domains retain the highest degree of
conservation, including six critical Cys residues in the extracellular domains (three in each loop)
that are essential for proper channel formation and subsequent docking. The intracellular domains,
however, show sequence divergence, the greatest of which occurs in the CL and CT domains. The
CT domain is of particular significance because it serves a regulatory role in all stages of the GJ
life cycle including trafficking, localization and turnover. Furthermore, the CT domain has been
shown to regulate intercellular communication via a number of PTMs and protein partner
interactions [14, 425]. Additionally, the CT domain is an important regulator of channel properties
such as junctional conductance, open probability, and voltage sensitivity [223, 426, 427]. The
importance of the CT domain to Cx function lends itself to being a potentially useful therapeutic
target that could differentiate between Cx family members [428-430].
Cxs have been found in nearly all cell types and organs, where their expression is often
regulated spatiotemporally [32]. One example is in the heart, where the primary family members
expressed are Cx43, Cx40, and Cx45. Cx43 is expressed throughout most of the working
myocardium. While Cx45 expression in the adult is restricted to cells of the specialized conductance
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and pace making system, however, this is altered compared to embryonic expression where Cx45
is found throughout the heart and loss of its expression is lethal [32, 66, 67]. In the specialized
conductance system, channel properties of Cx45 make it ideal for propagating impulses from the
atria to the ventricles, preventing reentrant arrhythmias [32, 66, 67]. In the ventricles of healthy
adult hearts, GJs are made up primarily of Cx43, however, in failing hearts Cx45 is upregulated.
Cx45 has also been implicated in coupling of Cx43-null ventricular myocytes. [83, 431]. This leads
to altered coupling and slower conductance, contributing to increased incidence of ventricular
tachy-arrhythmias [432]. The possibility also exists that in Cx43-KO mice, residual conduction may
be mediated by ephaptic signaling from the NaV1.5 channel [433, 434]. Although normal
intercellular current flow mediated by Cx45 is considered near non-existent in healthy hearts, in the
pathological situation Cx45 mediated coupling becomes dominant due to overexpression in the
ventricles. This is further confounded by the ability of Cx45 to form heteromeric channels with
residual Cx43 thereby reducing current flow and voltage sensitivity, in ways that could still be
managed with simple remodeling of Cx43 alone [82, 87, 432, 435-438]. Importantly, there is a lack
of clear delineation of the mechanisms which make each cardiac Cx family member unique,
including what makes Cx45 channel properties so different from Cx43 or Cx40, and how its
upregulation makes it a potential substrate for arrhythmogenesis. As a result of this deficit and
previous observations in the field we sought to better understand the possibility that interactions
between the two CT domains of Cx45 molecules (i.e., dimerization) affect GJ regulation.
Work done previously in our laboratory identified a novel feature of the Cx45CT, high
affinity dimerization (KD ~100 nM). This dimerization was mediated by the presence of six key
hydrophobic residues, positioned such that they create a hydrophobic face on the α-helical region
(A333-N361) [247, 439]. Replacement of all six hydrophobic residues by Glu (L335E, L338E,
I324E, L349E, I353E, Y356E; Cx45CT 6E; Fig. 2.18) disrupted dimerization yet maintained αhelical conformation [247]. Dimerization of cytosolic domains has previously been demonstrated to
be critical regulators for ion channels (e.g., IP3 receptor [440]), and the importance of the Cx CT
domain to proper channel function through modulation of protein partner interactions is well

52

established [153]. Basing our study on these notions, here we study the physiological role for
dimerization of the Cx45CT and how it regulates Cx45 channel function and properties.
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6. Materials and Methods
6.1 Cell Culture and Transient Transfections
MDCK cells (gift from Dr. Paul Lampe, Fred Hutchinson Cancer Center), HeLa cells (gift
from Dr. Steve Caplan, University of Nebraska Medical Center) and HEK293T cells (gift from Dr.
Myron Toews, University of Nebraska Medical Center) were cultured in Dulbecco’s modified Eagle
medium (Corning) at 37°C in a humidified 5% CO 2 atmosphere. Medium was supplemented with
10% fetal bovine serum (FBS, Seradigm), 2 mM L-glutamine (HyClone), 1% pen-strep (Corning),
and 0.2% Normocin (Invivogen). The selective agent puromycin (Tocris) was used, when
appropriate, at empirically determined concentrations. MDCK or HeLa cells at ~70% confluence
were lipofected using the MDCK Avalanche (EZ Biosystems) reagent at 2.5:3.5 (plasmid:reagent)
and Lipofectamine 2000/XtremeGene 9 (LifeTech/Roche) at (1:3/1:4 ratio) respectively, diluted in
OptiMem under antibiotic free conditions. MDCK cells were analyzed 24-48 hr post-transfection
while HeLa were analyzed 48 hr after transfection.
6.2 Stable Cell Line Generation
70% confluent MDCK, HeLa, and HEK293T cells were lipofected with indicated SalI
linearized plasmid using either MDCK Avalanche (MDCK; 2.5:3.5) or Lipofectamine 2000
(HEK293T; 1:1) in OptiMem. Transfections were carried out under antibiotic free conditions, and
cells were cultured 48-72 hr prior to addition of selection media. MDCK and HEK293T were
selected with 5 µg/mL and 2 µg/mL puromycin respectively. Cells were either maintained as bulk
(polyclonal) or clonally (monoclonal) selected cell lines. Monoclonal lines were obtained using
Whatman paper cloning disks. Western blots and immunofluorescence were used to screen clones.
6.3 Antibodies and Immunostaining
All primary and secondary antibodies, detection reagents and concentration ranges utilized
are summarized in Table 2. Cells seeded on glass coverslips were rinsed 2x with 1x phosphate
buffered saline (PBS) and then fixed and permeabilized with either ice cold methanol at -20°C for
15 min or buffered formalin (1x PBS, 3.7% formaldehyde, 0.3% TX-100) at 37°C for 30 min.
Coverslips were washed 3x 5 min in 1x PBS with gentle agitation and then blocked for 60-90 min
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at 37°C (1x PBS containing 1% bovine serum albumin (BSA) and 0.3% TX-100). Coverslips were
then incubated with the indicated primary antibodies diluted in blocking buffer for either 1 hr at RT
or ON at 4°C. Coverslips were washed 3x with 1x PBS and then incubated with secondary antibody
(if necessary) 1 hr at RT and then washed 1x for 5 min with 1x PBS containing 100 ng/mL DAPI
and then 2x 5 min with 1x PBS. Coverslips were mounted with SlowFade (LifeTech) and sealed
with clear nail polish and imaged. All images acquired on either Zeiss 710 or 800 LSM microscope.
6.4 Live Imaging
Live imaging dishes (In Vitro Scientific) were coated with bovine plasma fibronectin (Sigma)
at 10 µg/mL. MDCK clones expressing Cx45 WT-eGFP or 6E-eGFP were seeded and imaged at
confluence. Images were acquired over a 1 hr period at 1 min intervals on a Zeiss 710 LSM confocal
microscope with definite focus module.
6.5 Cell Lysis for Direct Western blot
Cultured cells were rinsed 2x with 1x PBS and then incubated with protease inhibitor buffer
(PIB; 1x PBS containing 1x Roche Complete + ethylenediaminetetraacetic acid (EDTA), 2 mM
PMSF, 2 mM Pepstatin A) on ice for 20 min and then harvested with a cell scraper. Cell
suspensions were pelleted at 1500 RPM for 5 min at 4°C. PIB was removed and cell pellet
resuspended in an appropriate volume of lysis buffer (PIB + 1% TX-100, unless otherwise
specified), mechanically lysed and incubated on ice for 30 min. Lysates were quantified by
bicinchoninic acid assay (BCA; Pierce) and normalized with lysis buffer. 30 μg of total protein lysate
(unless otherwise indicated) was resolved.
6.6 Co-IP and Western blot
Co-IP: MDCK cells stably expressing either Cx45 WT or 6E were seeded in either 10 or
15 cm plates and grown to confluence. Cells were rinsed 2x with 1x tris buffered saline (TBS) +
1mM EDTA and then scraped up an either 0.5 or 1.0 mL of IP lysis buffer (25 mM Tris(hydroxymethyl)aminomethane (Tris), 150 mM sodium chloride (NaCl), 0.25% sodium
deoxycholate, 0.05% SDS, 1% TX-100 plus protease and phosphatase inhibitors).
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Antibodies and Reagents
1° Antibody

Manufacturer

Applications

Concentration

Cx45 (MAB3101)

Millipore

WB/IF/IP

1:2000/1:200/1:500

Cx45 (ACC-207)

Alomone

WB/IP

1:2000/1:500

Cx43 (C6219)

Sigma

WB/IF

1:2000/1:200

Cx43 pS272/282

Fred Hutchinson

WB

1:500

Cx43 pS368

Cell Signaling

WB

1:1000

Cx43 pY247

Fred Hutchinson

WB

1:1000

Cx43 pY265

Fred Hutchinson

WB

1:1000

Cx43 pY313 (in-house)

LifeTein

WB

1:500

β-Tubulin (T8328)

Sigma

WB

1:500

Drebrin (AB10140)

Millipore

WB

1:3000

ZO-1 (61-7300)

Zymed

WB

1:500

Nedd4 (07-049)

Millipore

WB

1:3000

pTyr (pTyr-1000)

Cell Signaling

WB

1:1000

pSer (A4A)

Millipore

WB

1:500

β-Catenin (C2206)

Sigma

IF

1:200

E-cadherin (Alexa-488; 24E10)

Cell Signaling

IF

1:100

HA-Tag (Alexa-647; 6E2)

Cell Signaling

IF

1:50

Myc-Tag (Alexa-555; 9B11)

Cell Signaling

IF

1:100

2° Antibody

Manufacturer

Applications

Concentration

Goat α-mouse (Alexa-647)

Cell Signaling

IF

1:500

Goat α-rabbit (Alexa-555)

Cell Signaling

IF

1:500

Goat α-mouse-HRP

Millipore

WB

1:100,000

Goat α-rabbit-HRP

Alpha Diagnostics

WB

1:50,000

Veriblot

Abcam

WB

1:4,000

Goat α-rabbit light-chain HRP

Jackson Immuno

WB

1:300,000

Fluorescent Dye/Protein

Manufacturer

Applications

Concentration

Neurobiotin

Vector Labs

Fluorescence

2.0 mg/mL

Lucifer Yellow CH

LifeTech

Fluorescence

0.25 mg/mL

Texas Red Dextran (10,000 Da; fixable)

LifeTech

Fluorescence

1.0 mg/mL

Streptavidin (Alexa-647 or Alexa-488)

LifeTech/Jackson Immuno

Fluorescence

1:100 (1 mg/mL stock)

Table 2. Antibodies and reagents.
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Cells were mechanically lysed and then incubated for 30 min at 4°C with rotation. Lysates were
precleared with normal rabbit IgG (2 µg) bound protein G agarose for 1 hr at 4°C and then clarified
by centrifugation. Clarified lysates were quantified by BCA (Pierce) and normalized. Input samples
were reserved and either 2 or 5 mg of lysate was subjected to IP with either 2 or 3 μg of rabbit αCx45 (Alomone) ON at 4°C. Immune-protein complexes were captured by 2 hr 4°C incubation with
protein G agarose (Pierce), washed 5x with IP wash buffer (IP lysis buffer excluding sodium
deoxycholate) captured proteins were eluted using 35-50 μL 3x SDS sample buffer. Equal volumes
of each sample were analyzed by Western blot and to avoid cross reactivity with the IP antibody a
light chain specific secondary antibody (Jackson) or Veriblot (Abcam) were utilized for detection.
Western blot: Protein samples were resolved by SDS-PAGE with an appropriate gel
concentration, transferred to PVDF (EMD Millipore), blocked either 2 hr at RT or ON at 4°C with
either 5% non-fat milk/PBS + Tween 20 (PBST) or 5% BSA/TBS + Tween 20 (TBST) and incubated
with indicated primary antibody in blocking buffer either 1 hr at RT or ON at 4°C. Blots were washed
3x for 10 min with either PBST or TBST, and then incubated for 1 hr at RT with secondary antibody.
Membranes were then washed 4x 10 min each with either PBST or TBST and detected using Signal
West Femto kit (Thermo) per manufacturer protocol and exposed to autoradiography film.
Quantifications were done using NIH ImageJ software using a minimum of three independent
replicates.
6.7 RT-PCR
MDCK clones expressing mCx45 WT and 6E were seeded and cultured to confluence.
Cells were rinsed 2x with 1x PBS and lysed for RNA content using the GeneJet RNA Isolation kit
(Thermo) per manufacturer protocol. Equivalent masses of RNA were reverse transcribed using
the MuMV-RT kit (NEB) per manufacturer protocol with OligoDT priming. Equal volumes of each
RT reaction were used as template for standard PCR reactions with primers to mCx45-WT/6E (5’ACAGTAAAAGGAGGGAACTTGAT-3’ and 5’- TGGCTTTGTTTTGCTTGTAGG-3’) and GAPDH
(5’- GTAGTGAAGCAGGCATCGGA-3’ and 5’- GTCGAAGGTGGAAGAGTGGG-3’) using Taq
Green Master Mix (Thermo). Cycling was carried out as follows: Initial denaturation 95°C for 2 min,
followed by 30 cycles of 95°C denaturation for 30 s, 54.5°C annealing for 30 s, and 72°C extension
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for 30 s, followed by final extension of 5 min at 72°C. Equal samples volumes were analyzed by
2% Agarose/TAE electrophoresis spiked with ethidium bromide. No reverse transcriptase reactions
were used to subtract genomic background. Quantification was done using NIH ImageJ software,
normalizing samples to GAPDH loading control. Quantification was done using three independent
replicates.
6.8 Cycloheximide Chase
MDCK clones expressing mCx45-WT or mCx45-6E were cultured to approximately 90%
confluent. Cells were rinsed 2x with 1x PBS and the incubated with fresh medium containing 80
μg/mL cycloheximide (CHX; Cell Signaling) for the indicated time points. Following the desired
incubation time the cell media was spiked with 10x Roche Complete + EDTA and the cells were
harvested and pelleted at 1500 RPM for 5 min at 4°C. The supernatant was removed and the cells
were lysed directly in 1x sample buffer supplemented to 1x PBS, with protease inhibitors and 50
units Benzonase. Equal volumes of sample were resolved by SDS-PAGE and analyzed by Western
blot. Each time point was normalized to loading control and then to the starting time point.
6.9 Scrape Loading Dye Transfer Assay
Cells were scrape loaded as previously described [340]. Briefly, all buffers were prewarmed to 37°C prior to beginning the experiment. Stable expressing MDCK clones or transiently
transfected HeLa cells were seeded on bovine plasma fibronectin (Sigma; 10 µg/mL) coated 35
mm live imaging dishes (CellStar). MDCK cells were transfected with Cx43 siRNA with
Lipofectamine RNAiMAX (LifeTech) according to manufacturer protocol and then cultured for 48 hr
prior to scrape loading. After transfection cells were washed 1x with 1x PBS and then overlaid with
dye tracer mix (1x PBS containing Lucifer yellow, NB, and Texas Red Dextran). Scrapes were
introduced using a fine edged micro-scalpel and incubated at RT for 1 min. Tracer dye was gently
washed away with 1x PBS and media was added and the cells returned to the incubator to culture
for 5 min to allow dye to transfer. Following the dye transfer period the cells were washed with 1x
PBS containing 1 mM CaCl2 and 1 mM MgCl2 to stop dye spread. Coverslips were then formalin
fixed and stained as described above and imaged. 15 consecutive fields of view were acquired per
replicate.
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6.10 Triton X-100 Solubility Assays
Biochemical: The TX-100 solubility assay was modified from a method described
previously [412]. Briefly, MDCK cells grown in 10-cm plates were washed with PBS and incubated
in 1 mL PIB for 20 min at 4°C, harvested in the same buffer and gently pelleted. Supernatant was
aspirated, and cell pellet resuspended in 1 mL of fresh PIB supplemented with 50 units of
Benzonase and mechanically lysed. Lysates were quantified by BCA and normalized. A total of
450 µL of cell lysate was brought to 1% SDS with 10% SDS and reserved as total lysate. Another
450 µL was brought to 1% TX-100 with 10% TX-100 in 1x PBS and incubated at 4°C for 30 min
with agitation. The TX-100 lysate was then separated into non-junctional (supernatant; soluble) and
junctional (pellet; insoluble) fractions by ultracentrifugation at 100,000 xg for 1 hr at 4°C. The
supernatant was carefully removed and retained as the soluble fraction. The pellet was solubilized
in 500 µL of solubilization buffer (1x PBS, 8 M urea, 2.5% SDS, 0.1 M dithiothreitol (DTT), 1x Roche
complete + EDTA, 2 mM PMSF, and 2 µM Pepstatin A). Volume normalized samples of total lysate
(T), TX-100 soluble (S) and TX-100 insoluble (I) portions were analyzed by Western blot. Soluble
and insoluble fractions were quantified as a function of total lysate. Quantification was done using
NIH ImageJ software from three independent replicates. In situ TX-100 extraction: The in situ
detergent extraction was previously described by [340]. Briefly, MDCK cells were seeded on glass
coverslips (Neuvitro) and cultured to ~90% confluence. Coverslips were rinsed 2x with 1x PBS and
then incubated for 30 min at 4°C with gentle agitation with either mock extraction buffer (1x PBS
containing 1x Roche complete + EDTA, 2 mM PMSF, and 2 µM Pepstatin A) or extraction buffer
(mock buffer + 1% TX-100). Following extraction, the cells were fixed, immunostained, and images
acquired. Extractions were performed on three independent replicates to ensure reproducibility.
Quantification of remaining immunostain was done by taking the DAPI normalized MFI of the Cx
signal in extracted images as a percent of signal in the mock images using ImageJ.
6.11 siRNA Knock-down of Cx43
MDCK clones stably expressing Cx45 WT or 6E at approximately 60% confluent were
lipofected with stealth siRNA designed against endogenous canine Cx43 using Lipofectamine
RNAiMAX according to manufacturer protocol under antibiotic free conditions, cells were cultured
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48 hr prior to any analysis. Complexes were generated in OptiMem. siRNA was designed using the
Invitrogen design tool against the coding region (CDS) of accession number NM_001002951.3.
siRNA duplex sequence: 5’-UAA CAC UCA ACA GCC UGG UUG UGA A-3’ and 5’-UUC ACA ACC
AGG CUG UUG AGU GUU A-3.’
6.12 Bimolecular Fluorescence Complementation
MDCK cells seeded on coverslips were transiently co-transfected with Lyn-HA-Cx45/6ECT-mVenusN and Lyn-Myc-Cx45/6E-CT-mVenusC. Approximately 20 hr after transfection the cells
were rinsed 2x with 1x PBS and ice-cold methanol fixed and immunostained as described below,
and imaged. Plasma membrane measurements were made using the Zeiss profile measurement
tool of at least 90 double-transfected cells for each condition at 630X and signal calculated as area
under the curve. For ER/Golgi measurements images were exported to NIH ImageJ and ROIs were
used to isolate the ER/Golgi and signal was measured as mean fluorescent intensity. Quantification
of mVenus signal was normalized individually to both HA and Myc signal.
6.13 Blue-Native PAGE
Post nuclear triton soluble lysates were prepared as described for the TX-100 solubility
assay. Samples were resolved on Blue-Native PAGE gels prepared freshly as described in [137,
441]. Gels were run on ice or in cold room with blue cathode buffer (0.01% Coomassie Blue (G250))
until dye front migrated approximately two-thirds through the gel. The cathode buffer was then
exchanged for dye free cathode buffer and run to completion. Gel was incubated with 0.1% SDS
containing semi-dry transfer buffer and then transferred to PVDF and blotted as described above.
6.14 Sucrose Density Gradient Fractionation
Gradient preparation: Stock sucrose solutions were prepared by dissolving the appropriate
mass of sucrose in 1x PBS containing 0.1% TX-100 and 0.02% azide. Gradients were prepared
segmented from stock solutions with greater sucrose concentrations on the bottom. A 200 μL
cushion of 25% sucrose was added to the bottom of a 4 mL polyallomar tube (Beckman) and snap
frozen, then 850 μL of each 20%, 15%, 10%, and 5% sucrose was layered on the previous layer
snap freezing between layers. Gradients were stored at -20°C until use. On the day of use the
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gradients were removed from -20°C and allowed to thaw at room temp for 30 min, and then tilted
30° from horizontal for 90 min to linearize the gradient by diffusion. Oligomerization assay: To
determine the location of oligomerization we modified the protocol of Koval et al. [143]. Briefly,
MDCK clones expressing either Cx45 WT or 6E were seeded in 10 cm plates and cultured to
confluence and then treated for 4 hr with 10 µM Monensin A ((MonA); Sigma). After treatment cells
were washed 2x with 1x PBS and then incubated on ice in protease inhibitor buffer PIB for 20 min.
Cells were scraped up and pelleted at 1500 RPM for 5 min at 4°C. PIB was removed and cell pellet
resuspended in 0.5mL lysis buffer (PIB + 1% TX-100 and 50 units Benzonase) and mechanically
lysed. Lysates were quantified by BCA and normalized. Normalized lysates were fractionated into
soluble and insoluble fractions as described above. An aliquot of the supernatant was retained as
input, and the remainder was overlaid on a 5-25% sucrose gradient, prepared as described above.
Gradients were centrifuged at 148,000 x g for 16 hr at 4°C. 500 μL fractions were obtained by
pipetting down from the top maintaining the pipette tip at the meniscus, and then vortexed. An
aliquot of each fraction was resolved by SDS-PAGE and analyzed by Western blot. Sucrose
determination: Remaining gradient fraction volumes were vortexed and allowed to warm to room
temperature. 50 μL aliquots were analyzed by a Brix refractometer (Milwaukee Instruments,
MA871) in triplicate and the mean of the three reads taken as °Brix. °Brix was then converted to
sucrose concentration (% w/v) by a standard curve generated using stock solutions at 2.5, 5.0, 7.5,
10.0, 12.5, 15.0, 17.5, 20.0, 22.5, and 25.0% sucrose. The equation for the trend-line generated
from the standard curve shown as equation 2:
1) 𝑦 = °𝐵𝑟𝑖𝑥
2) 𝑦 = 0.7743𝑥 + 2.26
3) °𝐵𝑟𝑖𝑥 − 2.26/.7743 = [𝑠𝑢𝑐𝑟𝑜𝑠𝑒]
6.15 Calmodulin Binding Assay
The LCK-GCaMP2 construct was shuttled from the pN1 vector purchased from AddGene
(#24794) to the pD2529 mammalian expression vector by PCR and Gibson assembly. The A333N361 region of Cx45 WT or 6E were QuikChanged to replace the M13 domain of myosin light chain
kinase using megaprimers derived by PCR in the new LCK-GCaMP2 pD2529 vector, called WT61

and 6E-LCK-GCxaMP2 respectively. Newly developed vectors were sent for Sanger sequencing
to ensure correct sequence, midi-prepped, and stably transfected into MDCK cells. Stable clones
of parental LCK-GCaMP2, WT- and 6E-LCK-GCxaMP2 were chosen based on similar levels of
protein expression. Clones were seeded in triplicate in live imaging dishes and cultured to
confluence in phenol free DMEM. At confluence cells were rinsed 2x with 1x PBS and the medium
was replenished. Images were acquired every 5 s using definite focus module on a Zeiss 800 LSM
with 5% CO2 infusion and 37°C incubation. After 3 min of baseline (36 images) image acquisition
dishes were spiked with Ionomycin to a final concentration of 15 µM and images were acquired for
an additional 5 min. Mean fluorescent intensity was taken for the total field of view for each image.
6.16 Hemichannel Dye Uptake Assay
To assess hemichannel activity we modified the protocol described by [442]. Briefly, all
buffers were pre-warmed to 37°C prior to beginning the experiment. MDCK clones expressing
either Cx45 WT or 6E were seeded on glass coverslips were cultured to approximately ~90%
confluent. Some wells were pretreated with either 100 µM La3+ (Sigma) or freshly prepared 100 µM
pervanadate or both for 15 min prior to Ca2+ washout and dye uptake. The presence of La3+ was
maintained during dye uptake. Cells were rinsed 1x with HBSS + Ca2+/Mg2+ (LifeTech) and then 2x
with HBSS – Ca2+/Mg2+ (LifeTech). Cells were then incubated at 37°C with HBSS – Ca2+/Mg2+
containing NB (0.1 mg/mL; Vector labs) for 10 min. Cells were then washed 2x with HBSS +
Ca2+/Mg2+ to close hemichannels and GJs. Cells were formalin fixed and stained with streptavidin
647 conjugate (LifeTech) and imaged. Control cells were treated identically except all incubations
were done in HBSS + Ca2+/Mg2+. Three independent replicates were used for quantification
calculated by DAPI normalized mean fluorescent intensity in Zen Blue (2012) where 15 fields of
view were acquired per replicate. Results presented as mean + s.e.m. of all replicates.
6.17 Statistical Analysis
All data were analyzed by using GraphPad Prism 5.0 and were presented as the mean +
s.e.m. Statistical analysis performed in GraphPad Prism 5.0 was either one-way ANOVA with a
Newman-Keuls post-hoc analysis or Student’s T-Test (one or two-tailed as appropriate) where
appropriate. P-values <0.05 were considered statistically significant.
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7. Results
7.1 Cx45CT WT Dimerizes at the Plasma Membrane
Dimerization of the Cx45CT was initially identified by Kopanic et al. using a recombinantly
expressed Cx45CT peptide in vitro [247]. We hypothesized that the salient features of the peptide
(structure and oligomeric state) would be present in the context of the cytosol of the cell in proximity
to the plasma membrane. To address this, we sought to determine if the CT domains expressed at
the plasma membrane would in fact dimerize if expressed exogenously in cyto. We implemented a
bimolecular fluorescence complementation (BiFC) approach to investigate this [443]. In this assay,
the use of a fluorescent protein tag (mVenus) that has been expressed as separate N- and Ctermini on the same protein (either Cx45CT WT or Cx45CT 6E) yields fluorescent signal when the
protein of interest interacts with itself. Design of the BiFC constructs is illustrated in Fig. 2.1. In
order to target the proteins to the plasma membrane, in the absence of the transmembrane
domains, the first 16 residues of Lyn kinase domain were included on the N-terminus to mediate
membrane anchoring via myristoylation and palmitoylation. To differentiate N- and C-terminal
mVenus constructs as well as provide a reference signal to quantify against, we included HA- or
Myc-tags, respectively. When expressed in MDCK cells mVenus signal fluorescent signal should
be detected only if two Cx45CT domains interact, which places the mVenus fragments in close
enough proximity to properly refold and result in fluorophore maturation. mVenus signal was
detected for both the Cx45CT WT and 6E constructs, however, was restricted only to cells
transfected with both HA- and Myc-tagged constructs (Fig. 2.2A; single transfections not shown).
Using the profile measurement tool to isolate fluorescence signal present at the plasma membrane
we quantified the area under the curve from 90 WT and 92 6E cells that had immunoreactivity to
both HA- and Myc-tags (collected across three independent experiments). To quantify (and control
for potential differences in expression and trafficking to the plasma membrane) the mVenus signal
was normalized to the Myc-tag signal for each construct (Fig. 2.2B). For the Cx45CT WT construct,
the plasma membrane signal observed was 2.46-fold greater (P <0.0001) than that for Cx45CT 6E.
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Figure 2.1. Schematic of Cx45CT BiFC constructs for in cyto dimerization
assay.
The Cx45CT (WT or 6E) was c-terminally fused to the first 16 residues of Lyn kinase with
either and HA- or Myc-tag as a linker. To the c-terminus of the Cx45CT for HA-tagged
constructs the mVenus (V2-E173) were fused, similarly to the Myc-tagged constructs mVenus
(Q155-Y238) was fused. Proximity of the two halves of the mVenus fragments results in
refolding and measurable fluorescence. This figure is modified from Trease et al., (2017).
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This data suggested that the CT domain of Cx45 was indeed dimerized when anchored to the
plasma membrane, and furthermore indicated the mutations of the 6E were sufficient to inhibit
dimerization. Our results are further supported by a similar trend observed when using the HA-tag
to normalize the mVenus signal at the plasma membrane. Using the HA-tag we observed a 4.40fold (P <0.0001) increase in the mVenus signal of Cx45CT WT compared to that of the 6E. It is
likely differences in antibody affinity for the HA and Myc tags lead to the larger difference seen with
the HA-tag. Of note, significant mVenus signal was observed for both the Cx45CT WT and 6E
present in the endoplasmic reticulum (ER)/Golgi apparatus. As a result, we quantified this region
independently of the plasma membrane signal and determined it to be of similar albeit not identical
levels (Fig. 2.2B). We believe the signal we observed in Cx45CT 6E expressing cells is the result
of localized concentration, as refolding of the mVenus is dependent on proximity. Indeed, the
degree of signal observed for both Cx45CT WT and 6E in the ER/Golgi supports this hypothesis.
Further support of this hypothesis is a conflict in the quantification of the ER/Golgi mVenus using
the HA-tag to normalize instead of the Myc-tag. Consequently, proximity leads to “background”
mVenus signals that are not the result of bona fide dimerization. Despite this limitation, any
reduction of the Myc normalized mVenus signal of Cx45CT 6E compared to Cx45CT WT indicates
less dimerization and is therefore significant. We sought to test if this assay would work properly
on full length Cx45 WT and 6E, however, we failed to observe a significant difference in the mVenus
signal between the Cx45 WT and 6E constructs in this manner (data not shown). We speculate the
since mVenus refolding is contingent upon proximity and thereby localized concentration, CT
domains of adjacent Cxs in a connexon would be close enough together to allow refolding to occur
independent of dimerization interactions. Indeed, when taken together with the ER/Golgi mVenus
signal this hypothesis is supported, as there is an accumulation of protein in close proximity in the
ER/Golgi similar to that the condition in a connexon.
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Figure 2.2. Cx45CT WT dimerizes at the plasma membrane.
MDCK cells transiently transfected with the Cx45CT WT or 6E versions of Lyn-HA-CxCT-mVenN and LynMyc-CxCT-mVenC were assessed for complemented mVenus signal. A) Representative immunofluorescence
images of double transfected MDCK cells. B) Calculated area under the curve and mean fluorescent intensity
of mVenus signal normalized to either the Myc- or HA-tag fluorescence at the plasma membrane (top) and
Golgi/ER (bottom), respectively. Statistics are one tailed unpaired student’s T-test between the Cx45CT WT
and 6E groups; ***P <0.0001. Scale bar = 10 μm. This figure is modified from Trease et al., (2017).
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Figure 2.3. Localization of Cx45 WT and Cx45 6E in HeLa cells.
HeLa cells were transiently transfected with either Cx45 WT or Cx45 6E for approximately 20 hr, fixed
and immunostained for Cx45 (red). White arrows indicate GJ plaques for Cx45 WT at cell appositions,
while for Cx45 6E indicate the presence of protein at the plasma membrane in absence of apposition of
another expressing cell. DAPI (blue) was used to stain the nuclei. Scale bar = 20 µm
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7.2 Inhibiting CT Dimerization of Cx45 Alters Protein Localization
In order to determine if inhibiting dimerization affects proper Cx45 function our first
approach was to transiently transfect Cx45 WT and 6E into Cx-deficient HeLa cells. Following
transfection, the cells were cultured approximately 20 hr, fixed, and stained for Cx45. Similar to
what has been shown in the literature, our immunofluorescent images demonstrate that Cx45 WT
and 6E localized in the cell differently. Cx45 WT formed the expected small punctate GJs at cell to
cell interfaces, while the 6E presented as a predominantly linear structure covering the bulk of the
plasma membrane of each transfected cell independent of expression in apposed cells or cell-cell
contact (Fig. 2.3; white arrows). To confirm this phenotype in a second cell line we also transiently
transfected MDCK cells with either Cx45 WT or 6E. As we expected, immunofluorescence of the
MDCK cells revealed a similar pattern as we observed in the HeLa cells for both WT and mutant
Cx45 (data not shown). To further investigate the importance of Cx45 CT dimerization we then
sought to create stable expressing Cx45 WT and 6E cell lines using MDCK cells as the transgene
recipient. MDCK cells were chosen over HeLa cells for this portion of the study as they have been
used extensively in the literature to study GJs and are capable of consistent GJ formation.
Furthermore, the flattened shape of the cell line lends itself well to microscopic studies. Stables cell
lines were clonally selected for clones that best represented the transiently expressed phenotype
by immunofluorescence (Fig. 2.4). In addition to determining if protein localization was altered by
loss of CT dimerization, we also measured the apparent GJ size for both Cx45 WT and 6E proteins
using the built-in measure function of Zen software. Quantification of the length confirmed
differences between the apparent length of Cx45 WT and 6E GJ plaques (Table 3). As the Cx45
WT stable cell line expressed a residual amount of Cx43, we sought to determine if the presence
of Cx43 affected Cx45 localization by use of siRNA mediated knock down of endogenous Cx43.
Western blot and immunofluorescent imaging indicated that the presence of Cx43 did not affect the
expression levels of Cx45 or alter Cx45 localization (Fig. 2.5A and 2.5B).
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Figure 2.4. Inhibition of Cx45CT dimerization alters proteins localization.
MDCK cells were stably transfected with either Cx45 WT or Cx45 6E and were clonally selected.
Representative images of the clones utilized for this study are presented here. Cx45 (red) and Ecadherin (green) were stained. DAPI (blue) was used to stain the nuclei. White arrows represent
apparent GJ plaques. Scale bar = 20 µm. This figure is modified from Trease et al., (2017).
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Protein

Species

Host Cell

Average Length (nm)

Plaques Measured

WT

Mouse

MDCK

602 ± 141

113

6E

Mouse

MDCK

1330 ± 343

208

WT

Human

MDCK

640 ± 236

311

6E

Human

MDCK

1756 ± 340

131

WT

Mouse

HEK-293

749 ± 365

141

6E

Mouse

HEK-293

1325 ± 776

137

T-Test P value
<0.0001

<0.0001

<0.0001

Table 3. Measurements of GJ plaque length.
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Figure 2.5. Endogenous Cx43 does not alter Cx45 expression or localization.
MDCK cells expressing Cx45 were analyzed for expression of Cx45 and Cx43 and localization of Cx45
after siRNA mediated knock-down of the endogenous Cx43. A) Western blot and quantification of the
expression of Cx45 and Cx43 in the stable MDCK cells. B) Representative immunofluorescent images
of the localization of Cx45 (red). E-caderin (green) was used to mark the plasma membrane, and DAPI
(blue) was used to stain the nuclei. White arrows indicate GJ plaques. Scale bar = 20 µm. This figure is
modified from Trease et al., (2017).
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Finally, we hypothesized that the phenotype we were observing was independent of host
cell type or species of origin for the Cx45. Thus, we created humanized versions of Cx45 WT and
6E and expressed them in MDCK cells, as well as expressed mouse Cx45 WT and 6E in HEK293T
cells. Similarly, we immunostained these proteins to assess cellular localization, and as we
expected observed similar localization and GJ morphology to that of our stable cell lines (Fig. 2.6).
We additionally, measured the GJ lengths under these conditions to compare to mouse Cx45 WT
and mouse 6E. As we expected the trend for these permutations were consistent with what we
observed for mouse Cx45 WT and 6E expressed in MDCK cells. The measurements are
summarized in Table 3. Finally, we wanted to confirm our observations were not caused by
differences in antibody affinity or an artifact of fixation. To accomplish this, we generated stable
expression cell lines of C-terminal eGFP-fusions for each of our Cx45 WT and 6E constructs and
used live imaging to determine protein localization (Fig. 2.7). Confirming what we observed in the
fixed and stained cells Cx45 WT was restricted to puncta along the plasma membrane while the
6E was expressed as a diffuse staining all along the plasma membrane. Of note, for Cx43, the
inclusion of a C-terminal eGFP-tag resulted in an increase in apparent GJ length which was
determined to result from disrupted associations with the scaffolding protein ZO-1 [166].
Interestingly, when we measured the length of the Cx45-eGFP WT GJs we obtained a length of
667 ± 240 nm from a total of 12 plaques, suggesting that eGFP fusions are not altering the length
of Cx45 WT GJs and consequently are unlikely to cause the diffuse membrane signal observed for
the Cx45-eGFP 6E.
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Figure 2.6. Localization of Cx45 WT and 6E are not species specific.
Representative immunofluorescent images of Cx45 WT and 6E in MDCK (A) and
HEK293T (B) cells. A) Human Cx45 WT and Cx45 6E were stably expressed in bulk
selected MDCK cells and immunostained for Cx45 (red) and E-cadherin (green). B)
Mouse Cx45 WT and 6E were stably expressed in bulk selected HEK293T and
immunostained for Cx45 (red) and β-Catenin (green). DAPI (blue) was used to stain the
nuclei of both. White arrows indicate apparent GJ plaques. Scale bar = 20 µm. This
figure is modified from Trease et al., (2017).
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Figure 2.7. Live imaging using Cx45-eGFP WT or 6E reveals diffuse
localization of Cx45 6E along plasma membrane.
Representative single time point live fluorescent images of Cx45 WT (left) or 6E (right)
with c-terminal eGFP fusions. Notably the bulk of 6E-eGFP fluorescence is observed
diffusely across the entire plasma membrane. White arrows indicate apparent GJ
plaques. Scale bar = 10 µm. This figure is modified from Trease et al., (2017).
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7.3 Cx45 6E Has Altered Protein Expression
Noting the increased expression of the Cx45 6E at the plasma membrane compared to
that of WT, we wanted to determine if this was the result of a difference in protein expression level.
To address this, we used Western blot to determine if CT dimerization was affecting protein
expression levels. Our results indicated that Cx45 6E was expressing protein at approximately 1.6fold that of WT (Fig. 2.8A). Notably, we simultaneously tested both stable lines for expression of
endogenous Cx43 and our results indicate our 6E line does not express any of the endogenous
Cx43 (Fig. 2.8A). We reasoned the increase in protein expression could be the result of either
increased transcription (enhancing translation) or impaired turnover (enhancing stability) of the 6E
mutant. We first sought to determine if increased translation was contributing to the increased
protein express of the 6E mutant. To assess this, we measured the level of Cx45 WT and 6E
transcripts by RT-qPCR. Relative levels of Cx45 transcript were compared to that of the
housekeeping gene, GAPDH (Fig. 2.8B). We determined compared to GAPDH the levels of Cx45
WT and 6E transcript to be identical. This suggested to us that the increased 6E protein expression
was likely a consequence of altered 6E turnover. To test this, we used a CHX chase assay to
measure the degradation time of Cx45 WT and 6E. MDCK cells were treated over the course of 12
hr with 80 µM CHX and samples were analyzed by Western blot (Fig. 2.8C). The Western blot
results indicate that the Cx45 WT protein was degraded to near completion (~14% remaining) in
12 hr. In contrast, the 6E protein expression was relatively unchanged over the 12 hr period.
Although the relative stability of the 6E protein prevented calculation of half-life, we calculated the
half-life of the Cx45 WT protein to be 4.18 ± 0.90 hr; a result similar to previously published results
for Cxs [189]. Taken together with the RT-qPCR data this suggests that the increase in 6E protein
expression is the result of decreased turnover rather than increased synthesis.
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Figure 2.8. Inhibiting Cx45CT dimerization disrupts protein degradation.
Three different MDCK cells expressing either Cx45 WT or 6E were assessed for expression at the protein
and transcript levels. A) Western blots and quantification of Cx45 WT, Cx45 6E, and Cx43 expression. B)
RT-PCR gel images and quantification of Cx45 WT and 6E transcripts. C) Western blots and quantification
of Cx45 WT or 6E subjected to a 12 hr CHX chase. Results presented as the mean + s.e.m. (n=3). Statistics
are used to analyze the data were two-tailed unpaired Student’s T-test (A, n=3, *P<0.05; and C, n=3, ns,
*P<0.9056) and one-way ANOVA with a Newman-Keuls post hoc test (B, n=3; *P<0.05, **P<0.001
comparing Cx45 WT and 6E, and ##P<0.001 compared to time = 0). This figure is reprinted from Trease et
al., (2017).
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7.4 Cx45CT Dimerization is Essential for Proper GJIC
By inhibiting Cx45CT dimerization we determined an increased proportion of Cx45 6E was
present at the plasma membrane relative to WT. We were curious if this increased amount of Cx
protein would correlate with increase GJIC. To test this, we used scrape loading dye transfer of
NB, a 322.8 Da cationic molecule that Cx45 channels have been demonstrated to be permeable to
[86]. In addition to NB we utilized Lucifer Yellow CH (LY), a 457.2 Da anionic fluorescent dye as a
negative control, as Cx45 channels have conversely been shown to be impermeable to LY [86].
Scrape loading takes advantage of the ability to “load” cells with membrane impermeable dyes
through a cut introduced into a monolayer of cells. Stable Cx45 WT and 6E cells were cultured to
confluence in live imaging dishes, scrape loaded, fixed, and stained with Streptavidin-647
conjugate to identify the NB. Confocal microscopy was used to image dishes and to determine the
degree of dye transfer. As a marker of cells damaged by the scrape that take up the dye, a large
(10,000 Da) fluorescently labelled dextran was utilized for its inability to pass through GJs. Similar
to what has been published previously for the Cx45 WT we observed substantial dye coupling with
respect to NB, in some cases dye spread reached greater than 5 th order (5 rows of cells from
scrape) transfer (Fig. 2.8 (top); green). Consistent with the literature we also observed little-to-no
permeability of Cx45 WT channels to LY (Fig. 2.8 (top); yellow). When we repeated the assay with
the 6E cells, to our surprise we observed severely impaired dye coupling with respect to NB,
reaching 2nd-3rd order transfer very rarely (Fig. 2.8 (bottom); green). Furthermore, LY transfer was
not altered relative to Cx45 WT remaining only in the cells immediately adjacent to the scrape (Fig.
2.8 (bottom); yellow). These data suggest a role for Cx45 CT dimerization in proper GJIC.
Furthermore, the reduced coupling of NB in the 6E cells could be explained by fewer junctional
channels, reduced channel open time/probability, or by reduced NB permeability.
7.5 Inhibition of Cx45 CT Dimerization Impairs GJ Plaque Formation
Our experiments on the localization of Cx45 indicated that a larger pool of Cx45 protein
was present at the plasma membrane when CT dimerization was inhibited that correlated with a
decreased communication of NB dye. This led us to question whether this increased plasma
membrane protein was incorporated into GJ plaques. To test this, we utilized the TX-100 solubility
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Figure 2.9. Inhibiting Cx45CT dimerization impairs gap junction intercellular
communication.
MDCK cells expressing Cx45 WT (top) or 6E (bottom) were scrape loaded with tracer dyes to assess
the degree of intercellular communication. Red, Texas red dextran (MW 10,000 Da); yellow, Lucifer
yellow CH (MW 443 Da; −2 charge), green, NB (MW 287 Da; +1 charge); and blue, DAPI. Images are
representative of greater than six independent experiments. Scale bar in = 100 μm. This figure is
modified from Trease et al., (2017)
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assay which allows for the separation and quantification of non-junctional (soluble; hemichannels
and non-oligomerized Cx proteins in secretory pathway) from junctional (insoluble; GJ plaques) Cx
protein. We found that for Cx45 WT, protein segregated reproducibly into 58.57 ± 3.006% soluble
and 39.17 ± 2.154% insoluble. When we tested the 6E we determined that 86.43 ± 4.654% of the
protein segregated into the soluble fraction while only 22.59 ± 5.422% of the protein was found in
the junctional pool (Fig. 2.9A). We determined this to result in a 1.47-fold increase (N=3,P < 0.0001,
one-way ANOVA) in the soluble protein pool when dimerization was inhibited. Utilizing an in-situ
TX-100 followed by immunofluorescence we obtained results that were comparable to the Western
blot data (Fig. 2.9B). Quantification of the percentage of residual Cx protein following extraction
indicated 37.17% of Cx45 WT fluorescent signal remained after extraction while only 17.37% of 6E
signal remained (Fig. 2.9B). Taken together this indicates that the increased protein expression at
the plasma membrane seen in the 6E expressing cells is non-junctional. Furthermore, we sought
to ensure co-expression of Cx43 in the Cx45 WT clone did not significantly impact segregation of
Cx45 WT into GJ plaques. To determine this, we again performed the TX-100 solubility assay on
Cx45 WT cells that had been treated with siRNA against the endogenous Cx43. We determined
our knockdown efficiency of the endogenous Cx43 to be 91.25% (see Fig. 2.5A). With the TX-100
solubility assay we found that 39.56 ± 4.81% of the Cx45 was present in the soluble pool, while
60.44 ± 18.46% was present in the junctional pool when cells were mock transfected (Fig. 2.10).
Similarly, when Cx43 was knocked down by transfection with siRNA we found 39.45 ± 6.22% and
60.55 ± 9.95% of Cx45 in the non- and junctional pools, respectively. Therefore, the presence of
Cx43 did not alter Cx45 GJ formation. Taken together with the dye transfer data our results
demonstrate that Cx45 CT dimerization contributes to the stability of Cx45 at the GJ plaque.
Furthermore, our reduced dye transfer in the 6E expressing cells is consistent with the decreased
percentage of GJ channels.
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Figure 2.10. Inhibiting Cx45CT dimerization impairs GJ plaque formation.
A) TX-100 solubility was used to compare MDCK cells expressing Cx45 WT or 6E. A) Western blot image of
TX-100 extracted protein; total lysate (T), soluble (S), and insoluble (I) fractions. Below is the quantification of
protein in the T, S, and I fractions. Statistics represent one-way ANOVA with a Newman-Keuls post-hoc
correction (n=3, **P<0.001, ***P<0.0001). B) Representative fluorescent images (left) and quantification (right)
of in situ TX-100 and mock (1x PBS) extracted Cx45 WT or 6E in MDCK cells (red, Cx45; blue, DAPI). This
figure was modified from Trease et al., (2017).
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Figure 2.11. Endogenous Cx43 does not impact Cx45 GJ plaque formation.
Representative Western blot and quantification of total (T), Triton soluble (S), and Triton insoluble
(I) Cx45 WT after siRNA mediated knockdown of Cx43. Data presented as the mean + s.e.m. of
three independent experiments. Statistics for the TX-100 solubility assay were one-way ANOVA
with a Newman-Keuls post hoc test (n=3). This figure was modified from Trease et al., (2017).
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7.6 Inhibiting Dimerization Does Not Alter Oligomerization
Since our previous experiments revealed inhibiting Cx45CT dimerization affected both
protein localization and GJ plaque formation we hypothesized that it may alter oligomerization. As
an initial test to determine if overall oligomerization was affected by inhibiting dimerization we used
Blue Native PAGE to assess the oligomeric status of Cx45 WT and 6E from TX-100 soluble
fractions. MDCK cells expressing either Cx45 WT or 6E were lysed in buffer containing 1% TX100, fractionated by high speed centrifugation, and the supernatant was applied to Blue Native
PAGE, resolved, and then interrogated by Western blot. Our results demonstrated that both Cx45
WT and 6E formed proper oligomers as indicated by the immunoreactivity of a species consistent
in molecular weight with a connexon (Fig. 2.11A). Furthermore, and to our surprise, we found that
Cx45 WT did not show any appreciable banding or immunoreactivity at a molecular weight that
would be consistent with the monomeric Cx, however, showed a smear with some discrete banding
present for higher order (dimer, tetramer, etc.) oligomers while 6E showed clear banding for all
species from monomeric Cx to hexameric connexon. This led us to wonder if dimerization of the
Cx45CT would occur prior to channel oligomerization. For Cx43 it was shown that oligomerization
of Cxs into connexons occurred in the TGN [137, 147]. As such we sought to determine if
oligomerization of Cx45 would occur in the TGN, as well as determine if inhibiting CT dimerization
would alter this. To test this, we used linear sucrose gradient (5-25%) centrifugation to separate
non- from oligomerized Cx45 WT and 6E. Work from other labs has indicated that suboligomeric
Cx43 sediments below 15% sucrose [143]. Specifically, monomeric Cx43 sediments at ~8%
sucrose, while hexameric Cx43 sediments at 15% sucrose. We applied Cx45 WT or 6E from 1%
TX-100 soluble fractions to linear 5-25% sucrose gradients and centrifuged them overnight. We
fractionated the gradients in 0.5 mL fractions in a top down manner and analyzed them for Cx
content by Western blot. In order to accumulate the Cx45 in the cis-Golgi we treated the cells with
MonA to block transport to the medial-Golgi and subsequently TGN compartment. MonA treated
samples were compared to vehicle (EtOH) treated. In EtOH treated cells, we observed little
difference between Cx45 WT and 6E. This was characterized by two peaks, one at lower sucrose
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Figure 2.12. Inhibiting Cx45CT dimerization does not impact oligomerization state or cell
compartment.
Post-nuclear TX-100 soluble lysates from MDCK cell stably expressing Cx45 WT or Cx45 6E were analyzed
by Blue Native PAGE and sucrose density centrifugation. A) Representative Western blot of Blue Native PAGE
samples. B) Plots of Western blotted fractions of Cx45 WT and Cx45 6E from sucrose density centrifugation
following 4 hr treatment with MonA.
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concentration, corresponding to suboligomeric Cx45 and one at ~15% corresponding to connexons
(Fig. 2.11B; solid line). However, for MonA treated samples we observed a shift away from the
peak corresponding to connexons and an accumulation of Cx45 in a lower sucrose density.
Specifically, peak sedimentation of Cx45 WT corresponded to ~8.0% sucrose while for 6E this peak
was present at ~5.7% sucrose (Fig. 2.11B; dashed line). The data suggests that oligomerization of
Cx45 is not affected by inhibiting dimerization. Additionally, when taken together with the Blue
Native PAGE results, this data suggests that Cx45CT dimerization occurs prior to oligomerization,
consistent with a slightly larger molecular species for Cx45 WT as indicated by the slight shift to
higher sucrose concentration when compared to that of 6E (Fig. 2.11B; dashed line).
7.7 Increased Membrane Cx45 6E Mediates Increased Hemichannel Activity
Having determined the excess 6E at the plasma membrane was not incorporated into GJ
plaques we reasoned they may be available to mediate hemichannel activity. To test for this, we
used an established hemichannel dye uptake assay [442]. Briefly, depletion of extra cellular Ca2+
results in a positive membrane potential that leads Cx hemichannels to open [442]. The degree of
hemichannel opening can be quantified as a function of NB dye uptake. We found for the control
condition (+Ca2+) both Cx45 WT and 6E expressing MDCK cells minimally took up NB as indicated
by the limited staining with Streptavidin (DAPI normalized MFI WT = 0.5873 ± 0.03083 vs. 6E =
0.4180 ± 0.02306; ns, Fig. 2.12A). Conversely, following extracellular Ca2+ depletion we determined
the 6E expressing cells took up approximately 2-fold NB compared to Cx45 WT (DAPI normalized
MFI WT = 0.8866 ± 0.02859 vs. 6E = 2.042 ± 0.1397, P <0.0001, n=15, N=3, Fig. 2.12A).
Additionally, we wanted to test if increasing Tyr phosphorylation (a stimulus that inhibits Cx43 GJ
channels) would alter Cx45 WT hemichannel activity. To test this, we pretreated the Cx45 WT
expressing cells with 100 µM pervanadate for 15 min to inhibit normal dephosphorylation and again
measured dye uptake [444]. Compared to untreated Cx45 WT expressing cells no difference in dye
uptake was observed in normal Ca2+ or during Ca2+ depletion or (Normal Ca2+: DAPI normalized
MFI untreated = 0.5873 ± 0.03083 vs. pervanadate = 0.6217 ± 0.02705, ns, n=15, N=3, Fig 2.12A;
Ca2+ depletion: DAPI normalized MFI untreated = 0.8866 ± 0.02859 vs. pervanadate = 0.8737 ±
0.03953, ns, n=15, N=3, Fig. 2.12A). The degree of change in Tyr phosphorylation in response to
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pervanadate treatment was determined by IP of Cx45 and Western blotting with a general pTyr
antibody (Fig. 2.12B). We found that treatment with pervanadate increased the amount of Cx45
total Tyr phosphorylation by 3.38-fold (pTyr: Cx45; untreated = 0.05023 ± 0.00776 vs. pervanadate
= 0.1698 ± 0.0439, P <0.05, N=3). Our data in indicate that increased Tyr phosphorylation does
not alter Cx45 hemichannel mediated dye uptake. The data also demonstrates that pervanadate
did not alter the requirement for Ca2+ depletion to open Cx45 hemichannels. Finally, we sought to
confirm that our dye uptake was mediated by Cx45 hemichannels rather than some other
membrane channel protein and we used the GJ hemichannel blocker La3+ to inhibit hemichannel
channel activity. Confirming our dye uptake was mediated by Cx45 hemichannels, treatment with
La3+ reduced dye uptake to levels similar as seen when normal Ca 2+ bathing solution was used
(DAPI normalized MFI WT = 0.6272 ± 0.0275, WT + pervanadate = 0.7102 ± 0.0664, 6E = 0.6462
± 0.0440, ns, n=15, N=3, Fig 2.12A). Taken together with the scrape loading experiments our data
indicate 6E hemichannels and channels are permeable to NB, albeit channel permeability appears
reduced relative to Cx45 WT. Furthermore, when correlated with the TX-100 solubility assay data
the differences in NB transfer (hemichannels-higher, channels-lower) are consistent with the
location of Cx45 (hemichannels vs. GJ channels; i.e., less Cx45 in the GJ correlates with increased
hemichannel activity).
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Figure 2.13. Inhibiting Cx45CT dimerization affects hemichannel dye uptake.
A) MDCK cells stably expressing Cx45 WT or 6E were subjected to conditions that activate hemichannels
activity (Ca2+ deprivation) and the level of NB uptake was measured. Representative fluorescent micrographs
of cells loaded with NB and probed with streptavidin-647 conjugate (red). Quantification of DAPI (blue)
normalized mean fluorescent intensity (MFI) from 3 replicates, 15 random 100X FOVs were acquired per
replicate. Statistics are one-way ANOVA with a Newman-Keuls multiple comparison test (***P<0.0001 relative
to +Ca2+ within same group, ^ and ^^^P<0.05 and <0.0001 respectively, relative to −Ca 2+ within same group;
###P<0.0001 between −Ca2+ treatment groups; •••P<0.0001 compared to WT + pervanadate). Scale bar =
50 μm. B) MDCK cells expressing Cx45 WT were treated with 100 μM pervanadate for 15 min, captured by
IP with α-Cx45, analyzed by Western blot (left), and quantified using ImageJ (right). Data presented as the
mean + s.e.m. of three independent experiments. Statistical analysis was done using a one-tailed unpaired
Student’s T-Test (P< 0.05). This figure was modified from Trease et al., (2017).
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7.8 Cx45CT Dimerization Reduces Hemichannel Currents
Since we observed increased hemichannel mediated dye uptake in our stable MDCK cell
lines it is important to note that dye uptake/transfer does not always correlate with current
conductance due to issues with permselectivity [445]. To determine if our increase dye uptake
coincided with increased hemichannel currents we measured the macroscopic conductance of
Cx45 WT and 6E channels expressed in Xenopus oocytes by cell attached electrophysiology.
Identical amounts of Cx45 WT or 6E cRNA were injected into oocytes, together with DNA antisense
to the endogenous XenCx38. After voltage clamping the oocytes, hemichannel opening was
induced by successive depolarizing voltage steps followed by measurement of the macroscopic
conductance (Fig. 2.13). In congruence with our hemichannel dye uptake results we determined
that inhibiting dimerization greatly increased hemichannel currents Furthermore, it was determined
that initial rate constants for the transition from the closed state to the open state was increased for
6E channels as compared to WT. The results illustrated are representative of data from multiple
injected oocytes (WT, n=8; 6E, n=4). Importantly, these data clearly illustrate 6E channels are
functional, and mediate a much greater degree of current flow that Cx45 WT channels under
identical stimuli, it is unclear at this time whether this increase observed in the 6E hemichannels is
the result of a single factor or several. Possible explanations include: the greater degree of “soluble”
plasma membrane expression, shifted Po-V relationships, or increased unitary conductance.
Although it requires further investigation, it is likely to be determined that a combination of these
factors result in the greatly enhanced hemichannel currents (and dye uptake) seen with 6E
channels.
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Figure 2.14. Inhibiting Cx45CT dimerization affects hemichannel currents.
Oocytes injected with equal amounts of cRNA coding for Cx45 WT or the 6E mutant were voltage clamped
and hemichannel currents elicited by large depolarizing voltage steps from −50 to +80 mV in 10 mV increments
from a holding potential of −80 mV. A) Representation of voltage protocol. Under the same voltage protocols,
the WT channels mediated substantially less current than the 6E channels. Representative current plots from
(B) WT and (C) 6E expressing oocytes. This figure is reprinted from Trease et al., (2017).

88

7.9 Cx45CT Dimerization Enhances Tyrosine but Not Serine Phosphorylation
Amongst most Cxs it has been shown consistently that changes in phosphorylation level
affect GJIC [86, 306, 340, 385]. The effect has been shown via a number of mechanisms including
affecting trafficking, GJ plaque stability, modulating protein partner interactions, altering turnover,
or directly modulating channel properties such as open probability or conductance state [306, 309,
446]. Consequently, we hypothesized inhibiting dimerization would impact total levels of Cx45
phosphorylation and may in part influence the 6E phenotype. We therefore used IP to selectively
concentrate either Cx45 WT and 6E from our stable MDCK cells and probed the eluted Cx45 by
Western blot with either a general pTyr antibody (Fig. 2.14A) or pSer antibody (Fig. 2.14B). We
determined that the basal level of Tyr phosphorylation of 6E was ~2.28-fold (N=3,P <0.001; WT
0.8635  0.69 vs. 6E 1.971  0.217) greater than that of Cx45 WT. Conversely, we did not observe
a significant change in Ser phosphorylation from Cx45 6E to WT. Importantly, due to the lack of
phosphospecific Cx45 antibodies we were unable to determine the locations of phosphorylated
residues and therefore the possibility exists that for Tyr phosphorylation both an increase in the
degree of phosphorylation as well as an alteration of the residues phosphorylated may exist, while
for Ser phosphorylation only the possibility of alterations to the location of phosphorylated residues
exists.
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Figure 2.15. Inhibiting Cx45CT dimerization increases Tyr but not Ser
phosphorylation.
IP was used to selectively concentrate Cx45 WT and 6E from MDCK cell lysate and probed
for total levels of phosphorylation. A) Representative Western blot and quantification of Tyr
phosphorylation using a general pTyr antibody. B) Representative Western blot and
quantification of Ser phosphorylation using a general pSer antibody. Data presented as
mean fold change + s.e.m. relative to the first WT replicate. Statistics are two-tailed unpaired
Student’s T-test. (n=3, ** P<0.01). This figure is modified from Trease et al., (2017).
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7.10 Cx45CT Dimerization Affects Cytoskeletal Adapter Protein Partner Interactions
Our data indicating the 6E expressing cells contain a reduced number of docked GJ
channels, increased overall plasma membrane expression and altered localization combined,
strongly suggest trafficking to, at, or away from the GJ plaque is altered. Furthermore, consistent
with our observation of increased Tyr phosphorylation of the 6E, trafficking of Cx43 is also affected
by changes in Tyr phosphorylation. Work from our laboratory and others demonstrated that
phosphorylation of Cx43 by Src kinase disrupts microtubule binding (β-tubulin) and anchoring to
the actin cytoskeleton Drebrin and ZO-1 [286, 377, 378]. To determine if the increased Tyr
phosphorylation observed for 6E correlated with altered cytoskeletal anchoring we used IP of Cx45
WT or 6E and Western blot to detect β-tubulin, Drebrin, and ZO-1 in the eluate (Fig. 2.15).
Compared to Cx45 WT we observed a significant increase in the amount of pulled-down Drebrin
(~1.97-foldP <0.01; WT 0.9005  0.104 vs. 6E 1.753  0.138; Fig. 2.15B), a significant decrease
for β-tubulin (~5.17-foldP <0.0001; WT 0.6095  0.079 vs. 6E 0.1180 0.043; Fig. 2.15A) and nonsignificant albeit trending decrease in the association with ZO-1 (~1.45-fold ns; WT 1.173  0.199
vs. 6E 0.8103  0.184; Fig. 2.15C). Taken together with our phosphorylation data, these results
suggest that the phenotypic difference between Cx45 WT and 6E may be in part the result of altered
cytoskeletal interactions.
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Figure 2.16. Loss of Cx45CT dimerization alters cytoskeletal anchoring.
MDCK cells stably expressing Cx45 WT or 6E were cultured, lysed, and enriched by IP to
assess interactions with β-tubulin, Drebrin, and ZO-1. A) Representative Western blots of
eluted Cx45 WT or 6E blotting against β-tubulin (n=7, ***P<0.001), B) Drebrin (n=3, **P<0.01),
and C) ZO-1 (n=3, ns) pulled-down by IP of either Cx45 WT or 6E. Data presented as mean
fold change + s.e.m. relative to the first WT replicate. Statistics are two-tailed unpaired
Student’s T-test. This figure is modified from Trease et al., (2017).
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7.11 Inhibiting Cx45CT Dimerization Disrupts Nedd4 but Not TSG101 Interactions
In addition to altered plasma membrane localization, we observed a significant increase in
the total expression of Cx45 6E compared to WT that could not be explained by altered synthesis
but rather impaired degradation (see Fig. 2.8). It is possible altered interactions with proteins
involved in turnover and recycling of Cxs could result in the increase in 6E protein expression. For
Cx43 a number of studies have highlighted the role of Nedd4, an E3 ubiquitin ligase, as an
important regulator of turnover at the plasma membrane [203, 204, 447]. While intracellularly,
TSG101 regulates trafficking of Cx43 to lysosomes or segregation for recycling back to the plasma
membrane [448]. Additionally, previous work from our laboratory demonstrated a direct interaction
via NMR between the Cx45CT domain and the WW2 domain of Nedd4 and the UEV domain of
TSG101 [247]. We therefore reasoned Cx45CT dimerization may influence the interaction with
these proteins. To test this, we used IP to concentrate Cx45 WT and 6E from MDCK cells and
Western blotted for Nedd4 and TSG101 (Fig. 2.16). Compared to Cx45 WT, we determined 6E
pulled-down significantly more Nedd4 (~2.05-fold P <0.01; WT 1.088  0.085 vs. 6E 0.5297  0.086;
Fig. 2.16A) and a comparable amount of TSG101 (Fig. 2.16A). The data, consistent with the CHX
chase, suggests that the increase in 6E protein expression is likely the result of impaired turnover
through decreased association with the E3 ligase Nedd4. Our data also suggests that altered
recycling or trafficking to the lysosome is not a contributor to the phenotype.
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Figure 2.17. Inhibiting Cx45CT dimerization correlates with decreased associated
of Nedd4 but not TSG101.
MDCK cells stably expressing Cx45 WT or 6E were cultured, lysed, and captured by IP to assess
interactions with Nedd4 and TSG101. A) Representative Western blots of the IP of Cx45 WT or 6E
blotting with against A) Nedd4 (n=3, **P<0.01) and B) TSG101 (n=3; ns) pulled-down by either Cx45
WT or 6E. Data presented as mean fold change + s.e.m. relative to the first WT replicate. Statistics
are two-tailed unpaired Student’s T-test. This figure is modified from Trease et al., (2017).
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7.12 The Cx45CT A333-N361 Contains a Potential CaM IQ Motif
Another protein known to regulate channel closure for Cxs is CaM [239]. Work from a
number of laboratories including our own, have identified CaM binding sites in the Cx43 CL and CT
domains (Sorgen Laboratory, unpublished data; [238, 246]). Previously, we demonstrated a direct
interaction of CaM with the Cx45CT domain over residues (Y275-P288 and T302-N314) [247]. We
posited that CaM may serve a similar function for Cx45 and sought to determine if there were
additional CaM binding sites in Cx45. Using the online bioinformatics resource Calmodulin Target
Database Binding Site Search and Analysis tool (http://calcium.uhnres.utoronto.ca/ctdb/ctdb/sequence.html),
we scanned the full-length Cx45 sequence as well as the isolated CL and CT for additional potential
CaM binding sites (Fig. 2.17). The analysis suggests that potential CaM binding sites exist in both
the Cx45 CL and CT. Interestingly, when analyzing our isolated CL sequence, no CaM binding
motif was identified, but one was identified for the CL in the full-length sequence, suggesting that
sequence information contained outside the CL was essential for prediction. Furthermore, the
region identified as a direct interaction with the Cx45CT by NMR was not identified by motif
prediction either. Focusing the on the CT domain we determined the predicted motif was an IQ type
([FILV]Qxxx[RK]Gxxx[RK]xx[FILVWY]; underlined in Fig. 2.17), and furthermore determined that
our 6E mutations eliminated the motif by mutating the first essential bulky hydrophobic residue to
Glu (L338E). As the dimerization domain of Cx45 is not amenable to NMR interaction studies as
conditions that disrupt dimerization would disrupt most interactions, we decided to modify an
existing calcium flux sensing tool (GCaMp2) to meet our needs. GCaMp2 is a second-generation
calcium sensor that uses a fusion protein of the canonical CaM binding protein domain (M13
domain of myosin light chain kinase), CaM, and a (cyclically) modified eGFP to produce fluorescent
signal in response to CaM binding to M13 in the presence of Ca2+ [449]. We modified this construct
to replace the M13 domain with the dimerization domain region (A333-N361) of either Cx45 WT or
6E. After creating stable expressing MDCK cells we used live imaging to determine if each protein
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Figure 2.18. In silico prediction of Cx45 CaM binding motifs.
Full length Cx45 (mouse) as well as the CL and CT domains in isolation were
analzyed by the Calmodulin Target Database Binding Site Search and Analysis
tool for putative CaM binding motifs. Areas highlighted in red are predicted CaM
interaction motifs, residues within the motifs that are mutated in Cx45 6E are bold
and underlined. http://calcium.uhnres.utoronto.ca/ctdb/ctdb/sequence.html

96

possessed Ca2+ responsiveness as a method to interpret CaM binding to the domain. We used the
original GCaMp2 (M13) as positive control for the experiment. To accomplish the assay cells were
seeded in live imaging dishes in phenol free DMEM and maintained at 37°C 5% CO2 for the duration
of the experiment. Images were acquired every 5 s for 3 min, the dishes were then treated with 15
µM of the Ca2+ ionophore, Ionomycin, and images were acquired for an additional 3-5 min in 5 s
intervals. Addition of ionomycin to the control GCaMp2 expressing cell resulted in an acute sharp
increase in MFI that returned to baseline rapidly (Fig. 2.18). For both Cx45 WT and 6E, addition of
the ionomycin did not result in any appreciable increase in MFI (Fig. 2.18). The data indicates the
A333-N361 region of Cx45—although predicted to bind CaM—does not, and furthermore mutation
to the 6E does not alter this. Altogether indicating that differential CaM binding is not a factor which
contributes to the 6E phenotype.
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Figure 2.19. Cx45CT A333-N361 does not bind CaM.
MDCK cells were stable transfected with A) LCK-GCaMP2, B) WT-GCaMP2, or C) 6E-GCaMP2,
clonally selected and live imaged. To assess CaM binding eGFP fluorescence (green) images were
acquired every 5 s for 8 min. After 3 min of baseline acquisitons the dishes were treated with 3 µM
ionomycin to activate CaM. The mean fluorescent intensity of eGFP was recorded throughout.
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8. Discussion
Previous work from our laboratory revealed that the Cx45 family member has a unique
structural feature compared to other family members, high affinity dimerization (KD ~100 nM) [247].
This dimerization was mediated by the region comprised of residues A333-N361, which are highly
conserved (72.4%) across several species including mouse, rat, hamster, chicken, dog, and
human. In fact, 5/6 of the critical hydrophobic residues are identical in all orthologs and the other
highly conserved (Fig. 2.19). Based on results of a protein BLAST search with Cx45CT residues
A333-N361 as the query, limited to comparisons within the human genome, no significant homology
to any other protein exists, demonstrating this sequence and structure is unique to Cx45. The
importance of protein binding interactions to the regulation of other CxCT domains (especially that
of the Cx43CT) suggests that this interaction between Cx45CT domains, in part, influences the
unique channel properties of Cx45 GJs. Furthermore, it is reasonable to posit that inhibition of this
dimerization would also modulate Cx45 channel properties and function. From our studies
contained herein, the inferred effects we observed through inhibiting dimerization include:
increased protein at the plasma membrane due to inhibited degradation, decreased plaque
formation, increased hemichannel activity, retained regulation by Ca +2, increased Tyr
phosphorylation, decreased interaction with β-tubulin and Nedd4, increased interaction with
Drebrin, maintained interaction with ZO-1, and increased macroscopic currents.
Very few studies have characterized the functional role of the Cx45CT domain, and many
were limited to a context in which Cx43 was co-expressed. In one such study, chicken Cx45 WT
and CT truncation mutants (deletion of either the last 34 or 37 residues) were exogenously
expressed in rat osteosarcoma cell line (ROS) which endogenously expresses Cx43 [450]. In each
circumstance, the Cx45 WT or mutants were transported to the plasma membrane and the Cx45
WT and Δ34 displayed a punctate staining pattern reminiscent of what we show for Cx45 WT,
however, the Cx45 Δ37 displayed a more linear distribution about the plasma membrane [451].
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Figure 2.20. Sequence alignment of the Cx45CT dimerization domain (A333-N361) from
different species.
Sequence alignment of the A333-N361 region using Clustal Omega to all available Cx45 RefSeq
sequences revealed a high degree of conservation within this region, with 72.4% identical, 20.6%
conserved, and 6.9% non-conserved residues. For clarity, the sites of point mutations in the Cx45 6E
construct are indicated by the single letter code above the alignments. Degree of site conservation
(excluding Cx45 6E mutations) is indicated at the bottom, * = identical, : and . = high conservation and
intermediate conservation, respectively. Reprinted from Trease et al., (2017).
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Notably, neither truncation deleted any of the critical hydrophobic residues previously
shown to be involved in CT dimerization. One important difference between the two mutants was
the ability to co-IP ZO-1, which was inversely correlated with TX-100 solubility (Cx45 Δ37 did not
co-IP ZO-1 and was more TX-100 soluble) [451]. The authors suggested the lack of association
with ZO-1 may have prevented Cx45 Δ37 from being pulled from lipid rafts, and that WT Cx45 may
have a complex extended binding with ZO-1 or may harbor two smaller binding sites [451]. Previous
work from our laboratory using the CT domain of mouse Cx45 did not observe an extended
interaction of the Cx45CT with the PDZ2 domain of ZO-1, when compared to the binding of Cx43CT
[247, 286]. However, without being able to follow the resonances of the Cx45 dimerization domain
the possibility still exists that complex binding with ZO-1 occurs.
We observed a similar phenotype with the 6E, such that changes in the association with
the cytoskeleton (decreased association with β-tubulin and conversely increased association of
Drebrin) and proteins involved in Cx degradation (decreased binding of Nedd4) correlated with
altered membrane localization, GJIC, and preferential segregation into TX-100 soluble pools. Other
studies utilizing truncated forms of Cx45 highlight possible functional regulation mediated by the
Cx45 CT domain, however, whether dimerization of the Cx45CT domain in these studies is a
contributing factor is not clear. The aspects investigated in these studies include regulating GJ
conductance, channel permeability, and the ability of Cx45 to interact with Cx43 [189, 450, 452,
453]. Koval et al. demonstrated that Cx45 Δ37 enhanced communication of larger tracer dyes [450].
The same study also demonstrated that Cx45 channels are more selective of being the dye
recipient cell than the dye donor cell compared to the truncated mutant when forming heterotypic
GJs with Cx43 [450]. Similar to Koval et al., the Laing et al. study observed increased dye coupling
of for the Cx45 Δ37 as well as the Cx45 Δ34 mutant, compared to WT Cx45 [450, 451]. We similarly
observed a decrease in the co-IP of ZO-1 with Cx45 6E compared to WT (albeit non-significant)
which correlated with increased TX-100 solubility, lending support to Laing’s hypothesis [424, 451].
A difference we observed was the impaired communication of 6E [424]. Notably, from the results
of the Kopanic et al. study, truncation of the CT at residues c-terminal to the critical Y356 would be
expected to increase dimerization affinity between CTs due to decreased intrinsic disorder (as was
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seen with the A333-N361 peptide) [247]. Taken together with the observation of increased dye
coupling in the ROS cells with Cx45 truncations (increased dimer strength = increased
communication), this further supports our hypothesis that dimerization is essential for Cx45
coupling. An interesting finding was that expression of the Cx45CT domain together with a Cx43
mutant truncated after the 4th transmembrane domain could not restore pH sensitivity to Cx43CT
truncated channels, while co-expression of the Cx40CT could [229]. Another important result of the
truncation studies is that if the Cx45CT was used to replace that of either Cx43 or Cx40 (i.e., Cx43Cx45CT or Cx40-Cx45CT), they failed to form functional channels [453]. Potentially highlighting, a
critical effect of Cx45CT dimerization.
Many aspects of Cx regulation involve phosphorylation of the intracellular domains [308,
326-328]. The addition of a strong negative charge arising from the phosphate group has been
shown to affect the channel permeability to ions, influence the structure and positioning of the
transmembrane domains thereby altering pore size, or modulate the affinities of the extensive
number of protein partners which regulate Cxs. Importantly, if phosphorylation affects the rate of
either channel assembly/trafficking or turnover/degradation (e.g., Nedd4; [203, 204, 447]), GJIC
will be impacted. A limited number of studies have focused on determining how phosphorylation
regulates Cx45. Phosphoamino acid analysis of Cx45 identified phosphorylation of Cx45 Ser, Thr,
and Tyr residues [189]. Furthermore that same study determined that deletion of the final 26
residues of the Cx45 CT (containing 9 Ser) greatly reduced phosphorylation [189]. A few studies
have explored differences and similarities in the regulation of Cx45 and Cx43 by Ser
phosphorylation and highlight little conservation of effect. For example, PKA activation by
stimulation with the cAMP analogue, 8-Br-cAMP, reduced the junctional conductance of Cx45
channels while increasing that of Cx43 [306, 454]. This was in contrast to activation of protein
kinase G (PKG) by 8-Br-cGMP which was shown to have little-to-no effect on conductance of Cx45
channels, but severely impaired Cx43 junctional conductance [306, 454]. In two studies, activation
of PKC by the phorbol ester PMA was shown to decrease Cx43 junctional conductance [86],
however, the same studies show conflicting results for Cx45 with an increase in conductance in
one [306] and decreased in the other [86]. Of note, in the Martinez et al. [86] study, decreased
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junctional conductance of the Cx45 channels did not correlate with decreased transfer of the tracer
NB through Cx45 channels, although it did correlate with decreased NB transfer through Cx43
channels. Finally, phosphorylation of Cx45 unlike that of Cx43 did not alter the single channel
conductance of Cx45 (22 pS and 42 pS) (35). The authors suggesting phosphorylation affects the
open probability of Cx45 GJ channels [306], however, taken together with the decreased junctional
conductance and unaffected NB transfer it may be more likely channel permselectivity is altered.
Despite a number of differences in the regulation of Cx45 and Cx43 by Ser
phosphorylation, a commonality exists in the regulation of junctional conductance by pervanadate.
Through direct inhibition of Tyr phosphatases, pervanadate indirectly promotes increased Tyr
phosphorylation of the CT domain of both Cx43 and Cx45 subsequently impairing GJIC [306, 455,
456]. It is, however, unclear whether the mechanism(s) (e.g., altered localization vs. open
probability) that achieve this are the same. An example suggesting they may differ is Cx43 in cells
treated with pervanadate localizes intracellularly [457], conversely we observed that Cx45 is still
localized at the plasma membrane. A likely explanation for this is the only established Tyr kinases
that phosphorylate Cx43 (Src and Tyk2; residues Y247, Y265, and Y313) disrupt Cx43 cytoskeletal
anchoring by directly displacing β-tubulin and Drebrin [377, 378]. Unlike Tyk2, Src also indirectly
displaces ZO-1 by competing for PDZ2 domain binding titrating ZO-1 away from Cx43 [377, 378].
Conversely to Cx43, the CT of Cx40 is capable of simultaneously interacting with Src and ZO-1
[285]. Displacement of Cx43 from the microtubules and actin cytoskeleton would explain the
observed intracellular localization of Cx43. In our study, although Tyr kinases were not identified,
increased basal Tyr phosphorylation of 6E correlated with a decreased (albeit not statistically
significant) interaction with ZO-1 (actin) and β-tubulin (microtubules), increased association with
Drebrin (actin), and a decreased interaction with Nedd4. Consistent with previous literature reports,
our results further implicate ZO-1 in the regulation of GJ plaque size and accretion [458, 459], and
supports the notion that β-tubulin is essential for plaque formation [167, 460, 461] while Drebrin
stabilizes Cxs present at the appositional membrane [378, 379]. These studies in conjunction with
our findings would explain how pervanadate had no effect on Cx45 hemichannel activity in either
the presence or absence of Ca+2.
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Cell-cell coupling in healthy adult ventricular GJs primarily consists of Cx43, however, in
end-stage heart failure or the epicardial border zone after infarct, remodeling of Cx43 (decreased
expression and lateralization) sets the stage for an arrhythmic substrate. The remodeling of Cx43
although well tolerated, when coupled with aberrant upregulation of Cx45 expression (normally
very low in adult ventricles) greatly enhances propensity for lethal arrhythmias [83, 431, 462]. It is
likely this is in part mediated by the restrictive electrical properties of Cx45 channels (low
conductance, high voltage-sensitivity), and the fact that heteromeric Cx45/Cx43 channels are more
similar in electrical properties to Cx45 homomeric channels than that of Cx43 [463]. A number of
studies have highlighted the tendency for Cx45/Cx43 heteromeric channels to elicit properties
indicative of a dominant negative effect of Cx45 on Cx43 [31, 82, 86, 452, 464]. Furthermore, with
the dimerization of Cx45CT occurring prior to channel oligomerization in the TGN, it is likely that
stoichiometry within heteromeric GJ channels would favor incorporation of a minimum of two Cx45
subunits. Whether this is enough to exert the dominant negative effect remains to be explored but
depending the on the subunit arrangement it would not be unexpected for the dimerization of the
Cx45CT to exert some steric force on the transmembrane domains potentially altering pore
structure/diameter. Unfortunately, little work has been done to explore how the unique properties
of Cx45 channels make its expression in the ventricles detrimental. Based on our findings in this
study, Cx45CT dimerization is a structural feature essential to proper Cx45 function. Future studies
should focus on determining exactly what regulatory role(s) are mediated by Cx45CT dimerization,
especially if Cx45 dimerization is a key contributor to the dominant negative effect on Cx43-Cx45
heteromeric channels and whether it controls stoichiometry and subunit arrangement. Furthermore,
it should be investigated how kinases and specific CT binding partners that regulate Cx43 also
Cx45 function.
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CHAPTER THREE

Chimeric Cx45 Proteins Confirm
Cx45CT Dimerization Regulates
Localization, Hemichannel
Activity, and GJIC
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9. Introduction
In Chapter Two, we used a mutant of Cx45 which abolished CT domain dimerization
through the replacement of six hydrophobic residues with six Glu residues [424]. The absence of
dimerization in that context suggested that dimerization was a key structural element required for
the proper function of Cx45. Loss of dimerization correlated with increased plasma membrane
localization, hemichannel activity (dye uptake and macroscopic currents), and basal Tyr
phosphorylation, as well as decreased turnover, GJ plaque formation, and GJIC (measured by dye
coupling). Altered cytoskeletal interactions via Drebrin, β-Tubulin, and ZO-1 were also observed.
While the data offers a suggestive link between CT dimerization and channel function, a few
important questions remain. Was the phenotype in part mediated by altered charge of the CT (net
charge Cx45 WT = -1 vs. 6E = -7; pI Cx45 WT = 6.97 vs. 6E = 6.16)? Are there sequence or
structure specific features of the dimerization domain or is the requirement simply for a dimer?
The current link between CT dimerization and GJ function is, however, only correlative at
this point. This is more complex when the CT domain of the cardiac Cxs were swapped [453]. By
replacing the CT domain of either Cx43 or Cx40 with that of Cx45 GJs were rendered non-functional
[453]. Furthermore, replacement of the Cx45CT domain with the CT of either Cx43 or Cx40 resulted
in GJs that functioned comparable to WT, albeit GJ plaque size was altered [453]. Interestingly,
truncation of Cx45 at position 272 resulted in channels that failed to traffic properly, while the Cx45Cx43CT or Cx45-Cx40CT mutants trafficked normally, which suggests that for Cx45 channels a
CT domain is essential to proper trafficking [453]. Taken together this also suggests that Cx45CT
dimerization may be essential for Cx45 function in the context of its own CT domain. In order to
further investigate this we sought to use alternative modifications to the Cx45CT to modulate
dimerization. In this Chapter, we use a combinatorial approach of biophysical, cell biology, and
biochemical studies with chimeric, deletion, and scrambled Cx45 constructs to address these
questions more directly. Similar to what we observed by inhibiting the dimerization with the 6E
mutant, we observed increased membrane localization, TX-100 solubility, and hemichannel dye
uptake in all mutants that disrupted dimerization. For mutants that maintained dimerization, we
observed punctate GJ localization and GJ plaque formation (TX-100 insolubility) that were
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comparable to Cx45 WT. To our surprise when we assessed GJIC by scrape loading we observed
variable results suggesting a more complex mechanism regulates Cx45 coupling.
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10. Materials and Methods
10.1 Expression and Purification of Recombinant GST-tagged Proteins
Constructs designed for this project are summarized in Table 4. Cx45CT WT and mutants
were expressed and purified as previously described [247].
10.2 Analytical Ultracentrifugation (AUC): Sedimentation Equilibrium
AUC experiments were performed as previously described with minor modifications [247].
Briefly, purified recombinant proteins were buffer exchanged (if necessary) into 1x PBS pH 7.4
using a Nap 5 (GE Healthcare) column per manufacturer directions. Proteins were then loaded into
either an AN-50Ti or AN-60Ti rotor (Beckman Coulter; Indianapolis, IN) at three concentrations
(Abs280 nm of 0.5, 0.7, and 0.9) and speeds (15,000, 18,000, 21,000, and 24,000 RPM).
Sedimentation equilibrium experiments were performed at ether 7°C or 20°C with a Beckman
Optima XL-I analytical ultracentrifuge. Data were collected at various rotor speeds. Absorbance
scans at 280 nm were acquired after 12 hr, 14 hr, and 16 hr at each speed; attainment of equilibrium
was confirmed by overlay of all four time points. Analysis of the sedimentation equilibrium data was
performed using the

Beckman XL-A/XL-I software package ORIGIN

v6.0.

Sednterp

(http://www.rasmb.bbri.org) was used to calculate the buffer viscosities and densities as well as the
partial specific volume for each protein based on the primary sequence.
10.3 Circular Dichroism (CD): Secondary Structural Analysis
CD experiments were performed as described previously [247]. Briefly, data was collected
with a Jasco J-815 spectrophotometer with a Peltier temperature control system (Easton, MD).
Spectra for the protein samples were acquired in 1x PBS pH 7.4. For each sample, 5 scans
(wavelength range: 190–250 nm; response time: 1 s; scan rate: 50 nm/min; bandwidth 1.0 nm)
were collected using a 0.01 cm quartz cell and processed using Spectral Analysis (Jasco). Spectra
are presented as the averaged change in molar residual ellipticity (MRE; degree cm2 dmol−1) over
wavelength following buffer subtraction. Protein concentrations were determined using a NanoDrop
1000 (Thermo Scientific; Wilmington, DE) at 280 nm.
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Protein

Source of Chimeric Region

Cx45 WT

NA; Wild-type, K265-I396

Cx45 6E

NA; L335/L338/I342/L349/I353/Y356E

Cx45 DDSc

NA; A333-N361 randomly scrambled

Cx45 GCN4LZ

S. cerevisiae GCN4 R249MKQLEDKVEELLSKNYHLENEVARLKKLVGER281TS
(plus TS linker)

Cx45 BsubVD

E. coli F1/F0 ATP Synthase V25WPPLMAAIEKRQKEIADGLASAERAHKD53

Cx45 BsubAA

E. coli F1/F0 ATP Synthase A31AIEKRQKEIADGLASAERAHKDLDLAKA59

Cx45 ΔDD

NA; Deletion of Cx45CT A333-N361

Cx45 40MD

R. norvegicus P306EEGFIHTQYGQKPEQPSGAS326

Cx45 43MD

R. norvegicus Cx43 F335DFPDDNQNAKKVAAGHELQPLAIVDQR362

Table 4. Source of homologous and heterologous Cx45 mutants.
NA – not applicable (source is M. musculus Cx45)
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10.4 Cell Culture and Stable Cell Line Generation
MDCK cells (gift from Dr. Paul Lampe, Fred Hutchinson Cancer Center were cultured in
Dulbecco’s modified Eagle medium (Corning) at 37°C in a humidified 5% CO 2 atmosphere. Medium
was supplemented with 10% FBS (Seradigm), 2 mM L-glutamine (HyClone), 1% pen-strep
(Corning), and 0.2% Normocin (Invivogen). The selective agent puromycin (Tocris) was used, when
appropriate, at empirically determined concentrations. 70% confluent MDCK cells were lipofected
with indicated SalI linearized plasmid using MDCK Avalanche (MDCK; 2.5:3.5) in OptiMem.
Transfections were carried out under antibiotic free conditions, and cells were cultured 48-72 hr
prior to addition of selection media. MDCK were selected with 5 µg/mL. Cells were clonally
(monoclonal)

selected

using

Whatman

paper

cloning

disks.

Western

blots

and

immunofluorescence were used to screen clones.
10.5 Antibodies and Immunostaining
All primary and secondary antibodies, detection reagents and concentration ranges utilized
are summarized in Table 2. Cells seeded on glass coverslips were rinsed 2x with 1x PBS and then
fixed and permeabilized with either ice cold methanol at -20°C for 15 min or buffered formalin (1x
PBS, 3.7% formaldehyde, 0.3% TX-100) at 37°C for 30 min. Coverslips were washed 3x 5 min in
1x PBS with gentle agitation and then blocked for 60-90 min at 37°C (1x PBS containing 1% BSA
and 0.3% TX-100). Coverslips were then incubated with the indicated primary antibodies diluted in
blocking buffer for either 1 hr at RT or ON at 4°C. Coverslips were washed 3x with 1x PBS and
then incubated with secondary antibody (if necessary) 1 hr at RT and then washed 1x for 5 min
with 1x PBS containing 100 ng/mL DAPI and then 2x 5 min with 1x PBS. Coverslips were mounted
with SlowFade (LifeTech) and sealed with clear nail polish and imaged. All images acquired on
either a Zeiss 710 or 800 LSM microscope.
10.6 Cell Lysis for Direct Western blot
Cultured cells were rinsed 2x with 1x PBS and then incubated with protease inhibitor buffer
(PIB; 1x PBS containing 1x Roche Complete + EDTA, 2 mM PMSF, 2 mM Pepstatin A) on ice for
20 min and then harvested with a cell scraper. Cell suspensions were pelleted at 1500 RPM for 5
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min at 4°C. PIB was removed and cell pellet resuspended in an appropriate volume of lysis buffer
(PIB + 1% TX-100, unless otherwise specified), mechanically lysed and incubated on ice for 30
min. Lysates were quantified by BCA and normalized with lysis buffer. 30 μg of total protein lysate
(unless otherwise indicated) was resolved.
10.7 Western blot
Protein samples were resolved by SDS-PAGE with an appropriate gel concentration,
transferred to PVDF (Millipore), blocked either 2 hr at RT or ON at 4°C with either 5% non-fat
milk/PBST or 5% BSA/TBST and incubated with indicated primary antibody in blocking buffer either
1 hr at RT or ON at 4°C. Blots were washed 3x for 10 min with either PBST or TBST, and then
incubated for 1 hr at RT with secondary antibody. Membranes were then washed 4x 10 min each
with either PBST or TBST and detected using Signal West Femto kit (Thermo) per manufacturer
protocol and exposed to autoradiography film. Quantifications were done using NIH ImageJ
software using a minimum of three independent replicates.
10.8 Triton X-100 Solubility Assay
The TX-100 solubility assay was modified from a method described previously [412].
Briefly, MDCK cells grown in 10-cm dishes were washed with PBS and incubated in 1 mL PIB for
20 min at 4°C, harvested in the same buffer and gently pelleted. Supernatant was aspirated, and
cell pellet was resuspended in 1 mL of fresh PIB supplemented with 50 units of Benzonase and
mechanically lysed. Lysates were quantified by BCA and normalized. A total of 450 µL of cell lysate
was brought to 1% SDS with 10% SDS and reserved as total lysate. Another 450 µL was brought
to 1% TX-100 with 10% TX-100 in 1x PBS and incubated at 4°C for 30 min with agitation. The TX100 lysate was then separated into non-junctional (supernatant; soluble) and junctional (pellet;
insoluble) fractions by ultracentrifugation at 100,000 xg for 1 hr at 4°C. The supernatant was
carefully removed and retained as the soluble fraction. The pellet was solubilized in 500 µL of
solubilization buffer (1x PBS, 8 M urea, 2.5% SDS, 0.1 M DTT, 1x Roche complete + EDTA, 2 mM
PMSF, and 2 µM Pepstatin A). Volume normalized samples of total lysate (T), TX-100 soluble (S)
and TX-100 insoluble (I) portions were analyzed by Western blot. Soluble and insoluble fractions
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were quantified as a function of total lysate. Quantification was done using NIH ImageJ software
from three independent replicates.
10.9 Scrape Loading Dye Transfer Assay
Cells were scrape loaded as previously described [340]. Briefly, all buffers were prewarmed to 37°C prior to beginning the experiment. Stable expressing MDCK clones were seeded
on bovine plasma fibronectin (Sigma; 10 µg/mL) coated 35 mm live imaging dishes (CellStar).
MDCK cells were transfected with Cx43 siRNA with Lipofectamine RNAiMAX (LifeTech) according
to manufacturer protocol and then cultured for 48 hr prior to scrape loading. After transfection cells
were washed 1x with 1x PBS and then overlaid with dye tracer mix (1x PBS containing NB).
Scrapes were introduced using a fine edged micro-scalpel and incubated at RT for 1 min. Tracer
dye was gently washed away with 1x PBS and media was added and the cells returned to the
incubator to culture for 5 min to allow dye to transfer. Following the dye transfer period, the cells
were washed with 1x PBS containing 1 mM CaCl2 and 1 mM MgCl2 to stop dye spread. Coverslips
were then formalin fixed and stained as described above and imaged. 15 consecutive fields of view
were acquired per replicate.
10.10 Hemichannel Dye Uptake Assay
To assess hemichannel activity we modified the protocol described by [442]. Briefly, all
buffers were pre-warmed to 37°C prior to beginning the experiment. MDCK clones expressing
either Cx45 WT or 6E were seeded on glass coverslips were cultured to approximately ~90%
confluent. Some wells were pretreated with 50 µM carbenoxolone (CBX; AbCam) for 15 min prior
to Ca2+ washout and dye uptake. The presence of CBX was maintained during dye uptake. Cells
were rinsed 1x with HBSS + Ca2+/Mg2+ (LifeTech) and then 2x with HBSS – Ca2+/Mg2+ (LifeTech).
Cells were then incubated at 37°C with HBSS – Ca2+/Mg2+ containing NB (0.1 mg/mL; Vector labs)
for 10 min. Cells were then washed 2x with HBSS + Ca2+/Mg2+ to close hemichannels and GJs.
Cells were formalin fixed and stained with streptavidin 647 conjugate (LifeTech) and imaged.
Control cells were treated identically except all incubations were done in HBSS + Ca2+/Mg2+. 15
fields of view were acquired per sample.
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10.11 Statistical Analysis
All data were analyzed by using GraphPad Prism 5.0 and were presented as the mean +
s.e.m. Statistical analysis performed in GraphPad Prism 5.0 was either one-way ANOVA with a
Bonferroni post-test comparing all samples to either Cx45 WT or 6E. P-values <0.05 were
considered statistically significant.
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11. Results
11.1 Design of Cx45CT Chimeric Constructs
Since our previous study made use of a single dimerization incompetent Cx45 we sought
to design novel constructs that would either maintain or inhibit dimerization while assessing the
requirement for any Cx45 sequence specific regulatory roles of the A333-N361 region. To
accomplish this, we substituted Cx45CT A333-N361 with: a comparable helical dimer (Cx45CT
GCN4LZ, helical monomer (Cx45CT BsubVD and BsubAA), scrambled Cx45CT A333-N361 (Cx45CT
DDSc), unstructured monomeric homologous regions of Cx40CT (Cx45CT 40MD) and Cx43CT
(Cx45CT 43MD), and finally deletion of Cx45CT A333-N361 (Cx45CT ΔDD). A summary of the
chimeric proteins (source and sequence of substitution) is contained in Table 4. To determine if the
chimeric constructs would result in discernable interacting faces (i.e., hydrophobic or electrostatic)
the substituted residues were modeled using a helical wheel and Cx45CT A333-N361 was included
for reference (Fig. 3.1). For Cx45CT GCN4LZ, as expected, helical wheel modeling revealed a
substantial electrostatic face (blue colors Fig. 3.1) and validated the use of helical modeling for this
purpose [465]. Cx45CT BsubVD, BsubAA, and DDSc no major electrostatic or hydrophobic faces
were detected (Fig. 3.1). Cx45CT ΔDD, 40MD, and 43MD were not modeled as deletion of the domain
removes the structure, and the structures of both regions of Cx40 and Cx43 are published [231,
277].
11.2 Biophysical Characterization of Cx45CT Mutants
Following our helical wheel modeling of the Cx45CT mutants we next wanted to test their
ability to dimerize. To test this, we first expressed and purified Cx45CT WT, Cx45CT DDSc,
Cx45CT GCN4LZ, Cx45CT BsubVD, Cx45CT BsubAA, and Cx45CT ΔDD from E. coli (Cx43CT and
commercial lysozyme were used as purity comparisons; Fig. 3.2). Proteins (Cx45CT WT, Cx45CT
DDSc, Cx45CT GCN4LZ, Cx45CT BsubVD, Cx45CT BsubAA, and Cx45CT ΔDD) were then analyzed
by AUC sedimentation equilibrium at three concentrations (Abs 280 = 0.9, 0.7, 0.5) across of number
of rotor speeds (curves not shown). A summary of the results is contained in Table 5. For Cx45CT
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Figure 3.1. Helical wheel analysis of heterologous and scrambled Cx45 mutants.
The region corresponding to A333-N361 of Cx45 WT, heterologous, and scrambled homologous mutants
were modeled as α-helices and presented as a helical wheel projection. Blue colored residues are
electrostatic, green colored residue are bulky hydrophobic, orange represent small side chain, and red are
neutral.
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WT we observed similar mass and dimerization affinity as in [247]. For Cx45CT GCN4LZ, as
predicted, we observed the protein in a dimer conformation as indicated by an observed mass of
approximately 2-fold that of the calculated mass. Furthermore, the dimerization affinity (KD = 8.38
nM) was comparable to that of other GCN4 fusion proteins and mutants from [466]. We detected
Cx45CT DDSc, BsubAA, and ΔDD as monomers with observed masses similar to the calculated
mass (Table 5). Although we determined a monomeric conformation for Cx45CT DDSc and BsubAA
it is important to note that the observed masses are slightly below the calculated mass and therefore
indicate mild degradation. Similarly, we were unable to use the data for Cx45CT Bsub VD because
its observed mass indicated substantial degradation (data not shown). Interestingly, for Cx45CT
DDSc, although the observed mass is consistent with a monomer conformation the calculated
affinity for the monomer-dimer species was 211.39 µM (Table 5), which in the context of a connexon
would be present as a dimer (CT concentration approximately 25 mM in a connexon; [231]). The
affinities of Cx45CT BsubAA and ΔDD were calculated to be 1.45 M and 3.215 mM, respectively.
In addition to testing the mutant Cx45CT constructs for dimerization we determined the secondary
structure by circular dichroism (CD) spectroscopy (Fig. 3.3). Cx45CT WT (Fig. 3.3; black line) and
6E (Fig. 3.3; tan line) were included in the analysis as structure controls. For Cx45CT GCN4 LZ (Fig.
3.3; red line) were observed an increase in the helical character as compared to WT, indicated by
increased positivity in the maxima at 195 nm, and more negative minima at 208 and 222 nm. This
is not surprising as the length of the GCN4 substitution is 36 residues (Table 4) vs. 29 residues for
Cx45CT A333-N361. Our spectra of Cx45CT BsubVD and BsubAA, both indicated a loss of helical
character indicated by negative MRE values at 195 nm, and loss of the minima at 208 and 222 nm
(Fig. 3.3; blue and purple lines respectively). Despite this apparent loss in secondary structure,
both curves overlay with the Cx45CT 6E spectra (Fig. 3.3; tan line) and thus based on the Kopanic
et al. study, the loss of secondary structure is minimal [247]. As expected for the Cx45CT ΔDD
(Fig. 3.3; orange line), the spectra is consistent with deletion of the structured A333-N361 region.
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Figure 3.2. Purification of the CT domains of Cx45 WT and mutants.
The CT domain of Cx45 WT, Cx45 GCN4LZ, Cx45 BsubVD, Cx45 BsubAA,
Cx45 DDSc, and Cx45 ΔDD were cloned into the pGEX-KT vector, expressed
in E. coli, and purified as in (Kopanic et al. (2014). Resulting purity of proteins
were analyzed by SDS-PAGE. Cx43CT and commercial lysozyme were added
as purity controls.
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Protein

Mobs (kDa)

MCalc (kDa)

Conformation

KD

Cx45CT WT

31.098

15.006

Dimer

101.13 nM

Cx45CT GCN4LZ

32.068

15.713

Dimer

8.38 nM

Cx45CT DDSc

13.716

15.006

Monomer*

211.339 µM

Cx45CT BsubAA

12.802

14.647

Monomer

1.45 M

Cx45CT ΔDD

12.088

11.546

Monomer

3.215 mM

Table 5. Summary of observed mass and KD for Cx45 mutants.
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Figure 3.3. Circular dichroism spectra of Cx45CT WT and dimerization domain mutants.
The purified CT domains of the indicated Cx45 WT and mutants were analyzed for secondary structure by CD
spectroscopy from 250 – 190 nm. The curves are presented as mean residual ellipicity (MRE).
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11.3 Similar to Cx45 6E dimerization incompetent Cx45 mutants display increased plasma
membrane localization
To further investigate the functional consequences of inhibiting (or maintaining dimerization
Cx45 GCN4LZ and DDSc) we made full-length stable expressing MDCK cell lines of each mutant
Cx45CT construct. Similar to our characterization of Cx45 WT and 6E, we initially used
immunofluorescence as a tool to determine if localization was affected by the mutations in a manner
similar to the 6E cells (Fig. 3.4). Importantly, all the mutants trafficked to the plasma membrane,
indicating none of them were confined to intracellular compartments or suffer from misfolding and
ERAD [141, 142]. Similar to our results in the previous Chapter, for Cx45 WT we observed punctate
staining along the plasma membrane and intracellularly, and linear extended immunoreactivity of
the 6E. For both of the dimeric mutants (Cx45 DDSc and GCN4LZ) immunolocalization of the protein
was visually comparable to Cx45 WT, with punctate distribution along the plasma membrane and
intracellularly (Fig. 3.4). Similar to the 6E, the immunoreactivity for Cx45 BsubAA and ΔDD was
more linear and extended about the plasma membrane, with limited intracellular labeling (Fig. 3.4).
Interestingly, when we immunostained the Cx45 BsubVD mutant we observed an intermediate
localization phenotype, characterized by longer apparent GJ plaques than Cx45 WT but not as
extended as 6E. Furthermore, there was a large contribution from small intracellular puncta (Fig.
3.4). The immunolocalization of the mutants suggests dimerization is an important regulator of
Cx45 trafficking.
11.4 Loss of CT Dimerization Results in Decreased TX-100 Solubility
Following from our results in Chapter Two, we hypothesized that since we observed
increased plasma membrane trafficking of the dimerization incompetent mutants, they would
preferentially segregate into TX-100 soluble fractions. To test this, we lysed the MDCK cells
(excluding Cx45 DDSc) mechanically and then incubated in the presence of 1% TX-100 for 1 hr to
extract soluble proteins, and then fractionated the lysate by ultracentrifugation. Resulting total, TX100 soluble, and TX-100 insoluble fractions were then analyzed by SDS-PAGE and Western blot
(Fig. 3.5A). Using densitometry, five independent experiments were quantified and all mean values
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Figure 3.4. Immunofluorescence of Cx45 WT and mutants reveals altered plasma membrane
localization.
MDCK cells stably expressing Cx45 WT, Cx45 DDSc, Cx45 GCN4 LZ, Cx45 6E, Cx45 BsubAA, Cx45 ΔDD, and
Cx45 BsubVD were cultured on glass coverslips to confluence, fixed, and immunostained for Cx45 (green) and
the nuclei (blue) and imaged by confocal microscopy. Scale bar = 20 µm.
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cross-compared to both Cx45 WT and 6E by one-way ANOVA with a Bonferroni post-test (Fig.
3.5B; * compared to Cx45 WT, # compared to 6E). We observed a preference of Cx45 WT to
segregate into the TX-100 insoluble fraction (~28.8% soluble and ~71.2% insoluble, P <0.001) and
6E preferentially to the soluble fraction (~62.4% soluble and ~37.6% insoluble, P <0.001). We
observed Cx45 GCN4LZ to segregate primarily into the insoluble fraction (~28.1% soluble and
~71.9% insoluble, P <0.001), consistent with the notion that dimerization promotes GJ plaque
incorporation. For Cx45 BSubVD, where we observed an intermediate localization by
immunostaining, our TX-100 solubility results similarly suggest an intermediate phenotype with a
predominance of TX-100 insoluble segregation but to a lesser degree than either Cx45 WT or
GCN4LZ (~37.2% soluble and ~62.8% insoluble, P <0.001). The other Bsub mutant Cx45 BsubAA
also displayed an intermediate phenotype with regard to TX-100 solubility. Conversely to Cx45
BsubVD, BsubAA solubility trended towards the 6E phenotype (~55.4% soluble and ~44.6%
insoluble, P <0.001). Notably, despite the intermediate phenotype neither Cx45 BsubVD nor BsubAA
were statistically different from Cx45 WT or 6E, respectively. Finally, as predicted by the dimer
status, Cx45 ΔDD displayed a phenotype akin to 6E (~62.0% soluble and ~38.0% insoluble, P
<0.001). Worth noting is there is set of higher molecular weight bands of immunoreactivity detected
in the Western blots of lysate from all Cx45 cell lines. These may represent nonspecific labeling of
some other cellular protein, or potential phosphorylation dependent migratory isoforms, however
this remains to be determined, as such these bands were not included in the quantification. Similar
to the immunofluorescence images, the presence of the manipulations to the A333-N361 region
require the use of an alternate antibody (α-Cx45 CT vs. α-Cx45 CL).
11.5 Dimer Incompetent Cx45 Mutants Display Increased Hemichannel Dye Uptake
Our observed TX-100 solubility in Chapter Two and increased plasma membrane
localization correlated with hemichannel dye uptake when under conditions where Ca2+ was
depleted (see Figs. 2.4, 2.9, and 2.12). We hypothesized TX-100 solubility and plasma membrane
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Figure 3.5. Inhibiting Cx45CT dimerization increases TX-100 solubility.
MDCK cells stably expressing Cx45 WT and mutants were cultured, lysed, extracted with TX-100, and
fractionated into TX-100 soluble (non-junctional), and TX-100 insoluble (junctional) fractions. A)
Representative Western blot analysis of Cx45 WT and mutant (T – total, S – soluble, I – insoluble). B)
Quantification of Western blot results from 5 independent replicates. Statistical analysis is one-way ANOVA
with a Bonferroni post-test to compare all samples to Cx45 WT (*) and Cx45 6E (#).
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localization could be used as a predictor of hemichannel dye uptake and therefore predicted that
Cx45 BsubAA and ΔDD would take up more dye than GCN4LZ. To test this, we depleted cells grown
on glass coverslips of Ca2+ in presence of NB for 10 min, fix the cells, and stained with Streptavidin647 and imaged the coverslips. As a confirmation dye uptake was mediated by Cx hemichannels
we pretreated one group of coverslips with 50 µM CBX for 15 min prior to Ca2+ depletion. CBX, like
La3+, is a potent inhibitor of Cx hemichannels at concentrations of 25-50 µM [467]. Qualitative
analysis of the images revealed all Cx45 proteins tested exhibit some degree of NB uptake when
Ca2+ is depleted (Fig. 3.6, middle) compared to when extracellular Ca2+ levels were normal (Fig.
3.6, left). Similarly, all Cx45 proteins had NB uptake that returned to near control levels when the
cells were pretreated with CBX (Fig. 3.6, right). Importantly, Cx45 6E, BsubAA, and ΔDD all took up
more dye than WT, GCN4LZ, or BsubVD. The data taken together with the TX-100 and
immunofluorescent images further confirm the link between dimerization, forward trafficking, and
hemichannel activity. Additionally, they suggest that membrane localization and TX-100 solubility
combined can be a predictor of hemichannel activity.
11.6 Inhibiting Dimerization Correlates with Impaired GJIC
To complete our analysis of the chimeric and deletion mutants of Cx45 we measured GJIC
as a function of NB dye transfer in a scrape loading experiment. Since we observed impaired GJIC
for Cx45 6E in Chapter Two, we predicted increased TX-100 solubility would correlate with
decreased GJIC. MDCK cells were cultured in live imaging dishes to confluence and then loaded
with NB by scrape loading, cells were fixed, stained with Streptavidin-647 and imaged (Fig. 3.7).
For Cx45 WT and 6E our results were comparable to those seen previously. Cx45 WT (Fig. 3.7;
left-top) expressers transferred dye away from the scrape reaching 7th order transfer, while 6E (Fig.
3.7; left-middle) displayed severely impaired dye transfer yielding up to 3 rd order transfer with little
to no lateral transfer, suggesting networks of coupled cells are smaller in the 6E cells. We expected
Cx45 GCN4LZ expressing cells to be as competent as Cx45 WT cells in dye coupling, however, to
our surprise transfer of NB in these cells was much more similar to that of 6E (Fig. 3.7; left-bottom).
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Figure 3.6. Dimerization incompetent Cx45 mutants display increased neurobiotin
uptake through hemichannels.
MDCK cells stably expressing Cx45 WT or mutants were subjected to conditions that activate
hemichannels activity (Ca2+ deprivation) and the level of NB (NB) uptake was measured. Representative
fluorescent micrographs of cells loaded with NB and probed with streptavidin-647 conjugate (red). 15
random 100X FOVs were acquired per sample. Carbenoxolone (CBX) pretreatment was used to
demonstrate specificity of uptake through Cx hemichannels. Nuclei are stained with DAPI (blue) to show
confluence. Scale bar = 50 µm.
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Comparing our results to the observations of Koval et al. and Laing et al. indicates a more complex
link between Cx45CT dimerization and the regulation of GJIC [450, 451]. Since our Cx45CT
GCN4LZ dimer had a KD of 8.38 nM (~17-fold that of Cx45CT WT), it suggests that increased
dimerization (or alternatively some other uninvestigated aspect of this specific mutation) is
impairing GJIC. Since we observed TX-100 solubility and hemichannel activity comparable to Cx45
WT in the Cx45 BsubVD mutant, we predicted it would be comparable to Cx45 WT with respect to
NB dye coupling. As we predicted, Cx45 BsubVD cells were able to transfer dye to a similar extent
as Cx45 WT (Fig. 3.7; right-top). Taken together with the Cx45 GCN4LZ results, this mutant
suggests that the A333-N361 region is not essential for Cx45 dye coupling. The results also
suggest the Cx45 GCN4LZ mutation itself is leading to the impairment. Scrape loading of the Cx45
BsubAA and Cx45 ΔDD (Fig. 3.7; right-middle and right-bottom, respectively) mutants revealed, like
6E, both manipulations abolishing dimerization impaired NB dye coupling.
11.7 Homologous Mutations of A333-N361 from Cx40 or Cx43 Alter Trafficking
Our Cx45 substitution mutants (except Cx45 DDSc) to this point have relied on the use of
heterologous mutations and thus the potential for unintended consequences exists. Sahu et al.
demonstrated Cx45 channels were still functional when the CT domain was swapped with that of
either Cx40 or Cx43, despite the loss of Cx45CT dimerization [453]. We considered the possibility
that in the absence of dimerization homologous mutations may preserve some features of Cx45
function. To investigate this, we engineered Cx45 mutants with A333-N361 substituted with a
homologous region of either Cx40 or Cx43 and used them to generate stable MDCK cell lines
(Cx45 40MD and 43MD; Table 5). Similar, to our previous characterizations we used
immunofluorescence as an initial comparison of any phenotypic alterations. Since the structure and
dimerization status of the regions of Cx40 and Cx43 have been previously described we predicted
we would observe increase plasma membrane localization of both Cx45 40 MD and 43MD. Indeed,
the localization of both mutants was preferentially shifted towards a primary plasma membrane
localization (Fig. 3.8). Interestingly, even though we observed increased plasma membrane
localization, the pattern of immunoreactivity at the plasma membrane was more similar to Cx45
BsubVD than 6E (see Fig. 3.4) for both Cx45 40MD and 43MD (Fig. 3.8).
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Figure 3.7. Inhibiting Cx45CT dimerization impairs cell coupling of neurobiotin.
MDCK cells expressing Cx45 WT or mutants were scrape loaded with NB (green) to assess the degree
of intercellular communication. Nuclei are stained with DAPI (blue). Scale bar in = 100 μm.
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Figure 3.8. Homologous Cx45 mutants display increased plasma membrane localization.
MDCK cells were stably transfected with Cx45 40 MD (left) or Cx45 43MD (right), cultured to confluence on
glass coverslips, fixed, and immunostained for Cx45 (green). Nuclei were stained with DAPI (blue). Scale
bar = 20 µm.
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11.8 Cx45 40MD and Cx45 43MD Show Increased Hemichannel Dye Uptake
Following from observation that Cx45 40MD and 43MD displayed increased plasma
membrane localization consistent with having dimerization inhibited we predicted they would
similarly have increased NB dye uptake through hemichannels when depleted of Ca 2+. To test this,
we cultured MDCK cells expressing either Cx45 40MD or 43MD on glass coverslips to confluence
and then depleted Ca2+ in the presence of NB for 10 min. Afterward incubating with NB the cells
were fixed, stained with Streptavidin-647, and imaged. As we expected both Cx45 40MD and 43MD
had increased dye uptake compared to Cx45 WT when Ca2+ was depleted (Fig. 3.9; bottom-middle
and lower-middle). Surprisingly, Cx45 43MD appeared to take up more dye than even 6E (Fig. 3.9;
bottom-middle). Importantly, treatment with CBX abolished the dye uptake confirming Cx
hemichannels were involved (Fig. 3.9; right panels).
11.9 Homologous A333-N361 Mutations Preserve or Enhance GJIC
We lastly wanted to determine if, similar to the Sahu et al. chimeras, the Cx45 40MD and
43MD proteins would yield functional GJ channels despite inhibiting Cx45CT dimerization [453].
Although, all of our heterologous mutants negatively impacted NB dye transfer (including Cx45
GCN4LZ), the trend observed for the dimerization incompetent mutants was that loss of dimerization
equated to impaired GJIC (Fig. 3.7). If the lack of Cx45CT dimerization (regardless of manipulation)
in the context of the Cx45CT (all resides except A333-361) is essential for Cx45 GJIC, then loss of
dimerization in the context of either Cx45 40MD or 43MD should impair GJIC. In order to test this, we
cultured MDCK cells expressing either Cx45 40MD or 43MD in live imaging dishes to confluence, and
scrape loaded the cells with NB. After the incubation with NB the dishes were fixed, stained with
Streptavidin-647, and imaged. Much to our surprise unlike 6E both Cx45 40MD and 43MD were both
able to robustly transfer NB dye (Fig. 3.10; bottom panels). Furthermore, Cx45 40MD was more
competent than WT in dye transfer, almost filling the entire field of view (Fig. 3.10; lower middle).
Cx45 43MD mediated NB transfer was comparable to that WT (Fig. 3.10; bottom). Taken together
with our heterologous mutant data this supports our hypothesis that Cx45CT dimerization is an
essential structural feature of Cx45 that regulates GJIC in the context of its own CT.
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Figure 3.9. Homologous Cx45 mutants have increased hemichannel uptake of
neurobiotin.
MDCK cells stably expressing Cx45 40MD or Cx45 43MD mutants were subjected to conditions that activate
hemichannels activity (Ca2+ deprivation) and the level of NB uptake was measured. Representative
fluorescent micrographs of cells loaded with NB and probed with streptavidin-647 conjugate (red). 15
random 100X FOVs were acquired per sample. Carbenoxolone (CBX) pretreatment was used to
demonstrate specificity of uptake through Cx hemichannels. Nuclei are stained with DAPI (blue) to show
confluence. Cx45 WT and 6E from Fig. 3.6 were included for ease of comparison. Scale bar = 50 µm.
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Figure 3.10. Homologous Cx45 mutant maintain or
enhance neurobiotin transfer.
MDCK cells expressing Cx45 40MD or Cx45 43MD were cultured to
conlfuence in live imaging dishes, scrape loaded with NB (green) and
imaged. 15 fields of view per sample were acquired. Cx45 WT and
6E were included here from Fig. 3.7 for ease incomparison. Nuclei
were stained with DAPI (blue). Scale bar = 100 µm.
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12. Discussion
A notable similarity between the study in Chapter Two and the one contained in this
Chapter is the consistent increase and more widespread plasma membrane localization of the
dimerization incompetent mutants. Another similarity was the increased TX-100 solubility of these
mutants. Together the pieces of data suggest the dimerization is in some manner directly linked to
control mechanisms that limit the amount of the Cx45 that is present in the plasma membrane and
therefore the formation of GJs. Furthermore, we observed similar increases in hemichannel dye
uptake for the dimerization incompetent mutants. Although it is tempting to conclude this is directly
mediated by dimerization, it seems more likely that this is a secondary effect of the increased
trafficking and TX-100 solubility. Importantly, it is clear from localization of the Cx45 ΔDD (and
conversely Cx45 GCN4LZ and DDSc), that Cx45CT A333-N361 is not essential for the forward
trafficking of Cx45 to the plasma membrane (Fig. 3.4). These data also support our conclusion that
dimerization limits Cx45 membrane expression. Taken together with the turnover assay in Chapter
Two, it suggests this is accomplished by positively regulating degradation and the association with
Nedd4 (Fig. 2.8 and 2.16). A key difference in the studies between Chapters One and Two, was
the unpredictable nature of NB dye transfer (Cx45 GCN4LZ – impaired; 40MD and 43MD – functional).
The data suggest that Cx45CT dimerization either does not regulate cell coupling or a more
complex mechanism is involved. Testing the coupling ability of the Cx45 DDSc mutant will no doubt
provide further insight into this possibility. Furthermore, our data highlights an important caveat in
the interpretation of TX-100 solubility data, that increased solubility does not necessarily equate to
decrease GJIC.
Other studies investigating functional regulation of Cx45 by the CT domain have been
spurious over the last two and a half decades and narrow in focus. In one set of studies the focus
was using CT truncation mutants to investigate the role of the CT in cell coupling, localization, and
detergent solubility [450, 451]. In the Koval et al. study chick Cx45 truncated at position 357 (Cx45
Δ37) expressed in ROS cells was observed to correlate with increased intercellular transfer of 7hydroxycoumarin-carboxylic acid (HCCA), LY, and calcein [450]. Notably, this truncation is
immediately following the critical Y356 in the Cx45 dimerization domain and would likely increase
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the dimerization affinity. A second study from the same laboratory compared the Cx45 Δ37 to
another mutant Cx45 Δ34 [451]. In that study, the Cx45 Δ34 localized in a more punctate manner
(similar to dimer competent Cx45 mutants) than did the Cx45 Δ37 (which was more linear, similar
to Cx45 dimer incompetent mutants) [451]. Furthermore, it was revealed that the Cx45 Δ37 failed
to co-IP ZO-1 and was also more TX-100 soluble than either Cx45 WT or Cx45 Δ34, the authors
reasoned this was due to the presence of a second or more extended binding site for ZO-1 than
was previously reported for Cx43 [286, 451]. A number of pieces of data suggest that dimerization
of the Cx45CT may be essential for maintaining appropriate interactions with ZO-1. The most direct
piece of evidence we observed was a decrease (albeit non-significant) in the amount of ZO-1 eluted
with Cx45 6E compared to WT in Chapter Two (Fig. 2.15). Although this was not directly tested in
the current study, the phenotypic consistency of the dimerization incompetent mutants (increased
plasma membrane localization and TX-100 solubility), all of which in some way or another result in
a loss of Cx45 residues 357-361 (like Cx45 Δ37), is consistent with the Laing et al. study Cx45 Δ37
phenotype [451].
The nature of the loss of NB dye coupling for the heterologous (and deletion) mutants can
be possibly explained by one of two theories. 1) Dimerization is a critical regulator of cell coupling
either through enhancing protein-partner interactions, PTMs, or TM/EL positioning to favor docking;
and 2) the heterologous (and deletion) mutations lead to unintended consequences via sequence
specific mechanisms such as: gain/loss of protein partner interactions, or aberrant phosphorylation.
Taken alone, the data cannot rule out the first theory, however, when considering the homologous
Cx45 mutants this theory breaks down. The homologous mutants displayed comparable (Cx45
43MD) and even enhanced (40MD) NB dye coupling when compared to WT. This result is both
interesting and consistent with the results obtained by Sahu et al. when CT truncated Cx45 was
tethered with either the CT of Cx40 or Cx43 [453].
Cx45CT dimerization is a structural feature essential to controlling the amount of Cx45
present in the plasma membrane. Future studies should focus on determining how exactly ZO-1
interacts with the CT domain of Cx45 and how dimerization contributes. Furthermore, the studies
of Koval et al. and Laing et al. used ROS cells to exogenously express Cx45, the ROS cells
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endogenously express Cx43 (similar to the MDCK cells) [424, 450, 451]. A study focused on the
regulation of heteromeric GJ channels discovered that functional Cx proteins can functionally
rescue defective mutants by heterotypic pairing (docking) and are regulated normally (by the wildtype side) [452]. It is possible in the studies of Laing et al. and Koval et al. that a similar mechanism
occurred, however, since the Sahu et al. study utilized Neuro-2a (N2A) cells, which lack
endogenous Cx expression this would have not been a factor and lends greater support to the
validity of our conclusions [450, 451, 453]. Additionally, further studies should direct their focus to
understanding the role of Cx45CT dimerization in the context of heteromeric connexons.
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CHAPTER FOUR

Cx45 is Regulated by Kinases
Active During End-Stage Heart
Failure

135

13. Introduction
The previous two Chapters focused on the regulation of Cx45 function by
homodimerization of the CT domain, an intramolecular interaction that occurs prior to and is
maintained at the GJ plaque. While protein interactions, both intra- and inter-molecular, are
important for the regulation of Cxs in general, other regulatory mechanisms are critical as well.
Some of the mechanisms we discussed in Chapter One include transcriptional regulation, quality
control mechanisms in the ER (ERAD), gating (voltage, pH, and Ca2+), and diverse PTMs
(ubiquitination, carboxylation, acetylation, methylation, nitrosylation, and phosphorylation). An
important and widely studied modification of Cxs is phosphorylation. Despite being well
characterized for Cx43, little information exists about the regulation of other Cx family members by
phosphorylation. In this section, we focus on the importance of Cx phosphorylation to the function
and regulation of Cx43 and Cx45.
GJs are integral membrane proteins that enable the direct exchange of ions and small
cytoplasmic molecules (≤ 1kDa) between adjacent cells [468]. They mediate propagation and
amplification of signaling cascades initiated by many stimuli. The 21 human Cx family members
oligomerize into connexons which aggregate to form GJs [468]. Two important cardiac Cxs are
Cx43 and Cx45, the latter is the focus of this Chapter. Cx43, expressed in ventricular myocytes,
mediates propagation of cardiac action potentials and maintains a working cardiac rhythm [67].
Cx45 GJs, found primarily in the specialized conductance system, slow conduction velocity to allow
successive atrioventricular contraction and their high voltage sensitivity (i.e., responsiveness to
voltage gating) prevents current backflow [230, 464, 469]. In addition to voltage gating, Cx45 and
Cx43 differ significantly in pore size, conductance, selectivity, and pH sensitivity [470, 471].
Dysregulation of GJ distribution, expression, and gating negatively impacts normal impulse
propagation and can lead to arrhythmias [34, 36, 67, 71, 472]. The compartmentalization and
unique channel properties of Cx45 and Cx43 strongly suggest that any alterations to expression or
distribution, both associated with ischemia and heart failure, could lead to the generation of lethal
arrhythmias. In end stage failing hearts, increased Cx45 at the ID, combined with Cx43 remodeling
forms the basis for the arrhythmogenic substrate [432].
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While Cx45 and Cx43 share high sequence homology in the transmembrane and
extracellular domains, they are divergent in their cytosolic domains, especially the CTs. The CT of
Cxs are involved in Ca2+ and pH mediated channel closure, voltage gating, trafficking, assembly
and disassembly of GJs, and regular Cx turnover [149, 277, 285, 308, 473-475]. The CT domain is
a hub for Cx regulation through diverse protein interactions [231, 247, 248, 285, 473, 476].
Importantly, phosphorylation alters GJ function via changes in protein partner interactions [153,
300, 306, 308, 312, 477-479]. Phosphorylation of Cx43CT is an important regulator of both
increasing [153]. Phosphorylation of critical Ser residues by PKA has been attributed to enhanced
forward trafficking and increasing cell coupling [160, 343]. Additionally, phosphorylation by CK1 is
attributed to the P2 migratory phosphoisoform (not exclusively) and associated with increased
channel openness [311]. Phosphorylation of Cx43 Ser residue 373 stimulates transfer of Cx43 from
the perinexus into the GJ proper where it can participate in meaningful cell coupling [158, 159, 166,
459].
Conversely, phosphorylation is also a potent inhibitor of GJIC [153]. For example, Src
phosphorylation destabilizes Cx43 GJs by loss of binding to the cytoskeletal anchoring proteins –
β-tubulin, Drebrin, and ZO-1 [378, 480-483]. Src phosphorylation also induces channel closure and
promotes internalization by indirectly activating PKC and MAPK (which phosphorylate S368 and
S255/262/279/282, respectively), thereby decreasing GJIC [16, 376, 484]. Importantly, a number
of protein partners studied in our laboratory also interact with the Cx45CT. These include Drebrin,
ZO-1, Nedd4, and the GJ recycling protein TSG101 [247, 485, 486]. Notably, several of these
proteins interact with the Cx45CT in regions containing several phosphorylatable residues
suggesting phosphorylation may regulate the interactions [247]. Studies investigating the effects of
Cx45 regulation by phosphorylation are limited, however, Ser phosphorylation of Cx45 often results
in opposing effects compared to Cx43. For example, activation of PKC by PMA, triggers channel
closure to subconductance states and promotes internalization and turnover of Cx43 leading to
reduced GJIC, however, studies investigating the regulation of Cx45 by PKC have yielded
conflicting results [86, 306, 385]. In one study, activation of PKC by the PMA resulted in increased
gj, while in another gj was impaired (albeit to a lesser degree than Cx43) yet transfer of NB via Cx45
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channels was unaffected while Cx43 did not transfer any NB [86, 306]. Interestingly, one of the
earliest study to describe phosphorylation of Cx45 in any detail noted that phosphorylation of Cx45
(presumably by PKC) on far CT Ser residues promoted stability of Cx45 (another opposite of Cx43),
while loss of phosphorylation correlated with decreased half-life [189]. In another study, activation
of PKG by cGMP impaired communication of Cx43 channels but not those of Cx45 [487]. Taken
together these findings suggest that different Cx family members are likely differentially regulated
by the same kinase (if at all). Furthermore, if Cx45 is present at the ID to compensate for loss of
Cx43 coupling under the same conditions it strongly suggests the same kinases will have opposing
effects on Cx45 compared to Cx43.
In diseased hearts, dysregulated molecular processes lead to the activation of stress related
proteins such as AngII and signal cascades via altered kinase activation [488, 489]. A number of
kinases known to regulate Cx43 (and possibly Cx45) are directly activated by increased AngII levels
including PKC, Pyk2 and Src [490-497]. In the heart, Pyk2 is activated downstream of AngII
signaling by the AT1R due to increased [Ca2+] via PKC [489, 492, 498, 499]. Activation of Pyk2
links Ca2+ flux, integrin signaling, and G protein-coupled receptors with effectors in both the MAPK
and PI3K/PDK1/Akt pathways [500-502]. Pyk2 is also activated by JAK1/2 or Src phosphorylation
[499, 502-505]. Phosphorylation at Y579/580 by Src results in “enhanced” Pyk2 activation [505]. A
number of in vivo models show Pyk2 upregulation in the adult heart in disease states, including
models of hypertrophy [506, 507]. Despite these data, mechanisms defining how Pyk2 is involved
in cardiac disease are limited.
The connection between Src and the pathogenesis of heart disease is well established. In
the case of cardiac hypertrophy, upregulation of Src kinase expression and activity has been
reported in the ventricular myocytes of spontaneously hypertensive rats [508]. The study noted
decreases in the autoinhibitory phosphorylation site (Y529), and concomitant increase in
phosphorylation at the active site (Y418) when compared to age-matched control Kyoto-Wistar rats
[508]. Src is essential to stretch induced hypertrophy of the cardiomyocytes, a hallmark of
hypertensive heart failure [509]. The study of Wang et al. demonstrated mechanical stretch of
cardiomyocytes (as occurs in hypertension) activates the AT1R independently of AngII, leading to
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β-arrestin2 mediated activation of Src and subsequently the ERK1/2 pathway [509]. Interestingly,
the authors reported that ERK1/2 activation could be abrogated by the addition of Src inhibitors
only when the initiating stimulus was mechanical stretch, not AngII mediated signaling, suggesting
a bimodal role for the AT1R in the pathogenesis of hypertension induced heart failure [509]. Similar
results were reported by another study in the ventricles of hypertrophic cat hearts [510]. Although
both studies demonstrated a critical role of Src in the activation of the ERK1/2 cascade, the
Kuppuswamy et al. study suggested a critical requirement for integrin signaling not explored in the
Wang et al. report [509, 510]. Taken together these studies illustrate an important role for Src in
signal transduction pathways that lead to cardiac remodeling, including the direct phosphorylation
of the GJ proteins Cx43 and Cx45. Finally, in addition to Pyk2 and Src, PKC is a critical effector of
AT1R signaling, and forms a feedback activation loop with Src [511].
Similar to Src and Pyk2, PKC is activated downstream of the AT1R [496, 497, 509]. The
Wang et al. study discussed above demonstrated AngII independent activation of Src via
mechanical stretch induced AT1R activation [509]. Notably, they also described AngII-dependent
activation of PKC, mediated by the G-protein coupled receptor activity of the AT1R [509]. Several
PKC isoforms have been implicated in the progression of heart disease including PKCα, PKCβ,
PKCγ, PKCδ, and PKCζ (reviewed in [512]). AngII has been implicated in the activation of several
of the PKC isoforms (α, β(2), ε, γ, and ζ isoforms) resulting in translocation to the plasma membrane
[513]. Similarly, PKC isoforms α, β(2), and ζ were shown to be activated under hypoxic conditions
mimicking ischemia [513]. In Dahl salt-sensitive rats, expression of several PKC isoforms (α, β, δ,
and ε) increased in animals fed high-salt diet compared to low-salt diet for 11 weeks [514]. Although
expression of PKCε, returned to near control levels by 16 weeks high-salt, while expression of the
others (α, β, and δ) remained high compared to low-salt diet controls [514]. Despite the potential
involvement of several PKC isoforms in heart failure, PKCα has been implicated as particularly
important. For instance, in guinea pigs subjected to aortic banding (pressure overload model) PKCα
activity was shown to increase, this was however, reduced by treatment with ACE inhibitors [515].
Similarly, in rats subjected to pressure overload by aortic banding a selective upregulation of PKCα
and PKCδ was reported, while PKCε expression remained constant [516]. Furthermore, PKCα has
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been shown to be a critical mediator of cardiac contractility [517, 518]. Importantly, genetic ablation
of PKCα specifically, offered cardiac protection from heart failure induced by pressure overload and
dilated cardiac myopathy, as well as partial protection from infarct induced heart failure [517, 518].
Since Cx45 is expressed in the myocytes of the ventricle in human failing hearts it is
reasonable to assume that kinases activated in heart failure may regulate the function of Cx45.
Based on the lack of information available on the phosphorylation of Cx45 in end-stage heart
failure, the importance of AngII signaling and the kinases, Pyk2, Src, and PKC, in hypertensive
models of heart failure we sought to investigate the possibility Cx45 is phosphorylated (and
regulated) by these kinases using a combined approach of in vitro, proteomic, and
molecular/cellular biology techniques.
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14. Materials and Methods
14.1 Antibodies and Reagents
All antibodies and reagents for this study are contained in Table 2.
14.2 Expression and Purification of Cx45CT WT and Mutants
Constructs designed for this project are summarized in Table 6. Cloning of constructs was
achieved by the purchase of a GeneBlock gene fragments (IDT) for each of the single Tyr mutants.
GeneBlock gene fragments were cloned into pGEX-KT by NEBuilder (NEB) per manufacturer
protocol and sequence verified by Sanger sequencing. Cx45CT WT and mutants were expressed
and purified as previously described [247]. Following purification, proteins were buffer exchanged
into (5 mM 3-(N-morpholino)propanesulfonic acid (MOPS), pH 7.2) using a Nap 5 (GE Healthcare)
column per manufacturer protocol. Concentration of buffer exchanged proteins were determined
by Abs280 nm using a NanoDrop 1000 and Beer’s Law.
14.3 Kinase Screen (Eurofins KinaseProfiler)
Cx45CT WT expressed and purified as described above. Purified protein was diluted in 1x
PBS pH 7.4 to a final concentration of 200 µM in a final volume of 1 mL, flash frozen on dry ice and
shipped on dry ice to Eurofins Scientific for a custom Kinase Profiler Assay testing the Cx45CT as
substrate for the indicated kinases. Substrate diluted to 20 µM was incubated with the indicated
kinase and 200 µM ATP [γ-33P] for 40 min at RT. Substrate was then captured by either P30 or
FilterMat A filters and quantified by scintillation counter. Quantification of raw scintillation counts
were achieved by averaging the value of two experimental well following subtraction of the acid
buffer blank for each kinase. This value was normalized to the acid blank subtracted average of
two wells of the positive control peptide for each kinase tested.
14.4 In vitro Phosphorylation
Buffer exchanged pure Cx45CT (K265-I396) or single Tyr mutants (Table 6) were used as
substrate for in vitro phosphorylation by Src, Pyk2, and PKCα. Reactions were prepared, an
incubated ON at 30°C and stopped by the addition of 6X SDS loading buffer, and then analyzed by
SDS-PAGE and Western blot (2 nmol) or MS (15 nmol). Reactions were set up as follows:
141

Construct

Mutations

Remaining Tyr

Cx45CT WT

None

Y275/277/290/301/311/324/256

Cx45CT Y275

Y277/290/301/311/324/356F

Y275

Cx45CT Y277

Y275/290/301/311/324/356F

Y277

Cx45CT Y290

Y275/277/301/311/324/356F

Y290

Cx45CT Y301

Y275/277/290/311/324/356F

Y301

Cx45CT Y311

Y275/277/290/301/324/356F

Y311

Cx45CT Y324

Y275/277/290/301/311/356F

Y324

Cx45CT Y356

Y275/277/290/301/311/324F

Y356

Table 6. Cx45CT WT and single Tyr mutants.
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Src: 1.5 µg of recombinant full-length active human Src, pure Cx45CT or mutants, and 500
µM ATP were combined in reaction buffer (5 mM MOPS pH 7.2, 2.5 mM β-glycerol-phosphate, 4
mM MgCl2, 2.5 mM MnCl2, 1.0 mM ethyleneglycol tetra acetic acid (EGTA), 0.4 mM EDTA, 0.05
mM DTT, and 40 µg/mL BSA) in a total volume of 60 µL. For negative control the kinase was
substituted with reaction buffer.
Pyk2: 1.5 µg of recombinant active human Pyk2 (360-690), pure Cx45CT or mutants, and
500 µM ATP were combined in reaction buffer (5 mM MOPS pH 7.2, 2.5 mM β-glycerol-phosphate,
4 mM MgCl2, 2.5 mM MnCl2, 1.0 mM EGTA, 0.4 mM EDTA, 0.05 mM DTT, and 40 µg/mL BSA) in
a total volume of 60 µL. For negative control the kinase was substituted with reaction buffer.
PKCα: 1.5 µg recombinant full-length active human PKCα, pure Cx45CT or mutants, 6 µL
of lipid activator (0.5 mg/ml phosphatidylserine and 0.05 mg/ml diacylglycerol in 20 mM MOPS, pH
7.2, containing 1 mM CaCl2) and 500 µM ATP were combined in reaction buffer (5 mM MOPS pH
7.2, 2.5 mM β-glycerol-phosphate, 5 mM MgCl2, 1.0 mM EGTA, 0.4 mM EDTA, 0.05 mM DTT, 40
µg/mL BSA) in a total volume of 60 µL. For negative control the kinase was substituted with reaction
buffer.
14.5 Mass Spectrometry
10 nmol of purified mouse Cx45CT (K265-I396) subjected to in vitro phosphorylation by
the Src, Pyk2, or PKCα in Section 14.4 was resolved by SDS-PAGE, gel stained with Coomassie
bright blue, and then destained with pure methanol until bands appeared. The Cx45CT bands were
cut out, washed extensively with MilliQ water followed by 50% acetonitrile in MilliQ water, snap
frozen on dry ice, and shipped on dry ice to the Harvard Beth Israel Deaconess Medical Center
Mass Spectrometry Core Facility for post-translational mapping [519].
14.6 Validation of Mass Spectroscopy
2 nmol of purified Cx45CT WT and single Tyr mutants (Table 6) were subjected to in vitro
phosphorylation by Src or Pyk2 as in Section 14.4. Resolved by SDS-PAGE and analyzed for
phosphorylation by Western blot with a general pTyr antibody. As negative control, the kinase was
omitted and replaced with reaction buffer for each protein and kinase.
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14.7 Cell Culture and Stable Cell Line Generation
MDCK and LA25 cells (gifts from Dr. Paul Lampe, Fred Hutchinson Cancer Center), HeLa
cells (gift from Dr. Steve Caplan, University of Nebraska Medical Center) were cultured in
Dulbecco’s modified Eagle medium (Corning) at 37°C in a humidified 5% CO 2 atmosphere. Medium
was supplemented with 10% FBS (Seradigm), 2 mM L-glutamine (HyClone), 1% pen-strep
(Corning), and 0.2% Normocin (Invivogen). The selective agent puromycin (Tocris) was used, when
appropriate, at empirically determined concentrations. 70% confluent MDCK, HeLa, or LA25 cells
were lipofected with SalI linearized plasmid using Lipofectamine 2000 at a 1:2 ratio in OptiMem.
Transfections were carried out under antibiotic free conditions, and cells were cultured 48-72 hr
prior to addition of selection media. HeLa were selected with 2 µg/mL, MDCK were selected with 5
µg/mL, and LA25 cells were selected 7 µg/mL. Cells were clonally (monoclonal) selected using
Whatman paper cloning disks. Western blots and immunofluorescence were used to screen clones.
For LA25 cells Src activity was modulated by culturing the cells at 35°C (permissive – Src active),
37°C (intermediate), or 40°C (non-permissive – Src inactive) for 8 hr.
14.8 Transient Transfections
HeLa cells were cultured to approximately 90% confluence and lipofected using
Lipofectamine 2000 (1:2 ratio) in Optimem under antibiotic free conditions. Expression of the
transgene was maintained for approximately 24 hr prior to cell lysis or subsequent experimentation.
14.9 Co-IP and Western blot
Co-IP: MDCK, LA25, or HeLa cells stably expressing Cx45 WT were seeded in either 10
or 15 cm plates and grown to confluence. Cells were rinsed 2x with 1x TBS + 1 mM EDTA and then
scraped up an either 0.5 or 1.0 mL of IP lysis buffer (25 mM Tris, 150 mM NaCl, 0.25% sodium
deoxycholate, 0.05% SDS, 1% TX-100 plus protease and phosphatase inhibitors). Cells were
mechanically lysed and then incubated for 30 min at 4°C with rotation. Lysates were precleared
with normal rabbit IgG (2 µg) bound protein G agarose for 1 hr at 4°C and then clarified by
centrifugation. Clarified lysates were quantified by BCA (Pierce) and normalized. Input samples
were reserved and either 2 or 5 mg of lysate was captured by IP with either 2 or 3 μg of rabbit α-
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Cx45 (Alomone) or mouse α-Cx45 (Millipore) ON at 4°C. Immune-protein complexes were captured
by 2 hr 4°C incubation with protein G agarose (Pierce), washed 5x with IP wash buffer (IP lysis
buffer excluding sodium deoxycholate) proteins were eluted using 35-50 μL 3x SDS sample buffer.
Equal volumes of each sample were analyzed by Western blot and to avoid cross reactivity with
the IP antibody a light chain specific secondary antibody (Jackson) or Veriblot (Abcam) were
utilized for detection. HeLa and MDCK cells were treated with PMA (100 nM) for 1 hr prior to lysis,
LA25 cells were incubated at 35°C, 37°C, and 40°C for 8 hr prior to lysis. Western blot: Protein
samples were resolved by SDS-PAGE with an appropriate gel concentration, transferred to PVDF
(Millipore), blocked either 2 hr at RT or ON at 4°C with either 5% non-fat milk/PBST or 5%
BSA/TBST and incubated with indicated primary antibody in blocking buffer either 1 hr at RT or ON
at 4°C. Blots were washed 3x for 10 min with either PBST or TBST, and then incubated for 1 hr at
RT with secondary antibody. Membranes were then washed 4x 10 min each with either PBST or
TBST and detected using Signal West Femto kit (Thermo) per manufacturer protocol and exposed
to autoradiography film. Quantifications were done using NIH ImageJ software using a minimum of
three independent replicates.
14.10 Antibodies and Immunostaining
All primary and secondary antibodies, detection reagents and concentration ranges utilized
are summarized in Table 2. Cells seeded on glass coverslips were rinsed 2x with 1x PBS and then
fixed and permeabilized with either ice cold methanol at -20°C for 15 min or buffered formalin (1x
PBS, 3.7% formaldehyde, 0.3% TX-100) at 37°C for 30 min. For LA25 cells, the cells were
incubated at 35°C, 37°C, and 40°C for 8 hr prior to fixation. Coverslips were washed 3x 5 min in 1x
PBS with gentle agitation and then blocked for 60-90 min at 37°C (1x PBS containing 1% BSA and
0.3% TX-100). Coverslips were then incubated with the indicated primary antibodies diluted in
blocking buffer for either 1 hr at RT or ON at 4°C. Coverslips were washed 3x with 1x PBS and
then incubated with secondary antibody (if necessary) 1 hr at RT and then washed 1x for 5 min
with 1x PBS containing 100 ng/mL DAPI and then 2x 5 min with 1x PBS. Coverslips were mounted
with SlowFade (LifeTech) and sealed with clear nail polish and imaged. All images acquired on
either Zeiss 710 or 800 LSM microscope.
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14.11 Scrape Loading Dye Transfer Assay
Cells were scrape loaded as previously described [340]. Briefly, all buffers were prewarmed to 37°C prior to beginning the experiment. Stable expressing HeLa or LA25 clones were
seeded on bovine plasma fibronectin (Sigma; 10 µg/mL) coated 35 mm live imaging dishes
(CellStar). After appropriate treatments cells were washed 1x with 1x PBS and then overlaid with
dye tracer mix (1x PBS containing NB and Texas Red Dextran). LA25 cells were incubated for 8 hr
at either 35°C or 40°C prior to scrape loading. HeLa cells were either transiently transfected with
v-Src for 24 hr, treated with PMA (100 nM) for 1 hr, or serum starved for 24 hr and then treated with
either epidermal growth factor (EGF) (100 ng/mL) or human insulin (100 nM) for 1 hr and then
scrape loaded. Scrapes were introduced using a fine edged micro-scalpel and incubated at RT for
4 min. Tracer dye was gently washed away with 1x PBS and media was added and the cells
returned to the incubator to culture for 6 min to allow dye to transfer. Following the dye transfer
period, the cells were washed with 1x PBS containing 1 mM CaCl2 and 1 mM MgCl2 to stop dye
spread. Dishes were then formalin fixed and stained as described above and imaged. 15
consecutive fields of view were acquired per replicate. Dye spread was quantified using an ROI
tool in NIH ImageJ measuring the dye spread as a function of total area of field of view. Data is
presented as mean ± SD.
14.12 TX-100 Solubility Assay
The TX-100 solubility assay was modified from a method described previously [412].
Briefly, MDCK, LA25, or HeLa cells stably expressing Cx45 grown in 10-cm dishes were washed
with PBS, scraped into in 1 mL of fresh PIB and mechanically lysed by sonication (10 s at power
3). Lysates were quantified by BCA and normalized to 1.5 mg/mL. A total of 450 µL of cell lysate
was brought to 1% SDS with 10% SDS and reserved as total lysate. Another 450 µL was brought
to 1% TX-100 with 10% TX-100 in 1x PBS and incubated at 4°C for 30 min with agitation. The TX100 lysate was then separated into non-junctional (supernatant; soluble) and junctional (pellet;
insoluble) fractions by ultracentrifugation at 100,000 xg for 1 hr at 4°C. The supernatant was
carefully removed and retained as the soluble fraction. The pellet was solubilized in 500 µL of
solubilization buffer (1x PBS, 8 M urea, 2.5% SDS, 0.1 M DTT, 1x Roche complete + EDTA, 2 mM
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PMSF, and 2 µM Pepstatin A). Volume normalized samples of total lysate (T), TX-100 soluble (S)
and TX-100 insoluble (I) portions were analyzed by Western blot. MDCK cells were treated prior to
analysis for the indicated time with PMA (100 nM) or 15 min with 100 µM pervanadate (freshly
prepared). HeLa cells were transiently transfected for 24 hr with v-Src prior to analysis. LA25 cells
were incubated at 35°C and 40°C for 8 hr prior to analysis. Soluble and insoluble fractions were
quantified as a function of total lysate. Quantification was done using NIH ImageJ software from
three independent replicates. Data is presented as the mean  s.e.m.
14.13 Circular Dichroism (CD): Secondary Structural Analysis
Peptides for Cx45 A333-N361 (A333-N361 npY356, and A333-N361 pY356) were
purchased from LifeTein. CD experiments were performed as described previously [247]. Briefly,
data was collected with a Jasco J-815 spectrophotometer with a Peltier temperature control system
(Easton, MD). Spectra for the protein samples were acquired in 1x PBS pH 7.4 at 7°C. For each
sample, 5 scans (wavelength range: 190–250 nm; response time: 1 s; scan rate: 50 nm/min;
bandwidth 1.0 nm) were collected using a 0.01 cm quartz cell and processed using Spectral
Analysis (Jasco). Spectra are presented as the averaged change in molar residual ellipticity (MRE;
degree cm2 dmol−1) over wavelength following buffer subtraction. Peptide concentrations were
determined using a NanoDrop 2000 (Thermo Scientific; Wilmington, DE) at 205 nm.
14.14 Analytical Ultracentrifugation (AUC): Sedimentation Equilibrium
AUC experiments were performed as previously described with minor modifications [247].
Peptides for Cx45 A333-N361 (npY356 and pY356) were purchased from LifeTein. Briefly, peptides
were extensively dialyzed against 1x PBS pH 7.4 prior to sample preparation. Proteins were then
loaded into either an AN-50Ti or AN-60Ti rotor (Beckman Coulter; Indianapolis, IN) at three
concentrations (Abs280 nm of 0.5, 0.7, and 0.9) and speeds (24,000, 30,000, and 36,000 RPM).
Sedimentation equilibrium experiments were performed at 7°C with a Beckman Optima XL-I
analytical ultracentrifuge. Data were collected at various rotor speeds. Absorbance scans at 280
nm were acquired after 12 hr, 14 hr, and 16 hr at each speed; attainment of equilibrium was
confirmed by overlay of all four time points. Analysis of the sedimentation equilibrium data was
performed using the

Beckman XL-A/XL-I software package ORIGIN
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v6.0.

Sednterp

(http://www.rasmb.bbri.org) was used to calculate the buffer viscosities and densities as well as the
partial specific volume for each protein based on the primary sequence.
14.15 Statistical Analysis
All data were analyzed by using GraphPad Prism 5.0 and were presented as the mean ±
s.e.m (TX-100) or mean ± SD (scrape loading). Statistical analysis performed in GraphPad Prism
5.0 was either one-way ANOVA with a Newman-Keuls post-hoc analysis comparing all groups, or
two-tailed Student’s T-Test where appropriate. P-values <0.05 were considered statistically
significant.
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15. Results
15.1 Screen Identifies Kinases that Phosphorylate the Cx45CT
Little is known about the regulation of Cx45 by kinases and phosphorylation. Several
studies have identified Cx45 as a phosphoprotein and correlative links from various
phosphorylating conditions and some effect on Cx45 function [86, 189, 385, 487, 520]. Despite
these advances the relationship between Cx45, specific kinase(s), the sites phosphorylated, and
the physiological outcome remain unclear. Consequently, we set out to investigate how
phosphorylation regulates Cx45 function, identify several kinases and the residues of Cx45 they
phosphorylate.
Using a discovery-based approach, we expressed and purified recombinant mouse
Cx45CT (K265-I396; see Fig. 3.2 for representative purity) as in [247]. After purification, the protein
was buffer exchanged into 1x PBS pH 7.4 and submitted to Eurofins Scientific for custom
KinaseProfiler Assay. We screened a total of 40 kinases for the Cx45CT. Phosphorylated Cx45CT
or control peptide were captured by either FMA (Fig. 4.1A) or P30 filtermat (Fig. 4.1B) and signal
determined by scintillation. The results of the screen are summarized in Fig. 4.1A and Fig. 4.1B,
data presented is the mean percent of control peptide for each kinase after subtracting the signal
of acid blanks. Any kinase producing greater than 50% of control signal on either filtermat was
considered a positive result. A number of kinases relevant to cardiac function and disease (Fig.
4.1A and Fig. 4.1B; red bars) were able to phosphorylate the Cx45CT with at least 50% of control
peptide signal, including: Src, JAK2, PKC isoforms (α, β, and δ), Pyk2, and TAK1. Based on our
results and the importance that Src, PKCα, and Pyk2 have in the heart and interconnected signaling
pathways (see introduction for this Chapter) we chose to focus our efforts on validating and
characterizing the effects of these kinases.
15.2 Src, Pyk2, and PKCα Interact with Cx45 in HeLa Cells.
HeLa cells express Src, Pyk2, and PKCα, and thus were chosen to determine if the kinases
are capable of interacting with Cx45. To test this, we generated a HeLa cell line stable expressing
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Figure 4.1. Kinase screen reveals several kinases phosphorylate Cx45CT in vitro.
Cx45CT (K265-I396) was expressed in E. coli and purified as described in Kopanic et al. (2014). Pure Cx45CT
was submitted to Eurofins Scientific as test-substrate for phosphorylation in their KinaseProfiler assay.
Cx45CT data is presented as the percent signal of positive control substrate for each kinase captured on A)
FMA filtermat and B) P30 filtermat. Red bars represent kinases relevant to cardiac disease. Horizontal black
bars correspond 50% of positive control peptide signal.

150

Cx45 and used a co-IP experiment to determine if the kinases interact with Cx45 under basal
conditions. Lysates from the stable Cx45 expressing HeLa cells were subjected to IP ON with either
an antibody against the CL domain of Cx45 or normal rabbit IgG, and then captured with resin
conjugated with Protein G. Eluates were resolved by SDS-PAGE and Western blotted for Cx45,
Src, Pyk2, PKCα, and p21 activated kinase 2 (PAK2). PAK2 was used as a negative control.
Representative results from our co-IP experiment are shown in Fig. 4.2. We observed that Cx45
was able to co-IP Src, Pyk2, and PKCα as indicated by the presence of immunoreactivity for each
kinase. Furthermore, the amount that was detected by co-IP of Cx45 was greater in all three cases
compared to the background signal pulled down by normal rabbit IgG. Importantly, PAK2
immunoreactivity was not detected in either the lane corresponding to the IgG control nor the αCx45 lane validating our positive results and indicating our washing conditions were appropriate.
Although, our results for Src are not as pronounced as either Pyk2 or PKCα, they are further
supported by the NMR data in the Kopanic et al. study and consistent with the moderate KD
suggesting a more transient interaction potential [247].
15.3 Src Regulates Cx45 Phosphorylation in LA25 Cells
Having detected an interaction between Src and Cx45 using co-IP, we sought to determine
if Src regulates the phosphorylation state of Cx45. To accomplish this, we generated LA25 cells
that stably express Cx45. LA25 cells are useful in the study of regulation by Src because they
express a temperature sensitive mutant of v-Src where the activity is modulated by incubating at
alternative temperatures (35°C – Src permissive, 37°C – intermediate, 40°C – Src non-permissive)
[325]. We incubated LA25 cells that stably express Cx45 for 8 hr at 35°C, 37°C, and 40°C, then
lysed the cells and enriched for Cx45 by IP using antibodies raised against both the CL and the CT
domain (Fig. 4.3). Eluates were resolved by SDS-PAGE and Western blotted using antibodies
against general pTyr, Src, and PAK2. When Cx45 was captured using an antibody against the CL

151

Figure 4.2. Co-IP of Src, Pyk2, and PKCα by Cx45.
HeLa cells stably expressing Cx45 were cultured and lysed.
Cx45 was enriched by IP from the lysate using antibody raised
against the CL domain. Eluates were resolved by SDS-PAGE,
and Western blotted for the indicated kinases. Normal rabbit IgG
and PAK2 were used as negative controls.
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domain we observed a temperature (and Src activity) dependent increase in the amount of Src
associated with Cx45, while no PAK2 was observed to co-IP, in support of the data obtained in
HeLa cells (Fig. 4.3; middle). Additionally, general pTyr immunoreactivity was also detected, and
increased in intensity as Src activity increased, however, based on molecular weight, the observed
pTyr signal was actually derived from Cx43 also pulled-down by Cx45 (LA25 endogenously express
Cx43). Any general pTyr signal for Cx45 was being obscured by the large IgG heavy chain
immunoreactivity. To circumvent this, we also used an antibody against the CT domain to IP Cx45,
and analyzed those eluates simultaneously (Fig. 4.3; top). When using this antibody, we observed
a loss of detectable immunoreactivity to Src, suggesting the antibody against the CT domain was
blocking (or disrupting) the interaction. However, we now observed two sets of bands of general
pTyr immunoreactivity that increased in intensity with increasing Src activity, one consistent with
the molecular weight of Cx43 and the other consistent with the molecular weight of Cx45 (Fig. 4.3;
top). Interestingly, when analyzing the inputs, we observed a temperature dependent increase in
the total expression of Cx45, where increasing Src activity correlated with increased Cx45
expression (Fig. 4.3; bottom).
15.4 v-Src Activity Does Not Alter Cx45 Localization in LA25 Cells
Since we observed a temperature dependent increase in the Tyr phosphorylation of Cx45
in LA25 cells we hypothesized this would correlate with a difference in protein localization following
incubation at the Src permissive, intermediate, and non-permissive temperatures. We tested this
by culturing the Cx45 expressing LA25 on glass coverslips to confluence and then incubating for 8
hr at the various temperatures followed by chemical fixation and immunofluorescent staining.
Confocal imaging of the stained coverslips revealed little-to-no difference in the gross morphology
(localization or plaque size) of Cx45 GJs (Fig. 4.4; Cx45 in red). We also immunostained Cx43 (Fig.
4.4; Cx43 in green) to determine if the both Cx45 and Cx43 co-localized under each condition. We
visually observed similar colocalization between Cx45 and Cx43 under each temperature (Fig. 4.4;
overlap in yellow).
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Figure 4.3. Cx45 Tyr phosphorylation increases with Src
activity in LA25 cells.
LA25 cells engineered to stably express Cx45 were cultured at Src nonpermissive (40°C), intermediate (37°C), and Src permissive (35°C)
temperatures. Cx45 was captured by IP using antibodies raised against
either the CT or CL domain. Eluates were analyzed by SDS-PAGE and
Western blotted for general pTyr and Src. PAK2 was used as negative
control.
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15.5 v-Src Disrupts Cx45 GJ Plaque Formation in LA25 and HeLa Cells
In our immunofluorescence of Cx45 in LA25 cells at the Src permissive temperature we
observed little-to-no change in the localization of Cx45 compared to the Src non-permissive
temperature. We therefore hypothesized that Src activity would not affect GJ plaque formation. To
test this, we cultured LA25 cells stably expressing Cx45 to confluence and then incubated the cells
for 8 hr at either 35°C or 40°C. The cells were then lysed, extracted with TX-100, and fractionated
into soluble (non-junctional) and insoluble (junctional) Cx45 by ultracentrifugation. The resulting
fractions were resolved by SDS-PAGE and Western blotted for Cx45. Representative immunoblots
are presented in Fig. 4.5A. At the Src non-permissive temperature we observed approximately 50%
of the Cx45 immunoreactivity in each the soluble and insoluble fractions (Fig. 4.5A; left lanes, S –
50.5% vs. I – 49.5%, ns, N=3). Conversely, when incubated at the Src permissive temperature for
8 hr we observed a shift of Cx45 immunoreactivity from the junctional to the non-junctional pool.
Quantification of the results of three independent experiments indicated this was a statistically
significant change (Fig. 4.5, right lanes; S – 57.9% vs. I – 42.1%; one-way ANOVA, P <0.0001,
N=3;). When comparing non-permissive to permissive Src temperatures we observed a significant
difference in both the soluble and insoluble Cx45 pools (Fig. 4.5; S – 40°C 50.5% vs. 35°C 57.9%,
one-way ANOVA, P <0.01; I – 40°C 49.5% vs. 35°C 42.1%, one-way ANOVA, P <0.01). To
determine if this effect was isolated to LA25 cells, we tested the response of Cx45 to transient
transfection of v-Src in Cx45 expressing HeLa cells. HeLa cells stably expressing Cx45 were grown
to 90% confluent and transiently transfected with v-Src or empty plasmid for approximately 24 hr
prior to analysis. The obtained fractions were analyzed by SDS-PAGE and Western blot (Fig. 4.5B).
Similar to observations in LA25, under control conditions Cx45 was evenly partitioned between the
junctional and non-junctional pools (Fig. 4.5B; left lanes). Additionally, and again similar to the
results we obtained from LA25 cells, v-Src resulted in a statistically significant shift of Cx45 from
the insoluble to the soluble fraction (Fig. 4.5B; right lanes; one-way ANOVA; P <0.001 comparing
control to v-Src, N= 3). Quantification of three independent experiments indicated when v-Src was
expressed Cx45 in the soluble pool was 65.0% of the total, while the insoluble Cx45 represented
35.0% of total (Fig. 4.5B; graph). This was compared to control transfection conditions where Cx45
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Figure 4.4. Src activity does not appreciably alter the localization of Cx45 in LA25 cells.
LA25 cells stably expressing Cx45 were grown on glass coverlsips, fixed, and immunostained for Cx45 (red), Cx43 (green),
and nuclei (DAPI, blue). Prior to fixation cells were incubated for 8 hr at the Src permissive, intermediate, and nonpermissive temperatures.
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in the soluble pool was 51.9% of total, while the insoluble pool was 48.1% of total. Interestingly,
although we did not quantitate the difference in the amount of total Cx45 between either control
condition (empty plasmid transfection or 40°C) and the Src active condition (v-Src transfection or
35°C), we did observe an apparent increase in total Cx45 expression when Src was active, similar
to in Fig. 4.3. This may explain how little-to-no difference in the localization or GJ plaque distribution
was observed in LA25 cells by immunofluorescence (Fig. 4.4). Finally, in the HeLa cells we
observed a larger shift from junctional to non-functional pools of Cx45 as compared to LA25, this
is likely due to the difference in time before analysis (~24 hr for v-Src transfection in HeLa vs. ~8
hr for v-Src permissive temperature in LA25).
15.6 v-Src Negatively Regulates Cx45 GJIC in HeLa Cells
Our observation of decreased junctional segregation of Cx45 in both HeLa cells and LA25
led us to hypothesize that Src active conditions would decrease Cx45 GJIC as measured by scrape
loading transfer of NB. Since we observed a larger change in the segregation of Cx45 in HeLa cells
we reasoned this cell line would more reliably show a phenotypic change in communication if one
existed. Furthermore, since HeLa cells are deficient of endogenous Cx expression, they allow us
to study the effects of Src on Cx45 function in isolation. We tested this by culturing stable Cx45
expressing HeLa cells in live imaging dishes, scrape loaded them with NB, fixed, stained with
Streptavidin-488, and imaged. Representative immunofluorescent micrographs of our results are
presented in Fig. 4.6. Under control conditions NB dye was transferred away from the line of the
scrape an average 4-5 cell layers (Fig. 4.6; top). However, when cells were transfected with v-Src
for ~24 hr, NB dye transfer was impaired, with only 1-2 layers of cells on average showing staining
for NB (Fig. 4.6; bottom).
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Figure 4.5. Src activity disrupts Cx45 GJ plaque formation in LA25 and HeLa cells.
TX-100 solubility assays were used to determine the effect of Src on Cx45 GJ plaque formation in A) LA25
cells incuabted for 8 hr at either the Src non-permissive or permissive temperatures or B) HeLa cells trasniently
transfected with v-Src for 24 hr. Quantificaiton was done from thre indenpdent experiments using NIH ImageJ
for densitometry. Statistics are one-way ANOVA with a Newman-Keuls post-hoc comparison. *P <0.05, **P
<0.01. ***P <0.001
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15.7 Physiological Activation of Src by EGF Enhances Cx45 GJIC
Transfection of v-Src results in substantial Src activation [295]. It is possible that this
nonphysiological level of activation influences GJIC in ways that do not directly involve GJ proteins,
such as remodeling of actin cytoskeletal networks [521]. A more physiological stimulus for
activating c-Src is stimulation of the EGFR with EGF [522]. In order to test whether acute (and more
physiological) stimuli altered Cx45 GJIC, we starved HeLa cells stably expressing Cx45 of serum
for 24 hr and then treated with EGF for 1 hr before scrape loading the cells with NB and Texas Red
Dextran. After scrape loading the cells were fixed, stained with Streptavidin-488 and imaged. We
acquired a minimum of 15 non-overlapping fields of view per replicate. To quantify dye spread we
used the drawing tool of NIH ImageJ to draw regions of interest around the dye spread and
measured the area as function of percent of the field of view. Representative fluorescent
micrographs are presented in Fig. 4.7. GJIC of NB under serum starvation conditions was not
appreciably different from under standard growth media conditions (compare Fig. 4.7 top to Fig.
4.6 top). We measured the spread of the serum starved cells to be 18.75 ± 2.51% (n = 114). When
cells were treated for 1 hr with EGF prior to scrape loading we observed a statistically significant
increase in dye spread (18.75% (control) to 25.09 ± 2.40% (EGF), n = 82; one-way ANOVA; P
<0.0001). In order to confirm that the upregulation of GJIC was specific to the signaling of the EGFR
(and Src downstream) and not a function of a general stress response, we similarly serum starved
the cells for 24 hr and then treated the cells with human insulin for 1 hr before scrape loading. When
treated with insulin we observed little-to-no change in the NB dye spread compared to serum
starved control (18.75% vs. 18.98 ± 2.09%, n = 45; ns). Taken together the results suggest that
acute phosphorylation effects activated by EGF enhance Cx45 mediated cell coupling.
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Figure 4.6. Transfection with v-Src impairs Cx45 GJIC.
HeLa cells stably expressing Cx45 were cultured in glass bottom dishes, scrape loaded with NB, fixed, stained
with Streptavidin-488, and imaged. NB dye transfer (green) was assessed visually. Nuclei are stained with
DAPI (blue) to illustrate cell confluence.

160

15.8 Acute Exposure to Pervanadate Increases GJ Plaque Formation
To further investigate the effects of acute phosphorylation on Cx45 we used pervanadate
to transiently increase Tyr phosphorylation of Cx45 (see Fig. 2.12B). We tested the segregation of
Cx45 into junctional and non-junctional pools after pervanadate exposure. MDCK cells were grown
to confluence, treated with fresh pervanadate for 15 min, lysed, extracted, and fractionated the
protein by ultracentrifugation. Notably, 15 min of pervanadate treatment in our experience has been
the longest we can treat cells without observing significant loss of viability. Representative Western
blot analysis of the total, soluble, and insoluble fractions of Cx45 are shown in Fig. 4.8A.
Quantification of three independent experiments by densitometry indicated a statistically significant
increase in the junctional (insoluble) fraction of Cx45 after pervanadate treatment. The insoluble
portions of Cx45 under control conditions was 37.6 ± 0.92% and increased to 45.6 ± 4.2% when
treated with pervanadate (Fig. 4.8.B and C; T-test, P <0.05). The data taken together with scrape
loading data suggest acute and chronic effects on GJIC can be diverse.
15.9 PMA Enhances Anchoring of Cx45 to Cytoskeleton in MDCK and HeLa Cells
In addition to Src and Pyk2, we also detected phosphorylation of the Cx45CT by PKCα in
our kinase screen. Although several studies have examined the potential role for PKC regulation
of Cx45 by phosphorylation, the results have not been consistent [86, 189, 306, 385, 520].
Consequently, we wanted to assess the potential effects of activation of PKCα on Cx45 in our own
hands. Since the Hertlein et al. study suggested phosphorylation by PKCα promoted Cx45 stability
through the use of various mutants where loss of phosphorylatable Cx45 Ser residues correlated
with decreased protein stability, we sought to examine mechanistically how this may occur [189].
In order to address this, MDCK or HeLa cells stably expressing Cx45 were cultured, treated for 1
hr with PMA (or vehicle), and then analyzed by IP and Western blot for several proteins as well as
general Tyr and Ser phosphorylation. Representative Western blot for MDCK (Fig. 4.9) and HeLa
(Fig. 4.10) cells are presented here. In MDCK cells following treatment with PMA, we observed an
increase in the active pool of Pyk2 (activated downstream of PKCα via Src [489, 492, 498, 499])
as assessed by increase Pyk2 (pY402). This indicated our treatment with PMA was successful in
activating PKC. Furthermore, when we blotted for general pSer and pTyr, we observed a PMA
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dependent increase in both Cx45 Ser and Tyr phosphorylation (Fig. 4.9; black arrows). Importantly,
we observed this increase in total phosphorylation to correlate with increased association with the
cytoskeletal anchoring proteins ZO-1, Drebrin (Fig. 4.9; black arrow), and β-tubulin. The increases
in association of the cytoskeletal anchoring proteins is consistent the conclusions made by the
Hertlein et al. study on the stability of Cx45 [189]. Since the MDCK cells endogenously express
Cx43, we wanted to confirm our results in a cell line devoid of Cx43. We used our Cx45 stable
expressing HeLa cells to test this. Following the same approach as in the MDCK cells, we cultured
HeLa cells, treated for one hr with PMA, and analyzed the cells by IP and blotting for general
phosphorylation and the cytoskeletal protein partners. Similar to MDCK, PMA treatment for one hr
induced activation of Pyk2 (Fig. 4.10). We also detected increased activation of Src by Western
blotting for Src (pY416) and total Src. Interestingly, total levels of Src were observed to increase,
but not proportionally to the increase in detected active Src. Finally, we directly determined that
PMA activated PKCα blotting with an antibody against PKCα (pT638), observing an increase in the
active form of PKCα (Fig. 4.10; comparing total levels of PKCα and pT638). Notably, treatment with
PMA reduced the total expression of PKCα in both MDCK and HeLa cells. An early study of Cx45
phosphorylation by Laing et al. demonstrated that activation of PKC by PMA in a smooth musclelike cell derived from embryonic rat heart (BWEM cells) resulted in decreased expression of Cx45
[385]. It is likely the differences in observed total Cx45 expression levels may be cell line specific,
herein we demonstrate this effect occurs in two diverse cell lines confirming our results were not
impacted by co-expression of Cx43. In addition to increased total expression of Cx45, we observed
PMA dependent increases in both Ser and Tyr phosphorylation in HeLa cells, consistent with our
results in MDCK cells. Interestingly, the Laing et al. study, suggested that in BWEM, cells activation
of PKC with PMA did not alter Cx45 phosphorylation levels by radiography of [ 32P] metabolically
labeled cells [385]. This difference either highlights a cell-type specific pathway, differences in
treatment times and concentrations (30 min and 50 nM in Laing et al.; 1 hr and 100 nM herein), or
limitations in the ability of the Cx45 antibody used in the Laing et al. study to IP all phosphoisoforms
of Cx45 [385]. While all are reasonable possibilities the latter has been observed for Cx43 (for
example see [523]). In combination with our results from two diverse cell lines and the observation
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Figure 4.7. More physiologically relevant activation of Src by stimulation of the EGFR by
EGF enhances Cx45 GJIC.
HeLa cells stably expressing Cx45 were culture to confluence in glass bottom dishes, serum starved for 24
hr, and then treated with either EGF (100 ng/mL) or insulin (100 nM) for 1 hr. Cells were then scrape loaded
with NB and Texas Red Dextran, fixed, stained with Streptavidin-488, and imaged. NB dye spread was
measured as a function of total area of field of view from a minimum of 10 non-overlapping fields of view in
each of three independent replicates. Statistics are one-way ANOVA with a Newman-Keuls post-hoc
comparison. ***P <0.0001
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Figure 4.8. Acute pervanadate treatment enhances Cx45 GJ
plaque incorporation.
MDCK cells stably expressing Cx45 were cultured to confluence and then
treated with 100 µM pervanadate for 15 min to increase total Tyr
phosphorylation. Cells were then lysed, extracted with TX-100 and
fractionated into total (T), non-junctional (soluble – S), or junctional (insoluble
– I) pools of Cx45. A) Representative Western blot of the fractionation of
Cx45. B) Quantification of three independent experiments by densitometry.
C) Comparison of the total amount of insoluble Cx45. Statistics for B) are
one-way ANOVA with a Newman-Keuls post-hoc comparison and (*P <0.05,
**P <0.01) C) Two-tailed Student’s T-Test (*P <0.05).
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Figure 4.9. PMA increases Cx45 Tyr and Ser phosphorylation and
enhances cytoskeletal anchoring in MDCK cells.
MDCK cells stably expressing Cx45 were cultured and treated for 1 hr with 100 nM PMA
and lysed. Lysates were subjected to IP with an antibody against the Cx45 CL and
Western blotted with antibodies against general pSer, pTyr, Drebrin, β-tubulin, and ZO1. Phosphorylation of Pyk2 (pY402) was used as a marker for PKC activation.
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Figure 4.10. PMA increases Cx45 Ser and Tyr phosphorylation and enhances
interactions with cytoskeletal anchors in HeLa cells.
HeLa cells stably expressing Cx45 were cultured and treated for 1 hr with 100 nM PMA and lysed.
Lysates were subjected to IP with an antibody against the Cx45 CL and Western blotted with
antibodies against general pSer, pTyr, Drebrin, β-tubulin, ZO-1, and ZO-2. Phosphorylation of PKCα
(pT638), Pyk2 (pY402), and Src (pY416) were used as marker of PKC activation.
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that some Cx43 antibodies are conformation specific, it is highly likely this is the case and presents
an important caveat in the analysis of IP of phosphorylated proteins when changes in the amount
of precipitated protein are detected. When blotting for cytoskeletal partners, we observed an
appreciable increase in the association of Drebrin, ZO-1 and ZO-2 pulled-down by Cx45 after PMA
(a second tight-junction actin cytoskeletal anchoring protein). We were unable to test the
association of ZO-2 with Cx45 in MDCK cells as the available antibodies were not reactive to canine
ZO-1, however, our observations of increased ZO-1 and Drebrin are consistent with the results we
obtained in MDCK cells (Fig. 4.9). For β-tubulin little-to-no change in the amount that came down
with Cx45 was observed between vehicle and PMA treated cells (Fig. 4.10). It is possible that
regulation of the microtubule network in HeLa cells (a cancer line) and MDCK cells (a kidney
epithelial line) by signal transduction is different. Another possibility is that species specific
differences in the primary sequence of β-tubulin or binding site for β-tubulin on Cx45 may result in
different outcomes.
15.10 Treatment with PMA Does Not Affect Cx45 GJ Plaque Formation
Following our observation of increased association of the cytoskeleton anchors β-tubulin,
Drebrin, ZO-1, and ZO-2 we hypothesized this would correlate with an increase in the amount of
Cx45 present in the junctional pools. We therefore tested this by TX-100 solubility assay and
analyzed the results by SDS-PAGE and Western blot. To test this in absence of any influence from
Cx43, we treated and analyzed Cx45 from our stable HeLa line. We initially treated cells for 1 hr
with PMA as we did in our IP experiments previously. Comparing levels of junctional and nonjunctional Cx45 after 1 hr of PMA we observed little-to-no change in the immunoreactivity of Cx45
(Fig. 4.11A and B; S – 47.2% vs. 49.0%, I – 52.8% vs. 51.0%, ns). In order to determine if timedependent changes may occur beyond the 1 hr treatment period, we additionally treated cells for
2 and 4 hr and evaluated them in the same manner (Fig. 4.11A and B). Similar to 1 hr of PMA
treatment, we observed little-to-no change in either the soluble or insoluble pools of Cx45 (Fig.
4.11B; 2 hr S – 51.8% vs. 53.0%, I – 48.2% vs. 47.0%, ns; 4 hr S – 49.3% vs. 49.5%, I – 50.7% vs.
50.5%, ns). Finally, to determine if minute changes were present we compared the vehicle-to-PMA
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Figure 4.11. PMA does not affect Cx45 GJ plaque stability.
HeLa cells stably expressing Cx45 were cultured and treated with 100 nM PMA for 1, 2, and 4 hr periods and
then lysed, extracted with TX-100, and fractionated into total (T), non-junctional (soluble – S), and junctional
(insoluble – I) Cx45 pools by ultracentrifugation. Resulting fractions were analyzed by SDS-PAGE and
Western blot. A) Representative Western blots of Cx45 fractions. B) Quantification of three independent
replicates using densitometry by ImageJ. C) Ratio of vehicle:PMA treated samples of the S and I fractions at
each time point. Statistical analysis used was one-way ANOVA with a Newman-Keuls post-hoc comparison.
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ratios at each time-point for both soluble and insoluble pools of Cx45 (Fig. 4.11C; 1 hr S – 0.969, I
– 1.04; 2 hr S – 0.986, I – 1.03; 4 hr S – 0.998, I – 1.00). Consistent with our direct quantification
by densitometry no difference was detected between vehicle and PMA treatments at any time point.
15.11 Activation of PKC by Treatment with PMA Impairs Cx45 GJIC
Stemming from our observation that PMA did not alter the GJ plaque incorporation of Cx45
and the previous conflicting reports on the effects of PMA on Cx45 GJIC we sought to evaluate this
in our own hands as well. In the van Veen et al. study ROS cells were used which endogenously
co-express Cx43 [306]. Conversely, the Martinez et al. study used HeLa cells to study Cx45 in the
absence of influence from other Cx family members [86]. In order to assess the effect of PMA on
Cx45 in isolation in our study we similarly used HeLa cells. After culturing HeLa cells expressing
Cx45 to confluence, the cells were treated for 1 hr with PMA and scrape loaded with NB, fixed,
stained, and imaged. Representative fluorescent micrographs are presented in Fig. 4.12.
Importantly, NB dye spread was observed in vehicle treated cells comparably to the untreated cells
in Fig. 4.6. When quantified as a function of area of field of view vehicle treated cells were observed
to have a total dye spread of 23.6 ± 2.46% of the field area. When cells were treated with PMA
communication was still observed, however, the total area of dye spread was significantly reduced
(Fig. 4.12; vehicle 23.6% vs. PMA 19.74 ± 3.26%; T-Test; P <0.0001). This observation is in conflict
with the dye transfer results presented by the Martinez et al. study [86].
15.12 MS Identifies Cx45 Residues Phosphorylated by Src, Pyk2, and PKCα
Functionally, we have provided several pieces of data that suggest activation of Src, Pyk2
(indirectly), and PKCα regulate Cx45. Unfortunately, without explicit knowledge of the residues
phosphorylated by each of the kinases, attribution of a given effect to a specific kinase remains
correlative at best. For Cx43 phosphoisoform specific antibodies are essentially responsible for our
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Figure 4.12. Treatment with PMA impairs Cx45 GJIC in HeLa cells.
HeLa cells stably expressing Cx45 were culture to confluence in glass bottom dishes then treated with either
vehicle or PMA (100 nM) for 1 hr. Cells were then scrape loaded with NB and Texas Red Dextran, fixed,
stained with Streptavidin-488, and imaged. NB dye spread was measured as a function of total area of field
of view from a minimum of 15 non-overlapping fields of view in each of three independent replicates. Statistics
are two-tailed Student’s T-Test. ***P <0.0001
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current degree of understanding of the regulation of Cx43 by phosphorylation (reviewed in [524]).
Regrettably, while several high-quality commercial Cx43 phosphoisoform specific antibodies exist,
there are currently none for Cx45. In order to lay the groundwork for the development of
phosphoisoform

specific

Cx45

antibodies

and

simultaneously

identify

Cx45

residues

phosphorylated by Src, Pyk2, and PKCα we purified Cx45CT (K265-I396; for example of
purification, see Fig. 3.2) and phosphorylated it in vitro with Src (recombinant human full-length,
Sigma), Pyk2 (recombinant human residues 360-690, SignalChem), or PKCα (recombinant human
full-length, SignalChem). The resulting phospho- and non-phosphoproteins were resolved by SDSPAGE and the bands corresponding to Cx45CT were cut from the gel and submitted to the Beth
Israel Deaconess Mass Spectrometry Core Facility at Harvard for PTM mapping. A summary of the
residues identified as phosphorylated by each kinase is presented in Fig 4.13. For Src (Fig. 4.13A)
Tyr residues 324 and 356—the latter is present in the Cx45CT dimerization domain—were
identified by peptides that mapped to this region containing mass shifts of 80 Da, consistent with a
phosporyl moiety (data not shown). Similar to Src, for Pyk2 phosphorylated Cx45CT we also
identified Tyr residues 324 and 356 (Fig. 4.13B, peptides detected not shown). Interestingly, for
Cx43CT our laboratory has also detected identical phosphorylation by MS from Src and Pyk2 [295].
When we phosphorylated Cx45CT with PKCα and analyzed by MS we observed phosphorylation
of several Ser residues and one Thr residue (Fig. 4.13C). Specifically, we observed Ser
phosphorylation on residues 326, 376, 378, 381, 381, 384, and 385; and detected Thr
phosphorylation on residue 392 (Fig. 4.13C; peptides detected not shown). Of note, T392 is
immediately followed by a Ser residue, so the possibility exists that this is erroneous placement of
the phosphate during analysis, however, this remains to be tested.
15.13 Cx45CT Mutants Confirm MS and Identify Additional Phosphorylated Tyrosines
Although MS identified only two Tyr residues phosphorylated by either Src or Pyk2, at
least one other Tyr (Y301) has been identified as phosphorylated in other studies utilizing high
through-put MS that did not directly investigate Cx phosphorylation [525, 526]. Furthermore, despite
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Figure 4.13. MS reveals residues of Cx45CT phosphorylated in vitro by Src, Pyk2, and PKCα.
Cx45CT (K265-I396) was expressed in E. coli., purified as in Kopanic et al. (2014), and in vitro phosphorylated
by Src, Pyk2, or PKCα. Reactions were resolved by SDS-PAGE, the bands for Cx45CT were cut out and
submitted to the Beth Israel Deaconess Mass Spectrometry Core Facility at Harvard for PTM mapping.
Summary of residues phosphorylated (red) by A) Src, B) Pyk2, and C) PKCα.
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the high sensitivity of MS at a tool for identifying PTMs, there are limitations to its use, such as the
inherent failure of some peptides to fly in MALDI-TOF [320, 527]. Additionally, the high-throughput
discovery-type nature of MS requires subsequent validation of through the use of low-throughput
methods due to the high kinase concentration used in the reaction which can result in aberrant
hyperphosphorylation. In order to validate the results of our MS analysis on Src and Pyk2
phosphorylated Cx45CT we generated single Tyr mutants of Cx45CT (Table 6) where all CT Tyr
residues (7 total) except 1 were mutated to Phe to focus analysis to phosphorylation on a specific
residue. We in vitro phosphorylated Cx45CT WT and each of the 7 single Tyr mutants with either
Src (Fig. 4.14A) or Pyk2 (Fig. 4.14B), resolved the resulting proteins by SDS-PAGE, and then
Western blotted for pTyr using a general pTyr antibody. In addition to validating the MS data, this
method allows for determining the “primary” target of the specific kinase as it will be the mutant with
the highest degree of pTyr signal detected. As negative control a second reaction was prepared
replacing the kinase volume with excess reaction buffer. For Src we observed robust
phosphorylation of Cx45CT WT as expected. When analyzing the single Tyr mutants, Cx45CT
Y324 displayed the highest degree of pTyr signal, followed by Y301, then Y275, and finally Y356.
The data validates Tyr residues 324 and 356 as phosphorylated by Src (as detected in the MS
data), and identified novel Tyr residues 275, and 301. Importantly, the data identifies Cx45 Tyr
residue 324 as the primary target for Src. For Pyk2 we followed an identical approach to validate
the residues identified by MS. Similar to Src, we observed phosphorylation on the MS identified
sites as well as additional residues. In order of decreasing signal strength, we observed Tyr
phosphorylation of Cx45CT WT > Y324 > Y301 ≈ Y277 > Y275 ≈ Y356. Our results therefore
validate the MS identified Tyr residues (324 and 356) as well as identified novel Tyr residues (275,
277, and 301), of which Tyr 324 is also the primary target for Pyk2.
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Figure 4.14. Cx45CT single Tyr mutants reveal novel
phosphorylated residues and validate in vitro MS
results.
Cx45CT WT (K265-I396) and mutants where all but the indicated
Tyr residue have been mutated to Phe, were in vitro
phosphorylated by A) Src or B) Pyk2. Reactions were resolved
by SDS-PAGE and Western blotted with a general pTyr antibody
to detect phosphorylation.
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15.14 Phosphorylation of Y356 Reduces Cx45CT A333-N361 Dimerization Affinity
Although Y324 was identified as the primary target for both Src and Pyk2, we have
significant interest in Y356 as it is identified as a critical residue mediating the dimerization of the
Cx45CT domain [247]. As such we sought to determine if phosphorylation of Y356 would affect
Cx45CT dimerization. To test this, we purchased peptides (LifeTein) corresponding to Cx45CT
A333-N361 that was either not phosphorylated on Y356 (npY356) or was phosphorylated on Y356
(pY356) and subjected them to AUC sedimentation equilibrium (example curves shown in Fig.
4.15). Importantly, analysis of observed mass revealed both peptides sedimented primarily as
dimers (npY356 – 7.332 ± 0.17 kDa; pY356 – 6.541 ± 0.12 kDa). However, based on calculated
molecular weight the npY356 peptide (3.458 kDa), the observed mass suggests a small
contribution from the presence of higher order oligomers. Previous characterization of recombinant
Cx45CT A333-N361 observed a similar phenomenon, where the recombinant peptide (including a
linker not present in the synthesized peptide) sedimented with a mass consistent with a primarily
tetrameric arrangement [247]. In the same study the KD for the monomer-dimer species was
calculated to be 141 nM [247]. We did not calculate the KD for the npY356 peptide, however for the
pY365 peptide we calculated the KD and determined it to be 531 ± 284 µM. Taken together the data
indicates phosphorylation of Cx45 Y356 severely impacts the affinity of dimerization.
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Figure 4.15. Phosphorylation of Y356 reduces the dimerization affinity of
Cx45 A333-N361 by an order of seven magnitudes.
Peptides corresponding to A333-N361 with or without phosphorylation of Y356 were
synthesized by LifeTein. Peptides were dialyzed into 1x PBS pH 7.4 and their oligomeric
status was assessed by AUC sedimentation equilibrium. Observed mass and dimerization
affinity for the A333-N361 (pY356) peptide are inlaid on the left plots. Plots shown are for
speeds: 24,000 (left) and 30,000 (right) RPM.
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15.15 Cx45 Y356 Phosphorylation Does Not Alter Structure of A333-N361
Although there are many mechanism by which phosphorylation may be reducing the
dimerization affinity of Cx45 A333-A361, one possibility is that phosphorylation may alter the
secondary structure of residues A333-N361. Any change in structure that results in loss of the
hydrophobic face of the A333-N361 (either by loss of helix entirely or by “over-tightening” it as
acetonitrile does) would reasonably alter the KD of the homodimerization. To test whether
phosphorylation of Y356 affects A333-N361 secondary structure both npY356 and pY356 peptides
were subjected to CD spectroscopy to analyze overall secondary structure (Fig. 4.16). Similar to
what was observed in our previous study, the secondary structure of the npY356 (Fig. 4.16; black
line) peptide is consistent with that of an α-helix, indicated by the presence of a local maxima at
195 nm, and two local minima at 208 and 222 nm respectively. When phosphorylated on Y356 (Fig.
4.16; red line), we observed a decrease in the magnitude of the local maxima at 195 nm, as well
as a slight positive change in magnitude (i.e., less negative) for the local minima at 208 and 222
nm. This suggest there may be a mild decrease in the total amount of helical character, however,
the overall trace is consistent with an α-helical structure and we therefore conclude that
phosphorylation has not significantly altered the structure of the peptide. On a technical note, the
difference observed in the traces could also be explained by differences in calculated MRE as this
is a function that is concentration dependent. Phosphorylation of Tyr residues reduces the
extinction from 1,490 M-1cm-1 (ExPasy ProtParam value for Tyr) to ~650 M-1cm-1, thereby reducing
the reliability of A280 in determining concentration [528]. To circumvent this, A205 (measures the
peptide bond absorbance [529]) was utilized, however, the effect of phosphorylation of side chains
on the A205 of peptide to our knowledge has not been explored, and thus the possibility exists that
even using A205 may introduce a margin of error that modestly affects analysis.
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Figure 4.16. Phosphorylation of Y356 does not alter A333-N361 secondary structure.
Peptides corresponding to A333-N361 with or without phosphorylation of Y356 were synthesized by LifeTein.
Peptides were dialyzed against 1x PBS pH 7.4 and then the secondary structure was assessed by CD
spectroscopy from 190 – 250 nm. The curves are presented as mean residual ellipicity (MRE).
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15.16 Phosphomimetic Cx45 Y356E Localizes Similar to Cx45 WT
As one final experiment, we hypothesized phosphorylation of Cx45 Y356 may regulate
Cx45 in cells since it reduced the affinity of the dimer. To test this, we created a phosphomimetic
mutant Cx45 Y356E and used that to generate a stable expressing MDCK cell line. As we have on
numerous accounts, we used immunofluorescence of the localization of Cx45 as an indicator of
major phenotypic changes in trafficking, plaque incorporation, or degradation. Representative
immunofluorescent micrographs of Cx45 WT and Y356E expressed in MDCK cells are presented
as Fig. 4.17. Cx45 (green) is seen in both Cx45 WT and Y356E as primarily punctate GJ plaques
studding the cell surface with a significant contribution of intracellular puncta as well. This was not
surprising, as phosphorylation of the Tyr reduced dimerization affinity, but since the concentration
of CT domain present in the connexon would be in excess of 500 µM ([CT] in connexon ~ 25 mM;
[231]), even the CT of phosphorylated Cx45 would still be present primarily as a dimer.
Furthermore, the use of Glu as a substitution for pTyr, although well accepted in the GJ field is not
a perfect mimetic, as it lacks the ring stacking interactions and the negative charge is not equivalent.
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Figure 4.17. Phosphomimetic Cx45 Y356E similarly to Cx45 WT.
MDCK stably expressing Cx45 Y356E were cultured on glass coverslips, fixed, and immunostained for Cx45
(green) and imaged on a Zeiss LSM 800 confocal microscope. Nuclei were stained with DAPI (blue). Cx45
WT from Fig. 3.4 has been included for ease of comparison. Scale bar for Cx45 WT = 20 µm, and for Y356E
= 10 µm.
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16. Discussion
In this Chapter, we have presented numerous observations confirming and expanding
upon previous reports that Cx45 is a phosphoprotein [189, 385]. Although, these previous studies
detected Cx45 phosphorylation [189, 385], and in some cases attributed functional effects of
activation of a specific kinase [86, 306, 385], no direct connections to a specific kinase or
phosphorylated residue were presented. We used an in vitro screen to identify several kinases that
phosphorylate the Cx45CT. Specifically, a number of the kinases that were able to phosphorylate
the Cx45CT are known to be involved in AngII signaling [491, 492, 498, 499, 504, 509].
Upregulation of AngII in the bloodstream is a hallmark of both hypertensive patients and those
suffering from end-stage heart failure [530]. Similarly, Cx45 expression in the myocytes of ventricles
has been shown to increase in a number of models of heart disease and in human patient samples
[67, 75, 79, 82]. The understanding how phosphorylation of Cx45 affects its function in context of
heart disease is critical for the development of novel therapeutic targets. Importantly, while Cx45
expression increases in the ventricles, Cx43 expression is reduced [67, 71, 75, 84, 531]. Residual
Cx43 has therefore been demonstrated to form heteromeric channels with Cx45 and suggested to
form the basis for arrhythmias via altered electrical properties of the resultant heteromeric channels
[31, 86, 87]. Despite this notion, work in native cardiac murine GJs has suggested that the presence
of Cx45 in the ventricles did not alter the organ level electrical properties of the heart (i.e., ECG,
QRS duration, etc.) [83]. Additionally, the study identified a number of Cx45 residues
phosphorylated in vitro by CaMKII and CK1, several of which we also identified as phosphorylated
by PKC [83]. One caveat to the study of Bao et al. is their focus on the outcome of Cx45/Cx43
heteromeric channels in healthy hearts [83]. While this is important, it does little to examine how
the presence of Cx45 alters electrical properties of the heart in the diseased state, which is notably
characterized by a vastly altered kinase landscape, including increased expression and activation
of PKC, Pyk2, and Src [491, 492, 498, 499, 504, 509].
Our results demonstrate the Cx45CT domain is efficiently phosphorylated in vitro and in
cyto by Src, leading to impaired and enhanced GJIC under chronic and acute Src activation,
respectively. When v-Src was overexpressed, we observed a decrease in the total amount of
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junctional (TX-100 insoluble) Cx45, that correlated with impaired transfer of NB dye and increased
Tyr phosphorylation. The loss in junctional Cx45 was consistent between both LA25 cells at the
Src permissive temperature and HeLa cells transiently transfected with v-Src. Surprisingly, we did
not observe a gross change in the localization or punctate GJ staining of Cx45 in LA25 when Src
was active, which has been demonstrated for Cx43 [325]. The mechanism behind this remains to
be determined, however, one possibility is the anecdotal increase in total Cx45 expression when
Src was overexpressed (HeLa) or active (LA25). Contrastingly, we observed an increase in NB dye
transfer when we treated HeLa cells with EGF to achieve more physiological levels of Src
activation. Our results with EGF treatment highlight a difference in the regulation of Cx45 and Cx43
by the EGFR signaling. A study by Warn-Cramer et al. studying the regulation of Cx43 used EGF
to treat cells and measured the Cx43 mediated gj and observed a rapid decrease in coupling within
4 minutes of treatment [532]. The authors attributed this affect specifically to the Cx43 MAPK sites,
as mutation of S255,279,282 prevented the downregulation of GJIC by EGF treatments [532]. For
Cx45 in our system, whether this is directly linked to Src or alternate pathways activated by EGF
remains to be determined. Regardless, the result indicates a dichotomy may exist between acute
and chronic stimulation of signaling pathways or alternatively low vs. high levels of phosphorylation.
This is supported by variable results of several studies using EGF to affect GJIC [533-539]. In the
bulk of these studies EGF treatment disrupted GJIC on a short time frame (30 min to 1 hr), however
in the study by Vikhamar et al. an increase in Cx43 mediated GJIC was observed 2-3 hr after
treatment with EGF [533-539]. The authors speculated this may be a function of the low native
coupling observed in the K7 cells they used in the study [539]. Another acute effect we observed
was the increase in junctional Cx45 in MDCK cells treated with pervanadate, a stimulus we
previously demonstrated increases the amount of total Tyr phosphorylation on Cx45 [424]. Due to
the very short test period it is unclear what the fate of the Cx45 protein would have been 30-45 min
later. Finally, for Src we detected phosphorylation on Y275, Y301, Y324, and Y356, of which Y324
was the apparent primary target.
In addition to regulation by Src, our results suggest that Cx45 GJIC is also modulated by
PKC as well. Although we did not detect alterations in the GJ plaque dynamics of Cx45 in response
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to PKC activation, we did observe a number of phenomena worth discussing. First, we observed
increased ability of Cx45 to co-IP several cytoskeletal proteins when cells were treated with the
PKC activator PMA. In both HeLa cells and MDCK we observed an increase in the amount of
Drebrin and ZO-1 that precipitated with Cx45. In HeLa cells, we additionally detected an increase
in the amount of ZO-2 pulled down, which we were unable to assess in MDCK cells due to antibody
recognition issues. The only non-consistent change in protein partner binding we observed was for
β-Tubulin, in MDCK we observed an increase while in HeLa no change. Notably, when cells were
treated with PMA we observed an increase in the total levels of Cx45 Ser and Tyr phosphorylation
indicating that PMA is activating a Tyr kinase downstream of PKC that can phosphorylate Cx45,
perhaps Src [511]. Although we have not explored the signaling pathway in detail to determine
which kinases are contributing to the phosphorylation of Cx45 subsequent to PMA treatment, the
enhanced associations linking Cx45 to the structural network of the cell is of particular interest. This
is in contrast to Cx43, whose association with the cytoskeleton is generally disrupted by increased
Tyr phosphorylation [286, 295, 325, 378]. A notable difference between Cx43 and Cx45 is the
binding sites for the cytoskeletal proteins (predicted: β-Tubulin (R267-P273; MAPred [540]);
empirically determined: Drebrin (T283-K312; Sorgen Laboratory, unpublished data) and ZO-1
(K371-I396; Kopanic et al. [247])) is the lack of Tyr residues phosphorylated by Src, except Drebrin
which has one Tyr phosphorylated by Src while Cx43 has three in the Drebrin binding domain [295].
Consistent with the conclusions of Hertlein et al., the increased affinity of cytoskeletal proteins and
correlated stability (at least to 4 hr) suggest that phosphorylation of Cx45 by PKC contributes to
Cx45 GJ stability [189]. Importantly, residues identified by Hertlein et al. to contribute to Cx45
stability in their study were identified as phosphorylated by PKC in our MS analysis [189]. In contrast
to the studies of van Veen and Martinez et al., we observed a PMA dependent decrease in NB
transfer [86, 306]. Few differences exist between our study and that of van Veen et al. that may
explain the difference in our results, HeLa cells expressing mouse Cx45 were utilized in each study,
the major differences are the method of detection (macroscopic conductance vs. dye coupling) and
the timeframe addressed (0-5 min vs. 1 hr after addition of PMA). It is possible that on our time
scale we are observing effects mediated by downstream effectors of PKC, however to this will need
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to be addressed directly by future studies. Similar to the van Veen et al. study, Martinez et al. used
HeLa cells expressing mouse Cx45, they however measured both macroscopic conductance and
dye coupling [86]. Key differences in these two studies are the concentration of PMA used to treat
cells (100 nM vs. 200 nM)) and the timeframe of analyses, which for the Martinez et al. study was
more in line with our own [86, 306]. Although, Martinez et al. concluded no statistical difference in
the NB dye transfer of Cx45 channels after 30 min of PMA, they did observe a non-statistical
decrease [86]. It is possible this decrease would have become more pronounced at 1 hr if that
assay had been continued. Indeed, when they measured macroscopic conductance after 1 hr of
PMA treatment they did note a reduction in gj [86].
The study of contributions to the regulation of Cx45 by Pyk2 at this point are merely
correlative. We observed an increase in Pyk2 activity as measured by autophosphorylation of Y402
when cells were treated with PMA. In fact, lack of high-quality selective inhibitors for Pyk2 make
investigating its role in phosphorylating Cx45 difficult to separate from either Src or PKC. Despite
this, our results have shown a number of Cx45 residues that are phosphorylated by Pyk2, all but
one of which (Y277) are also targeted by Src. We have observed a similar trend for the
phosphorylation of Cx43 by Pyk2 and Src as well (Sorgen Laboratory, unpublished data). Current
models link Src and Pyk2 activity the scaffolding protein Paxillin, where Src is required for enhanced
activation of Pyk2 via phosphorylation of residues Y579/580 on Pyk2 [505, 541]. Due to the physical
link (Paxillin) between these two kinases and the reliance of Pyk2 on Src for its full activity, it is
unlikely Pyk2 is ever the “lone gunman” kinase, but rather fine-tunes the effects of Src. The
development of inhibitors selective for Pyk2 will no doubt be essential for delineating its specific
role in regulating Cx45 (and Cx43).
Although knowledge of the regulation of Cx43 by phosphorylation is broad, that of Cx45 is
quite limited. Very few studies investigate the outcome of activation of specific kinase programs on
Cx45 function and those that have do not make a direct link to phosphorylation of any specific
residue of Cx45. In this Chapter, we have used a diverse set of approaches (biophysical, cellular
and molecular biology, and proteomics) to investigate phosphorylation of Cx45. Our results confirm
previous studies that have demonstrated Cx45 is a phosphoprotein and expand on the notion that
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Cx45 is regulated by kinases active downstream of the AT1R [189, 385]. Additionally, our results
suggest that important differences may exist in the regulation of Cx45 by kinases when compared
to Cx43, a feature that may contribute to maintained Cx45 expression in the ventricles of diseased
hearts as well as the arrhythmogenic substrate.
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CHAPTER FIVE

Cross-regulation of the Cardiac
Connexins: Cx45 Protects Cx43
From Kinase Initiated Turnover
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17. Introduction
In Chapter Four we characterized the phosphorylation of Cx45 by kinases (Src, Pyk2,
PKCα) active downstream of the AT1R [491, 492, 498, 499, 504, 509]. Additionally, all three of the
kinases similarly phosphorylate Cx43 (Pyk2 – Sorgen Laboratory, unpublished data) [296, 300].
The effects of Src and PKC on Cx43 mediated GJIC are well characterized and lead to the downregulation of coupling through either channel closure, loss of cytoskeletal anchoring and
internalization, or the combination of these [19, 286, 295, 296, 300, 325, 337, 339, 351, 372-376,
480, 482-484, 542]. Our results in Chapter Four suggest that aspects of the regulation of Cx45 by
these kinases, at least in the acute stage are different than that of Cx43 (EGF increased Cx45 GJIC
and PMA enhanced cytoskeletal anchoring supporting plaque stability). Since Cx45 and Cx43 can
form heteromeric channels the question arises how these kinases would affect the regulation of
heteromeric channels. It stands to reason that in cells that express two or more Cx family members
compatible to form heteromeric channels, that regulation of all aspects of the heteromeric channels
are likely more complex than either individual counterpart. Indeed, a number of observations
support this. For example, dye coupling properties of Cx43-Cx45 heteromeric channels in HeLa
cells fail to couple LY (anionic) while NB dye coupling is maintained, suggesting Cx45 exerts a
dominant negative effect on Cx43 [86]. Similarly, in NRK cells stably transfected with the lens Cx56
(NRK-Cx56), the current-voltage relationship was altered compared to that of untransfected NRK
cells (endogenously express Cx43) [543]. Specifically, the untransfected NRK cells displayed a
decay of current following a voltage pulse of >50 mV and the rate of decay was proportional to the
magnitude of the voltage pulse [543]. Conversely, the NRK-Cx56 cells maintained current
conductance following the voltage pulse without appreciable decay, suggesting that the presence
of Cx43-Cx56 heteromeric [543]. Finally, two studies examining the formation of heteromeric
channels between Cx43 and Cx40 in vascular smooth muscle cells observed significant differences
in dye permeability and channel electrical properties [544, 545]. Although all of these studies
highlight differences in channel properties formed from intermixing of Cx family members, only the
Martinez et al. study investigated the regulation of the heteromeric channels by phosphorylation
[86]. In their study, they noted that NB coupling of Cx45 homomeric channels were unaffected by
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addition of PMA (contrary to our results in Chapter Four), however, when Cx43 was co-expressed
they observed significant reductions in NB dye coupling, suggesting the presence of Cx43 exerted
some regulatory role on Cx45 in response to phosphorylation [86].
Studies have hinted at the potential for heteromeric channel formation in the failing heart.
In the ventricles of human patients with heart failure, Yamada et al. noted an increase in the protein
expression of Cx45 by approximately 2-fold, that correlated with an increase in immunostaining by
3.5-fold compared to non-failing hearts [82]. Notably, Cx45 mRNA levels in the failing hearts was
unaltered suggesting that Cx45 protein stability was increased by some mechanism in the failing
hearts [82]. Additionally, the presence of Cx45 in the failing heart increases the susceptibility to
tachyarrhythmias [432]. While the mechanisms of how Cx45 expression was upregulated and
maintained in these systems was not explored, altered regulation by kinases maybe a contributing
factor. Notably, in Chapter Four, when we immunostained Cx45 and Cx43 in the stable Cx45
expressing LA25 cells we observed Cx43 still present at the GJ plaque where it colocalized with
Cx45 at the Src permissive temperature contrary to what was observed in our previous study by Li
et al. [340]. We therefore sought to investigate the potential cross-regulation of Cx45 on Cx43 in
heteromeric channels in LA25 cells.
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18. Materials and Methods
18.1 Antibodies and Reagents
All antibodies and reagents for this study are contained in Table 2.
18.2 Cell Culture and Stable Cell Line Generation
LA25 cells (gifts from Dr. Paul Lampe, Fred Hutchinson Cancer Center) were cultured in
Dulbecco’s modified Eagle medium (Corning) at 37°C in a humidified 5% CO 2 atmosphere. Medium
was supplemented with 10% FBS (Seradigm), 2 mM L-glutamine (HyClone), 1% pen-strep
(Corning), and 0.2% Normocin (Invivogen). The selective agent puromycin (Tocris) was used, when
appropriate, at empirically determined concentrations. 70% confluent LA25 cells were lipofected
with SalI linearized plasmid using Lipofectamine 2000 at a 1:2 ratio in OptiMem. Transfections were
carried out under antibiotic free conditions, and cells were cultured 48-72 hr prior to addition of
selection media. LA25 cells were selected 7 µg/mL. Cells were clonally (monoclonal) selected using
Whatman paper cloning disks. Western blots and immunofluorescence were used to screen clones.
Src activity, in LA25 cells, was modulated by culturing the cells at 35°C (permissive – Src active),
37°C (intermediate), or 40°C (non-permissive – Src inactive) for 8 hr.
18.3 siRNA Knock-down of Exogenous Cx45
Parental (Cx45-) LA25 cells or those stably expressing Cx45 (Cx45+) at approximately 60%
confluent were lipofected with stealth siRNA designed against the exogenous mouse Cx45 using
Lipofectamine RNAiMAX according to manufacturer protocol under antibiotic free conditions, cells
were cultured 48 hr prior to any analysis. Complexes were generated in OptiMem. siRNA was
designed using the Invitrogen design tool against the coding region (CDS) of accession number
NM_001159382.1. siRNA duplex sequence: 5’-UUUGCUUGUAGGCAAUCUUAGCAUU-3’ and 5’AAUGCUAAGAUUGCCUACAAGCAAA-3’
18.4 Antibodies and Immunostaining
All primary and secondary antibodies, detection reagents and concentration ranges utilized
are summarized in Table 2. Cells seeded on glass coverslips were rinsed 2x with 1x PBS and then
fixed and permeabilized with either ice cold methanol at -20°C for 15 min or buffered formalin (1x
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PBS, 3.7% formaldehyde, 0.3% TX-100) at 37°C for 30 min. LA25 cells were incubated at 35°C,
37°C, and 40°C for 8 hr prior to fixation. For siRNA mediated knock-down of exogenous Cx45, at
60% confluence cells were transiently transfected with siRNA as described in 18.3. Coverslips were
washed 3x 5 min in 1x PBS with gentle agitation and then blocked for 60-90 min at 37°C (1x PBS
containing 1% BSA and 0.3% TX-100). Coverslips were then incubated with the indicated primary
antibodies diluted in blocking buffer for either 1 hr at RT or ON at 4°C. Coverslips were washed 3x
with 1x PBS and then incubated with secondary antibody (if necessary) 1 hr at RT and then washed
1x for 5 min with 1x PBS containing 100 ng/mL DAPI and then 2x 5 min with 1x PBS. Coverslips
were mounted with SlowFade (LifeTech) and sealed with clear nail polish and imaged. All images
acquired on either Zeiss 710 or 800 LSM microscope.
18.5 Scrape Loading Dye Transfer Assay
Cells were scrape loaded as previously described [340]. Briefly, all buffers were prewarmed to 37°C prior to beginning the experiment. Cx45- or Cx45+ LA25 cells were seeded on
bovine plasma fibronectin (Sigma; 10 µg/mL) coated 35 mm live imaging dishes (CellStar). After
appropriate treatments cells were washed 1x with 1x PBS and then overlaid with dye tracer mix (1x
PBS containing NB). LA25 cells were incubated for 8 hr at either 35°C or 40°C prior to scrape
loading. Scrapes were introduced using a fine edged micro-scalpel and incubated at RT for 4 min.
Tracer dye was gently washed away with 1x PBS and media was added and the cells returned to
the incubator to culture for 6 min to allow dye to transfer. Following the dye transfer period, the cells
were washed with 1x PBS containing 1 mM CaCl2 and 1 mM MgCl2 to stop dye spread. Dishes
were then formalin fixed and stained as described above and imaged. 15 consecutive fields of view
were acquired per replicate. Dye spread was quantified using an ROI tool in NIH ImageJ measuring
the dye spread as a function of total area of field of view.
18.6 TX-100 Solubility Assay
The TX-100 solubility assay was modified from a method described previously [412].
Briefly, Cx45- or Cx45+ LA25 cells were grown in 10-cm dishes were washed with PBS, scraped
into in 1 mL of fresh PIB and mechanically lysed by sonication (10 s at power 3). Lysates were
quantified by BCA and normalized to 1.5 mg/mL. A total of 450 µL of cell lysate was brought to 1%
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SDS with 10% SDS and then reserved as total lysate. Another 450 µL was brought to 1% TX-100
with 10% TX-100 in 1x PBS and incubated at 4°C for 30 min with agitation. The TX-100 lysate was
then separated into non-junctional (supernatant; soluble) and junctional (pellet; insoluble) fractions
by ultracentrifugation at 100,000 xg for 1 hr at 4°C. The supernatant was carefully removed and
retained as the soluble fraction. The pellet was solubilized in 500 µL of solubilization buffer (1x
PBS, 8 M urea, 2.5% SDS, 0.1 M DTT, 1x Roche complete + EDTA, 2 mM PMSF, and 2 µM
Pepstatin A). Volume normalized samples of total lysate (T), TX-100 soluble (S) and TX-100
insoluble (I) portions were analyzed by Western blot. LA25 cells were incubated at either 35°C or
40°C for 8 hr prior to analysis. Soluble and insoluble fractions were quantified as a function of total
lysate. Specifically, for Cx43 quantification was done using samples resolved on a 15% SDS-PAGE
to ensure collapse of the multiple phosphorylation depended migratory forms into a single band.
Quantification was done using NIH ImageJ software from three independent replicates.
18.7 Statistical Analysis
All data were analyzed by using GraphPad Prism 5.0 and were presented as the mean +
s.e.m. Statistical analysis performed in GraphPad Prism 5.0 was either one-way ANOVA with a
Newman-Keuls post-hoc analysis comparing all groups, or two-tailed Student’s T-Test where
appropriate. P-values <0.05 were considered statistically significant.
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19. Results
19.1 Cx45 Prevents Src Mediated Turnover of Cx43 Containing GJs
Since we observed a maintenance of Cx43 immunoreactivity consistent with GJ plaques
in LA25 cells expressing Cx45 at the Src permissive temperature in Fig. 4.4 we hypothesized this
would correlate with reduced TX-100 solubility. To test this, we cultured Cx45- or Cx45+ LA25 cells
to confluence, then incubated them for 8 hr at either the Src non- or permissive temperatures.
Expression of Cx45 was assessed in both Cx45- or Cx45+ LA25 cells by Western (Fig. 5.1A)Cells
were lysed, extracted and resolved by SDS-PAGE and analyzed by Western blot for Cx43 (we
used a high percentage gel to collapse Cx43 phosphoisoforms into a single band for ease of
quantification) (Fig. 5.1B). At the Src non-permissive temperatures, we observed no difference in
the junctional pool of Cx43 regardless of Cx45 expression (Fig. 5.1C, dashed lines; Cx45- 56.5%
vs. Cx45+ 55.9%, ns, N=3). When comparing the Src permissive to the Src non-permissive
temperature within each group (i.e., Cx45- to Cx45-), we observed a significant decrease in the
amount of junctional Cx43 at the Src permissive temperature compared to the non-permissive (Fig.
5.1B, solid lines; Cx45- 40°C – 56.5% vs. 35°C – 30.7%, P <0.0001; Cx45+ 40°C – 55.9% vs. 35°C
– 39.6%, P <0.0001, N=3). Finally, when comparing the amount of non-junctional and junctional
Cx43 between the Cx45- and Cx45+ LA25 cells at the Src permissive temperature, we observed a
difference in the degree of change in Cx43 (Fig. 5.1C, dashed lines; Cx45- 30.7% vs. Cx45+ 39.6%,
P <0.05, N=3). In Cx45- LA25 cells we observed only 35% of Cx43 remaining in the junctional pool,
while for Cx45+ LA25 this was ~45%. Suggesting that Cx45 was stabilizing some of the Cx43 at
the GJ plaque. In parallel, we resolved Cx43 on our standard 10% SDS-PAGE gel to display the
multiple migratory forms (Fig. 5.1D).
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Figure 5.1. Cx45 mutes the effect of Src on Cx43, reducing the transition of junctional to
non-junctional Cx43.
Cx45- and Cx45+ LA25 cells were cultured to confluence and incubated at 40°C or 35°C for 8 hr. Cx43 was
extracted with TX-100 and fractionated into total (T), non-junctional (TX-100 soluble, S) and junctional (TX100 insoluble, I) fractions by ultracentrifugation. A) Representative Western blot showing the expression of
Cx45 in the Cx45- and Cx45+ LA25 cell lines B) Representative Western blot of resulting fractions analyzed
by 15% SDS-PAGE and probed for Cx43. C) Quantification of 15% blots from three independent experiments.
D). Representative Western blot of Cx43 fractions resolved on 10% SDS-PAGE demonstrating multiple
electrophoretic forms of Cx43. Statistics are one-way ANOVA with a Newman-Keuls post-hoc analysis, *P
<0.05, ***P <0.0001.
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19.2 Knock-down of Exogenous Cx45 Results in Src Mediated Cx43 Turnover
To follow up with our TX-100 data from the previous experiment, we hypothesized that the
increase in Cx43 GJ stability in the Cx45+ LA25 cells would be lost if expression of Cx45 was
abrogated. We cultured Cx45+ LA25 cells on glass coverslips to 60% confluent and then treated
with siRNA designed against the exogenous Cx45 for 48 hr. Following siRNA treatment, the cells
were maintained for 8 hr at the Src non-, intermediate, or permissive temperatures, fixed and
immunostained the cells. Representative immunofluorescent micrographs are presented in Fig.
5.2. As expected when LA25+ were treated with siRNA, we observed a stark decrease in the
expression of Cx45 indicating the knock-down was successful (Fig. 5.2; red; right panels). This was
surprisingly more efficient at the Src permissive temperature than either intermediate or nonpermissive. Immunoreactivity of Cx43 in the mock transfected LA25+ was similar in pattern and
degree at all three temperatures (Fig. 5.2; green; left panels), however, when Cx45 was knocked
down we observed a Src activity dependent loss of Cx43 immunoreactivity (Fig. 5.2; green; right
panels). In fact, after 8 hr at the Src permissive temperature the majority of Cx43 staining was
completely lost. Furthermore, few if any GJ plaques were observed. Taken together with the TX100 data, this further supports the hypothesis that Cx45 protects Cx43 from the effects of Src.
19.3 Presence of Cx45 Does Not Protect Against Src Mediated Channel Closure
Our immunostaining and TX-100 data suggest that expression of Cx45 is a factor that
contributes to maintained GJIC in cells expressing Cx43 when Src is active. We wanted to test this
using scrape loading transfer of NB in Cx45- and Cx45+ LA25 cells. Experimentally, we cultured
either Cx45- or Cx45+ LA25 in glass bottom dishes to confluence, incubated them at 35°C or 40°C
for 8 hr, and then scrape loaded them with NB. Following loading the cells were fixed, stained with
Streptavidin-488, and imaged. Representative fluorescent images are presented in Fig. 5.3. Dye
spread was quantified as a function of the percent of total area in the field of view. At the Src nonpermissive temperature, we observed no difference in the amount of NB transfer between Cx45or Cx45+ LA25 cells (Fig. 5.3, top panels, green; Cx45- 53.9 ± 7.67% vs. Cx45+ 53.2 ± 5.95%). To
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Figure 5.2. Knock-down of exogenous Cx45 restores Cx43 lability when Src is active.
Cx45- and Cx45+ LA25 cells were cultured to ~60% confluent on glass coverslips and either mock transfected
(left panels) or transfected with siRNA designed against the exogenous Cx45 (right panels). After 48 hr of
siRNA or mock transfection the cells were incubated at the Src non-permissive, intermediate, or permissive
temperature for 8 hr, followed by fixation and immunostaining for Cx43 (green) and Cx45 (red). Nuclei were
stained with DAPI (blue). Scale bars = 20 µm.
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our surprise, we observed a Src dependent decrease in the amount of NB dye transfer at the Src
permissive temperature for both cell lines (Fig. 5.3, bottom panels, green; Cx45- 28.1 ± 5.53% vs.
Cx45+ 27.6 ± 5.80%). Quantification indicated the degree of change in GJIC in response to Src
activation was comparable between Cx45- and Cx45+ LA25 cells (Fig. 5.3; right). Taking into
consideration our observation of Src mediated loss of coupling in HeLa cells when transiently
transfected with v-Src, the possibility exists that our model is resulting in aberrantly high levels of
phosphorylation not physiologically relevant. It would be interesting to determine how these cells
respond to EGF treatment.
19.4 Cx43 Maintained in GJs by Cx45 Shows Altered Phosphorylation Patterns
Since we observed a comparable Src dependent decrease in GJIC in both Cx45 - and
Cx45+ LA25 cells, yet a decrease in the amount of Cx43 GJ disassembly, we wanted to determine
whether the phosphorylation pattern of the residual junctional Cx43 was consistent with that of
open or closed channel conformations. To test this, we probed only the insoluble fraction of Cx43
from our experiment in Section 19.1 with several phosphospecific antibodies for Cx43 and
normalized to the amount of total insoluble Cx43 (Fig. 5.4). For Src phosphorylation sites, we
probed Cx43 with antibodies against pY247, pY265, and pY313. For pY247 we observed a nonsignificant increase (2.03-fold for Cx45+ at 35°C compared to 40°C; 1.66-fold for Cx45- at 35°C
compared to 40°C, N=3) in the amount of pY247 relative to total insoluble Cx43 (Fig. 5.4; top right
panel). For the primary Cx43 Src phosphorylation site, Y265 (first site phosphorylated by Src to
generate SH2 binding site), we observed a statistically significant increase (1.42-fold Cx45+ at 35°C
compared to 40°C; 1.01-fold change in Cx45- at 35°C compared to 40°C, P <0.05, N=3) in the
amount of pY265 in the Cx45+ LA25 cells at 35°C compared to Cx45- (Fig. 5.4; upper-central right
panel). For Cx43 Y313, we observed comparable levels of phosphorylation in the insoluble fraction
of both Cx45- and Cx45+ LA25 cells at the Src permissive temperature (Fig. 5.4; center right panel;
1.76-fold for Cx45+ at 35°C compared to 40°C; 1.82-fold for Cx45- at 35°C compared to 40°C, ns,
N=3). In addition to the Src phosphorylation sites, we also probed the Cx43 MAPK sites (S279/282)
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Figure 5.3. Cx45 does not prevent Src mediated downregulation of GJIC in LA25 cells.
Cx45- and Cx45+ LA25 cells were cultured to confluence in glass bottom dishes and subsequently incubated
for 8 hr at either 40°C (top panels) or 35°C (lower panels) and then scrape loaded with NB dye. Following
scrape loading the cells were fixed and stained with Streptavidin-488 (green) and DAPI (blue) to show cell
confluence, and then imaged. The degree of NB dye transfer was quantitated in ImageJ by measuring the
total area of dye spread as a function of total area of field of view. Images were acquired from a minimum of
10 non-overlapping fields of view from each of three independent replicates.
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for phosphorylation and our results indicate the presence of Cx45 significantly reduced the degree
of phosphorylation at S279/282 (Fig. 5.4 lower-center right panel; 1.71-fold for Cx45+ at 35°C
compared to 40°C; 4.14-fold for Cx45- at 35°C compared to 40°C, P <0.05, N=3). Finally, we probed
the insoluble Cx43 for phosphorylation of S368 (PKC site). Similar to the MAPK sites, we observed
a significant decrease in the amount of S368 phosphorylation in the Cx45+ LA25 cells (1.07-fold
change at 35°C compared to 40°C for Cx45+; 2.27-fold increase for Cx45- at 35°C compared to
40°C; P <0.0001, N=3). Taken together, the data suggest that the co-expression of Cx45 is altering
the phosphorylation landscape of Cx43 in response to increased Src activity. Although we did not
directly compare the levels of Cx43 phosphorylation at 40°C, it is worth noting that we did observed
increased Cx43 phosphorylation on Y247 and Y265 by co-expression of Cx45 alone, the
significance of this observation is unclear at this time.
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Figure 5.4. Cx43 is maintained the GJ plaque with altered phosphorylation landscape when
Cx45 is co-expressed in LA25 cells.
Cx45- and Cx45+ LA25 cells were cultured to confluence and incubated at 40°C or 35°C for 8 hr. Cx43 was
extracted with TX-100 and fractionated into total (T), non-junctional (TX-100 soluble, S) and junctional (TX100 insoluble, I) fractions by ultracentrifugation. Resulting insoluble fractions were resolved by SDS-PAGE
and Western blotted for total Cx43, and Cx43 phosphorylation at residues Y247, Y265, Y313, S272/282, and
S368. A) Representative Western blots of total and phospho Cx43 from the insoluble fractions. B-F)
Quantitation of Cx43 phosphorylation in the insoluble pool relative to total insoluble Cx43. Statistics are oneway ANOVA with a Bonferroni multiple comparison test comparing Cx45 - to Cx45+ in each temperature group.
*P <0.05, ***P <0.0001
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20. Discussion
Although the existence of heteromeric oligomerization of Cxs has been accepted for over
a decade, studies investigating them are not plentiful. Of the studies that do explore the
consequences of heteromeric channel formation, a vast majority have focused on aspects of
channel trafficking, GJIC, and gating (reviewed in [546, 547]). For example, Berthoud et al.
demonstrated altered the voltage dependence in heteromeric channels composed of Cx43 and
Cx56, compared to homomeric Cx43 channels [543]. Similary, in N2a cells Brink et al.
demonstrated channels composed of intermixed Cx37 and Cx43 displayed conductance/voltage
relationships different from either family member alone [548]. Consistent with the Brink et al. and
Berthoud et al. studies, a study by He et al. attributed altered GJ channel propertied in Ar75 (rat
vascular smooth muscle cells) to the co-expression of Cx40 and Cx43 [543, 544, 548]. Specifically,
they reported changes in voltage sensitivity and residual conductance at high voltage in the Ar75
compared to cell lines only expressing either Cx40 or Cx43 [544]. A 2008 study by the Dupont
group examined the effects of co-expressing Cx45 and Cx43 in HeLa and rat lung epithelial (RLE)
cells and concluded that expression of Cx45 significantly reduced GJ plaque size [88]. Notably,
several studies have examined the ability of wild-type Cxs to rescue trafficking (and functional)
defects of mutant Cxs (both homomerically and heteromerically) [452, 549-551]. Finally, Martinez
et al. also investigated heteromeric channels composed of Cx43 and Cx45 in HeLa cells, reporting
that co-expression reduced the dye permeability of the cells to LY, and resulted in the appearance
of single channel conductance recording that could not be attributed to Cx43 or Cx45 alone [86]. In
the same study, the authors examined the effects of PKC activation by PMA to determine if
heteromeric Cx43/Cx45 channels would respond to PKC more complexly than either homomeric
counterpart [86]. Compared to Cx43 homomeric GJs PKC similarly affected Cx43/Cx45, rapidly
reducing conductance and dye coupling, while compared to Cx45 PKC had much less pronounced
effect on conductance and did not affect dye coupling [86]. To our knowledge, the Martinez et al.
study is unique in investigating the link between response to kinase activation and connexon
composition [86]. Despite this, the data presented in the study only suggests a casual role for the
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kinase and did little to explore the mechanism leading to altered function in of the Cx43/Cx45
heteromers.
In this Chapter we took a cellular biology approach to begin to understand the outcome of
having two heterocompatible Cxs co-expressed in the context of Src kinase activation. Although
the work is preliminary it suggests that a heteromeric channels respond more complexly to
regulatory stimuli such as phosphorylation. One example we presented is the ability of Cx45 to
protect Cx43 from Src mediated turnover assessed by detergent solubility. Although the amount of
retained insoluble Cx43 in the Cx45+ cells was only ~10% greater than in Cx45- cells this actually
represents a substantial rescue of ~40%. Supporting our detergent solubility results, a second
example is when exogenous Cx45 was knocked down by siRNA, we observed Src activity
dependent loss of Cx43 GJs and expression that was not observed when Cx45 was expressed.
The significance of these results is two-fold, on one hand this could maintain coupling potential and
promote communication, however, due to the dominant negative effect of Cx45 on Cx43, in the
heart, this could explain why aberrant expression of Cx45 leads to arrhythmia while lateralization
and reduction in expression of Cx43 alone does not [72, 73, 76, 82, 84, 432, 438]. Although we
observed an increase in Cx43 retention at the GJ plaque, we did not observe a functional rescue
in terms of dye coupling. This raises the question: Why does heteromeric mixing of Cx43 and Cx45
result in plaque maintenance if the channels are still closed? It is possible that this is a protective
mechanism that would retain a working quantity of Cx43 at the GJ plaque poised to reopen upon
more favorable conditions thus promoting GJIC. This supposition is consistent with studies
describing: 1) A similar mechanism may occur involving CaM and its interaction with Cx32, in which
reduced Tyr phosphorylation of Cx32 by EGFR stimulation has was reported in the presence of
CaM [298]. 2) An interaction of CaM with the CT domain of Cx43 that would in part prevent the
internalization of Cx43 by blocking the Nedd4 and AP2 binding sites, potentially preventing
ubiquitination and subsequent clathrin mediated endocytosis (Sorgen Laboratory, unpublished
data). Furthermore, our probing of the insoluble fraction of Cx43 with phosphospecific antibodies
supports this as we observed a significant decrease in the percentage of Cx43 that was
phosphorylated by MAPK, which would reduce the affinity of Cx43 for Nedd4 and consequently
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reduce binding of AP2 [203, 382]. Consistent with MAPK phosphorylation of Cx43 occurring
simultaneously as phosphorylation by PKC, the decrease in phosphorylation of S279/282
correlated with a decrease in phosphorylation of S368 [325]. While this data in consistent with the
decrease in both turnover and phosphorylation of S279/282, the functional significance is unclear
at this time. In order to obtain a clearer picture, the ability to interrogate phosphorylation of Cx43 at
the CK1 and PKA sites (S325,328,330 and S365, respectively) would be essential. Nevertheless,
the data supports the concept that regulatory complexity increases as Cx proteins intermingle.
The work in this Chapter raises important novel questions about heteromeric channels: 1)
What determines which Cx family member is dominant, is it a function of stoichiometry? 2) Does
protomer arrangement within the connexon contribute to the regulation? 3) Do heteromeric
channels respond bimodally in response to acute/chronic signaling pathway activation (e.g., 1 hr
EGF vs. v-Src transfection for 24 hr)? 4) Physiologically speaking, what is the advantage of
maintaining GJs in the plasma membrane in situations that would normally lead to turnover? 4)
Furthermore, what does this reflect in terms of potential therapeutic value? Future studies should
focus efforts on addressing these questions as well as expanding them to other heterocompatible
Cx co-expression systems especially under endogenous or in vivo conditions.
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CHAPTER SIX

Regulation of Cx32 by Ephrin
Receptors and TC-PTP

The bulk of data presented in this Chapter is published Trease et al.

(2018), Journal of Biochemistry [552]
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21. Introduction
GJ are comprised of tight knit arrays of membrane channels that connect the cytoplasm of
adjacent cell and function to allow the passive transport of ions, small metabolites, and signaling
molecules between coupled cells. Their function is important for several cellular and tissue
processes including cell growth, maintenance, differentiation, and tissue synchronization. Of the 21
human family members, Cx32 is the primary GJ protein in both liver and brain, as well as the
reproductive tissues [553]. Mice harboring Cx32 KO suffer from increased incidence of
spontaneous tumors in the liver and are more susceptible to chemically induced liver tumors as
well [554, 555].

Additionally, other pathological conditions arise in Cx32 KO mice including

impaired innervated bile secretion, increases release of the enzyme amylase from the pancreas,
and loss of myelination in the peripheral nervous system [556-559]. Mutations in Cx32 are an
etiological source of the X-linked CMTX syndrome. Over 400 unique mutations have been identified
in Cx32, encompassing every domain of Cx32 [560]. Many of the mutations affect Cx32 GJ function
by impairing trafficking, gating properties, selectivity, interactions with protein partners, or the
phosphorylation status [561].
Phosphorylation is a critical regulator of every point in the Cx life cycle, such as accretion,
turnover, the regulation of channel opening/closure, and modulating the affinities for binding of
protein partners [328]. The intracellular domains of Cx32 contain 12 Ser residues (NT, 2; CL, 1;
CT, 9) and has been phosphorylated in vitro by CaMKII, PKA, and PKC [365, 478, 562]. Although
demonstration of changes in Cx32 phosphorylation status were not assessed, activation of the
MAP kinase p38, correlated with differentiation of rat mammary epithelial cells [563]. In addition to
Ser residues the intracellular domains of Cx32 also contains two Tyr residues (NT, Y7; CT, Y243).
A third Tyr (Y211) is present in a membrane juxtaposed region of the Cx32CT, however, may not
be accessible to cytoplasmic enzymes. If Y211 is accessible it is unlikely to interact with any
proteins (including enzymes) due to steric hindrance from the plasma membrane itself. Cx32 was
shown to be Tyr phosphorylated in purified liver membranes by stimulation of the RTK EGFR, and
this phosphorylation was prevented when excess CaM was present [248, 365]. Although Cx32 Tyr
phosphorylation was detected, neither the specific residue(s) phosphorylation nor the effect on
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Cx32 GJ function were determined [365]. Phosphorylation of Y7 was detected in a MS study
utilizing exogenous Cx32 expression in HeLa cells, however, potential kinases targeting this site
were not revealed [274]. The lack of information on the kinases involved, sites phosphorylated, and
downstream effects of Cx32 Tyr phosphorylation, we screened the Cx32NT and Cx32CT in vitro
for candidate kinases and identified the Ephrin type-B receptor 1 (EphB1) and Ephrin type-A
receptor 1 (EphA1) as novel Tyr kinases which phosphorylate Cx32.
Both Eph receptors and ligands (the ephrins) are integral membrane proteins and mediate
both forward (Eph receptor) and reverse (ephrin) signaling in response to cell-cell contact. Signaling
downstream of the Eph receptor has been shown to influence cell migration and sorting during
development, modulate adhesion, neuronal injury repair, and importantly GJ [366, 564-566]. Cx43
was demonstrated to co-IP EphB4, and when EphB4 was activated in primary rodent
cardiomyocytes Cx43 GJIC was inhibited [567]. Along the same lines it was shown by another
group that GJIC was reduced in ectopic ephrin boundaries and Cx43 localization was influenced
via interaction with ephrin-B1 [366]. Taken together these studies highlight a potential mechanism
by which cell coupling via GJs is regulated by cell-cell contact through Eph receptors and ephrins
that is both dependent and independent of phosphorylation of the GJ proteins. Whether the
phosphorylation of Cxs by Eph receptors is direct and whether this mechanism is general to multiple
Cx family members remains to be investigated.
In this study, we reveal that Eph receptors (EphB1 and EphA1) phosphorylate the Cx32CT
on residue Y243, and consequently (and conversely to what would be expected for Cx43) increase
GJIC. We also identify T-Cell Protein Tyr Phosphatase (TC-PTP) as a phosphatase that can
dephosphorylate Cx32CT residue pY243. This study provides further support that the outcome of
Cx phosphorylation by a given kinase is determined not by the kinase but by the cx family member,
and thus characterization of the same kinase for each Cx family member is essential for a complete
understanding of the regulation of Cxs by phosphorylation.
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22. Materials and Methods
22.1 Cell Culture and Treatments
Cx32 WT, Y243F, and Y243E cloned into the pD2529 vector as described previously, were
stably expressed in HeLa cells (ATCC) [424]. HeLa and Caco2 cells were grown in Dulbecco's
modiﬁed Eagle's medium (Hyclone, Thermo Fisher Scientific Inc.) supplemented with 10% FBS
(Hyclone, Thermo Fisher Scientific Inc.) and antibiotics. FHC cells were cultured in DMEM:F12
supplemented with 25 mM HEPES, 10 ng/mL cholera toxin, 0.005 mg/mL insulin and transferrin,
100 ng/mL hydrocortisone, 20 ng/mL human recombinant EGF, 10% FBS, and antibiotics. All cells
were cultured in an atmosphere of humidified 5% CO 2 at 37°C. Where appropriate, cells were
transiently transfected with either EphA1, EphB1, or a combination of either in conjunction with TCPTP1-314 using Lipofectamine 2000 (Invitrogen) according to manufacturer protocol. For single and
combination transfections, the amount of plasmid for the Eph receptor and TC-PTP1-314 was
equivalent. Cells were treated for 1 hr at 37°C with 1 µg/mL of either EphA1-Fc or EphB2-Fc
(SinoBiological) approximately 24 hr after transfection.
22.2 Antibodies and Immunostaining
The following antibodies were used in this study: Cx32 monoclonal antibody (SigmaAldrich); Cx32 polyclonal antibody (LifeTech); EphB1 and EphA1 antibodies (Cell Signaling);
EphA1 antibody (Cell Signaling); TC-PTP antibodies against the N-terminus and C-terminus
(Sigma-Aldrich); general pTyr antibody (Cell Signaling).
Cells were immunostained as described previously [424]. Briefly, cells grown on cover slips
to ~60% confluence were fixed with 2% para-formaldehyde for 15 min. Cells were blocked for 30
min at room temperature (RT) by MPS buffer (1x PBS, 1% Goat Serum) containing 0.2% TX-100
for permeabilization. Then, cells were immunostained with appropriate primary antibodies at RT for
1 hr, followed by several PBS-0.5% Tween washes. Secondary antibodies (Alexa 594-conjugated
goat αrabbit antibody and/or Alexa 488-conjugated goat αmouse antibody) were applied for 1 hr at
RT. Images of immunostained cells were acquired with a Zeiss 510 Meta Confocal Laser Scanning
Microscope using a 63×1.4 numerical aperture objective with appropriate filters.
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22.3 Co-IP and Western blot
Cx32 expressing HeLa cells were lysed in complete lysis buffer (50 mM Tris-HCl [pH 7.4],
150 mM NaCl, 0.5% Na-deoxycholate, 1% TX-100, 5 mM NaF, and one-half tablet of Complete
protease inhibitor (Roche) in 20 ml buffer), maintained on ice for 30 min, precleared with protein G
beads for 30 min at 4°C, and then spun at 12,000 rpm for 15 min. Total protein was assessed using
the BCA protein assay kit (Pierce). 2 mg of protein lysate was incubated with 2 μg of αCx32 or
mouse IgG (4 hr at 4°C) and then incubated with 100 μl of protein G sepharose (GE Healthcare)
(overnight (ON) at 4°C). The sepharose was washed 4x with cold lysis buffer and the co-IP was
analyzed by SDS-PAGE and Western blot. ΑEphB1 monoclonal antibody was used to detect
EphB1 co-IP with Cx32.
Protein levels were detected by SDS-PAGE and Western blot. One exception for detecting
Tyr phosphorylation was that 5 mM Na3VO4 was added in the blocking buffer and primer antibody
buffer in order to minimize the loss of phosphorylation. Western blot data were scanned and
quantified using Image J as described in [424].
22.4 GST Pull Downs
The GST pull down assay was modified from [203]. Briefly, purified GST, GST-Cx32NT, or
GST-Cx32CT were bound to glutathione-Sepharose beads in buffer containing 25 mM Tris-HCl
(pH=7.4),150 mM NaCl, 0.1% TX-100, 1 mM DTT, 0.1 mM EDTA and one-half tablet of Complete
protease inhibitor in 20 ml buffer. 5 mg of either purified TC-PTP1-314 was incubated with the GST
control or either fusion GST-fusion protein ON at 4°C on a rotating wheel. Beads were washed 5
times with buffer and bound proteins were eluted with SDS-PAGE sample buffer and analyzed by
Western blot.
To pull down Cx32 binding partners, 4 mg of MDA-MB-231 cell lysate protein (in cell lysis
buffer containing 25 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% TX-100, 0.5% sodium
deoxycholate, 2 mM EDTA, PhosSTOP (Roche), and Complete protease inhibitor) were incubated
with GST-fusion Cx32CT or the GST control for 6 hr at 4°C on a rotating wheel. Beads were washed
5 times with cell lysis buffer and bound proteins were eluted with SDS-PAGE sample buffer and
analyzed by Western blot.
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22.5 NMR-HSQC Experiment
NMR data were acquired using a 600 MHz Varian INOVA NMR Spectrometer outfitted with a
Bruker cryo-probe at the NMR Facility of the University of Nebraska Medical Center. Cx32CT 217-283
and TC-PTP1-314 were expressed and purified as described previously [248, 340]. Gradientenhanced two-dimensional 15N-HSQC experiments were acquired to detect backbone amide bond
resonances from the 15N-Cx32CT (30 μM) in the absence and presence of different concentration
of unlabeled TC-PTP1-314.
For testing the interaction with CaM, peptides corresponding to Cx32CT 217-266 (not
phosphorylated, nopY243) or Cx32CT217-266 pY243 were purchased (LifeTein) and

15N-CaM

was

expressed recombinantly and purified by affinity chromatography using a Phenyl HP column
(Amersham). Pure CaM was eluted with Tris-EGTA, dialyzed extensively against water, and
lyophilized. Gradient-enhanced two-dimensional
backbone amide bond resonances from the

15N-HSQC

15N-CaM

experiments were acquired to detect

(300 μM) in the absence and presence of

different concentration of either unlabeled Cx32CT 217-266 nopY243 or Cx32CT217-266 pY243. A similar
approach was used to test the impact of pY243 on the interaction with hDlg. 15N-HSQC experiments
were acquired to detect backbone amide bond resonances from

15N-Cx32CT

WT or Y243E (50

μM) in the absence and presence of unlabeled synapse associated protein 97-guanylate kinase
(SAP97-GUK701-924) domain. SAP97-GUK701-924 was purified as in [248]. NMR spectra were
processed using NMRPipe [568] and analyzed with NMRView [569]. Binding affinity from the

15N-

HSQC titration experiments were calculated by GraphPad Prism 5 (GraphPad Software, Inc.).
22.6 In vitro Phosphatase Assay
Cx32 phospho-peptide pY243 (HRLSPEpYKQNEIN) was used in the malachite green
assay (Millipore) to detect if they are substrates of TC-PTP in vitro. Positive and negative controls
were DADEpYL (described in [570]) and ARKRIpYPP (described in [571]), respectively. Peptides
and enzyme were dissolved and diluted in reaction buffer (60 mM HEPES [pH 7.2], 150 mM NaCl,
1 mM EDTA, 0.17 mM DTT, 0.83% glycerol, 0.017% BSA, and 0.002% Brij-35) and temperatureequilibrated for 15 min at RT. 500 μM of each peptide was added into a 96-well plate, and then TCPTP1-314 was added to each peptide at different time points. The final concentration of TC-PTP1-314
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was 0.6 nM. All reactions were terminated by adding 100 μl malachite green solution and incubated
for 15 min at RT to allow color development. Absorbance at 650 nm was read using a SpectraMax
190 spectrometer (Molecular devices).
The Malachite green assay was also used to measure the kinetic parameters of dephosphorylation [570]. The reaction was performed in 96-well plates with a final volume of 25 μl. A
standard curve of KH2PO4, used for calculating the release of inorganic phosphate, was determined
on the same plate as the reaction samples. Different concentrations of peptides [substrate] were
combined with 1.2 nmol TC-PTP1-314. Time points of the reaction were sampled from 0-15 min to
calculate the initial velocity (v) versus [substrate]. Lineweaver-Burk double-reciprocal plot
(rearranged from the Michaelis-Menten equation) was created based on 1/v and 1/[substrate]. The
kinetic parameters were determined by the linear equation from the Lineweaver-Burk doublereciprocal plot. All the reactions were conducted at pH 7.5, 25°C. The reported results were
calculated from three independent experiments.
22.7 Scrape Loading Assay
Cells were scrape-loaded as described in [248]. Briefly, either HeLa cells expressing Cx32 WT
or the Y243E mutant and Caco2 cells were seeded on cover slips 24 hr before performing the
assay. Cell culture medium from 100% confluent cells was removed and replaced with 1 ml of PBS
containing 0.25% Lucifer Yellow and Texas Red-conjugated fluorescent dextran (10 kDa, 1.5
mg/ml: fixable). Cells were scrape-loaded with a sterile scalpel by two longitudinal scratches and
then incubate at RT for 1 min for HeLa cells and 4 min for Caco2. Cells were washed quickly 3x
with warm PBS (containing MgCl2 and CaCl2) or cell culture medium followed by incubating at 37°C
for 5 min. After incubation, cells were washed 2 times with warm PBS, and fixed with 3.7% buffered
paraformaldehyde for 15 min. 0.1 M glycine was used to quench autofluorescence for 15 min.
Cover slips were mounted on glass slides in a droplet of SlowFade (Invitrogen). The result was
confirmed by repeating the experiment 3 times and for each trial, capturing 4 side-by-side images.
The method to quantify dye transfer was described previously [248]. Briefly, cells with Lucifer yellow
were counted while the cells with dextran, which indicated the initially loaded cells, were excluded.
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22.8 Statistical Analysis
All data were analyzed by GraphPad Prism 5.0 and presented as the mean ± standard
deviation (±S.D.). Either Student’s T-Test or one-way ANOVA with Newman-Keuls post hoc
analysis was used to compare differences between all groups, where appropriate. P <0.05 was
considered to be statistically significant.
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23. Results
23.1 EphB1 directly interacts and phosphorylates the Cx32CT domain
We initially used the web-based software tools GPS 2.0, NetPhos 2.0 Server, and
KinasePhos 2.0 to predict kinases that could phosphorylate Tyr residues on the NT and CT
domains of Cx32 (data not shown). Based on our in silico analysis, we chose five candidate Tyr
kinases to screen against the Cx32 NT and CT domains. We submitted purified Cx32NT (M1-G21;
Y7) and Cx32CT (C217-C283; Y243) as substrates to Eurofins Scientific for the in vitro screen
(KinaseProfiler; Fig. 6.1A). Of the five kinases EphB1 and Ron both phosphorylated the Cx32 CT
domain with greater than 50% and 40% of control peptide signal, respectively. EphB1 also
phosphorylated the Cx32NT to a level similar to that of the Cx32CT. Based on the importance of
Cx43CT Tyr phosphorylation in regulating Cx43 channel function, we sought to validate the
Cx32CT screen, and thus tested the ability of the EphB1, Ron, and EGFR (negative control) to
phosphorylate the purified Cx32CT in our laboratory. Our results, consistent with the Eurofins
screen, demonstrated clear phosphorylation of the Cx32CT domain by EphB1 and Ron kinase (Fig.
6.1B). Although we were unable to detect Tyr phosphorylation of the Cx32CT by EFGR, work from
Diez et al. used autoradiography to demonstrate that EGFR can phosphorylate IP enriched Cx32
in vitro [365]. This may suggest in our system the degree of phosphorylation was below the
detection limit of the general pTyr antibody, or alternatively that stimulation of EGFR leads to a
cascade that ultimately results in phosphorylation of Cx32 by some other downstream kinase. We
next sought to confirm an interaction of Cx32 with EphB1 and Ron using a GST pull down assay.
To accomplish this we purified GST alone, GST-Cx32NT, GST-Cx32CT and used these constructs
as bait for EphB1 and Ron from HeLa (expressing EphB1 and Ron, but not Cx32) cell lysate (Fig.
6.1C). We were able to successfully pull down EphB1 with the GST-Cx32CT, but not either GST
or GST-Cx32NT. The amount of EphB1 pulled down by the GST-Cx32CT was increased by the
addition of the chemical crosslinker DTSSP (3,3 ́-dithiobis[sulfosuccinimidylpropionate]; indicating
the interaction was stabilized [572]).
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Figure 6.1. EphB1 phosphorylates the Cx32CT domain in vitro.
A) The Cx32NT and CT domains were used as a substrate for the human EGFR, Blk, EphB1, Met, and Ron
kinases (performed by Eurofins Scientific). The amount of Cx32NT and CT phosphorylation was compared
with a positive control peptide for each kinase (% of control signal). The dashed line highlights 50% of the
control signal. B) An in vitro kinase assay for the Cx32CT was performed in our laboratory to repeat the kinase
screen performed by Eurofins Scientific (EphB1, Ron, and EGFR). A general anti-phospho-tyrosine antibody
was used to detect the phosphorylation level by Western blot. Control group used buffer to substitute the
kinases in the reactions. C) Purified GST alone, GST-Cx32CT (CT), or GST-Cx32NT (NT) bound on
glutathione-agarose beads were incubated without (-) or with (+) HeLa cell lysate and the pulled down proteins
were analyzed by Western blot using anti-EphB1 or anti-Ron antibodies. The chemical cross-linker DTSSP
was used to capture the weak and/or transient interactions. D) Co-IP was performed in HeLa cells stably
expressing Cx32. Lysates were captured by IP with anti-Cx32 or IgG and then blotted for Cx32 and EphB1.
Reprinted from Trease et al., (2018).
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Further confirming the interaction, co-IP revealed that EphB1 could complex with full-length
Cx32 from transfected HeLa cells (Fig. 6.1D). Although we detected robust phosphorylation of the
Cx32CT by Ron kinase in vitro, detection of Ron kinase in the GST pull down was very low, and
was not improved by the addition of DTSSP, nor was Ron detected to complex with Cx32 from
transfected HeLa cells in co-IP (data not shown). Thus, Ron was not included in any following
assays, highlighting a caveat in this type of in vitro screen where the phosphorylation in vitro does
not always correlate with a detectable interaction in cells.
23.2 TC-PTP interacts with and dephosphorylates Cx32CT residue pY243
Previous work from our laboratory demonstrated that TC-PTP dephosphorylates Cx43
residues Y247 and Y265, which promotes increased GJIC [340]. It is currently unknown whether
TC-PTP is able to target and dephosphorylate other Cx family members (e.g., Cx32 pY243). We
hypothesized TC-PTP may mediate a general mechanism by which Cx family members are
dephosphorylated and such sought to determine if it directly interacts with the Cx32CT domain. To
address this, we performed NMR titration experiments comparing purified Cx32CT alone to that of
Cx32CT mixed with the purified catalytic domain of TC-PTP (TC-PTP1-314). We acquired 15N-HSQC
spectra at a number of molar ratios of
6.2A). We observed changes in the

15N-labeled

15N-Cx32CT

Cx32CT217-283 and unlabeled TC-PTP1-314 (Fig.

spectra in response to increasing amount of TC-

PTP, such that at a 1:1 molar ratio, residues C217-S266 of Cx32CT (including Y243) had
broadened beyond detection (highlighted on the Cx32CT sequence in Fig. 6.2B; red peaks on
spectra).
The loss of 15N-Cx32CT signal from increasing TC-PTP1-314 concentrations was plotted and
fit according to the nonlinear least square method allowing for the determination of the KD (Fig.
6.2C), which was determined to be 19.9 ± 4.5 μM. To validate the NMR results we did a GST pull
down experiment with purified GST alone, GST-Cx32CT, or GST-Cx32NT as bait. The purified
proteins were incubated on glutathione-Sepharose with purified TC-PTP1-314, washed, and
analyzed by SDS-PAGE and Western blot. Analysis revealed a band consistent with the molecular
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Figure 6.2. Cx32CT residues affected by the direct interaction with TC-PTP.
A) Overlaid 15N-HSQC spectra of the 15N-Cx32CT alone (residues 217-283; 30 μM) and in the presence of
different concentrations of unlabeled TC-PTP1-314. The cross-peak color changes according to the
concentration ratio. The strongly affected peaks are labeled. B) Amino acid sequence of Cx32CT. Residues
affected by the addition of TC-PTP1-314 are highlighted in green. In red is Cx32 residues Y243. C) KD for the
TC-PTP1-314 interaction with Cx32CT was estimated by fitting the decrease in signal intensity as a function of
TC-PTP1-314 concentration. Represented are a subset of the residues used to calculate the KD. Reprinted from
Trease et al., (2018).
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weight of TC-PTP1-314, whose identity was confirmed as TC-PTP using an αTC-PTP NT antibody
that was pulled down by GST-Cx32CT, but not GST alone nor GST-Cx32NT (Fig. 6.3A, B). Taken
together with the NMR this demonstrates that TC-PTP directly interacts with the Cx32CT. We also
tested if GST-Cx32CT could pull down full length TC-PTP from HeLa cell lysate confirming by
Western blot (Fig. 6.3C).
Having confirmed a direct interaction between the Cx32CT and TC-PTP, we next sought
to determine if TC-PTP dephosphorylates Cx32 Y243. To test this, we ordered a peptide
corresponding to Cx32 residues H237-N249 phosphorylated on Y243 and incubated it with TCPTP1-314 in vitro. Using the Malachite green assay kit (Millipore) we observed an increase in the
absorbance of the reactions containing TC-PTP1-314 over time, indicating an accumulation of
inorganic phosphate (Fig. 6.3D). This confirmed that TC-PTP can dephosphorylate Cx32 Y243.
Importantly, when compared to the positive control peptide for TC-PTP we observed comparable
affinity of TC-PTP for both substrates as determined from the kinetic data in Table 7 (kcat/Km•10-6;
2.24±0.18 vs. 2.42±0.47).
23.3 EphB1 phosphorylates and TC-PTP dephosphorylates Cx32 in HeLa cells
Having demonstrated that EphB1 and TC-PTP modulate phosphorylation of Cx32 Y243 in
vitro we next wanted to determine if this effect could be reproduced in cells. We therefore transiently
transfected HeLa cells which stably expressed exogenous Cx32 WT with either EphB1 alone or in
conjunction with the TC-PTP1-314. We measured the level of Tyr phosphorylation by IP of Cx32 and
Western blotting with a general phospho-Tyr antibody (Fig. 6.4A, left lane). In the control condition
(no EphB1 or TC-PTP) we were unable to detect any Tyr phosphorylation on Cx32; however,
increased Tyr phosphorylation was detected when cells were transfected with EphB1 and activated
with the soluble ligand (Fig. 6.4A, middle lane). This effect was partially reversed by the cotransfection of TC-PTP1-314 with EphB1 (Fig. 6.4A, right lane).
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Figure 6.3. TC-PTP interacts
dephosphorylates pY243.

with

the

Cx32CT

domain

and

A) Purified GST, GST-Cx32NT, or GST-Cx32CT on glutathione sepharose beads were
incubated without (-) or with (+) purified TC-PTP catalytic domain (residues 1-314). After
washes, samples were run on SDS-PAGE gel and stained with Coomassie Blue. B) GST
pull down samples were blotted with the anti-TC-PTP NT antibody. The TC-PTP catalytic
domain is 36 kDa. C) Purified GST, GST-Cx32NT, or GST-Cx32CT bound on glutathione
beads were incubated with HeLa cell lysate containing endogenous TC-PTP. Pulled down
proteins were analyzed by Western blot using anti-TC-PTP NT or anti-GST antibodies. D)
Plot of the Malachite green assay shows the time course of Cx32 phospho-peptides
containing pY243 dephosphorylated by the TC-PTP catalytic domain (1.2 nmol). Data
were recorded based on readings at OD650. Each experiment was repeated three times.
Reprinted from Trease et al., (2018).
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Peptide

Km (mM)

kcat (s-1)

kcat/Km x 10-6 (M-1s-1)

Positive control*#

0.0220.001

52.810.6

2.420.47

pY243*

0.0280.007

63.313.8

2.240.18

*All data were collected at pH 7.5, 25°C.

Table 7. Kinetic constants for dephosphorylation of Cx32
pY243 by TC-PTP1-314.
Reprinted from Trease et al., (2018).
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Despite no detected interaction of the Cx32NT with EphB1 in our GST pull down (Fig. 6.2),
phosphorylation of the Cx32NT Y7 by EphB1 was detected in vitro, so we wanted to test if this
residue was phosphorylated in HeLa cells [274]. To accomplish this, we generated a Cx32 Y243F
mutant and created a stable expressing HeLa cell line. We used IP to enrich either Cx32 WT or
Cx32 Y243F from these cells and interrogated the level of Tyr phosphorylation by Western blot
(Fig. 6.4B). When the stable cells were transiently transfected with EphB1 we observed increased
Cx32 WT phosphorylation. Exogenous activation of the EphB1 receptor with a soluble version of
the high-affinity ligand ephrin-B2-Fc further increased the degree of Cx32 WT phosphorylation.
Confirming the specificity of EphB1 for phosphorylating Cx32 Y243 (not Y7 or Y211), no
appreciable Cx32 phosphorylation was detectable from cells expressing the Cx32 Y243F mutant.
23.4 Cx32 Y243E increases GJIC
In order to determine the specific effects of Y243 phosphorylation on Cx32 function, we generated
a Y243E mutant in addition to the Y243F mutant. Use of this mutant allows us to interpret the effects
of specific site phosphorylation as the mutation ensures there is enough “phosphorylated” protein
produced to observe a biological response. Use of the Glu substitutions for phosphorylated Tyr
residues is common accepted in the GJ field as a reasonable mimetic for phosphorylation, often
times reproducing the effects of bona fide phosphorylation (e.g., [344, 573]). Here, HeLa cells either
transiently or stably expressing Cx32 WT, Cx32 Y243F, or Y243E were used to determine the
impact of Y243 phosphorylation on Cx32 GJIC. We first wanted to determine if phosphorylation
altered subcellular localization of Cx32 and therefore immunostained HeLa cells transiently
transfected with Cx32 WT, Cx32 Y243F, or Cx32 Y243E (Fig. 6.5A). Our results suggest that
mimicking phosphorylation of Y243 did not disrupt trafficking to the plasma membrane or the ability
of the cells to make GJ plaques, as the Cx32 Y243E made GJ plaques of apparently similar size
and number (Fig. 6.5A; white arrows) although this was not directly quantified.
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Figure 6.4. EphB1 increases and TC-PTP decreases the Tyr phosphorylation level on Cx32.
A) HeLa cells stably expressing Cx32 were transfected with EphB1 and/or the TC-PTP catalytic domain
(residues 1-314). Cx32 was enriched by IP and tyrosine phosphorylation was detected with a general
phospho-tyrosine antibody. The level of tyrosine phosphorylation was quantified by densitometry from three
independent experiments. **P<0.01 (compared to control); ##P<0.01 (compared to EphrinB1) (One-way
ANOVA). B) HeLa cells stably expressing Cx32 wild-type (WT) or the Y243F mutant were transfected with
EphB1. EphrinB2-Fc was used to activate the EphB1 receptor. Cx32 was similarly enriched by IP and the level
of tyrosine phosphorylation detected by Western blot. **P<0.01 (compared to control); *** P<0.001 (compared
to EphrinB1) (One-way ANOVA). Black arrows indicate IgG light chain. Reprinted from Trease et al., (2018).
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Interestingly, the Cx32 Y243F mutant (mimicking non-phosphorylated Cx32 Y243) failed
to make any observable GJ plaques. To confirm this, we made stable expressing HeLa cell lines,
as expected, the localization and propensity to form GJ plaques mirrored that of the transient
transfections (Fig. 6.5A). To assess if the mutations affected protein expression levels we analyzed
stable cell lysates by Western blot (Fig. 6.5B). We determined that the expression of Cx32 WT
was 2-fold that of Cx32 Y243E (54% of WT), and approximately 6.5-fold that of Cx32 Y243F (14%
of WT), as a result we excluded Cx32 Y243F from any functional assay. Finally, to test the effect
of Y243 phosphorylation on cell coupling we measured the junctional transfer of the fluorescent
tracer LY by scrape loading assay (Fig. 6.5C). Although we observed an approximate 50%
reduction in the amount of Cx32 Y243E compared to Cx32 WT, we were surprised to observe a
significant increase in the number of cells positive for LY but negative for the labeled dextran. This
data suggests that phosphorylation of Cx32 Y243 positively regulates GJIC.
23.5 EphA1 also phosphorylates Cx32 on the CT domain
Following from our experiments establishing EphB1 as a kinase that phosphorylates and
thereby regulates Cx32, we were curious if other Eph receptor family members also phosphorylated
Cx32. To test this, we purified Cx32CT (C217-C283; Y243) and submitted it to Eurofins Scientific
for in vitro kinase screening with all other available Eph receptor family members (KinaseProfiler).
To validate the screen, EphB1 and Yes were screened as positive and negative controls,
respectively. Of the Eph receptors screened, only EphA1 was able to phosphorylate the Cx32CT
in vitro (Fig. 6.6A). Compared to control peptide it phosphorylated the Cx32CT at ~67% (Fig. 6.6A).
The phosphorylation by EphB1 was comparable to the previous screen, and Yes kinase did not
detectably phosphorylate the Cx32CT. Following our workflow for EphB1 we next transiently
transfected human EphA1 into the Cx32 stable expressing HeLa cell line and activated the receptor
with the soluble ligand, ephrin-A1-Fc. To determine the level of Tyr phosphorylation we captured
Cx32 by IP and Western blotted with a general pTyr antibody (Fig. 6.6B). Like when transfected
with EphB1 we observed a significant increase in Cx32 Tyr phosphorylation when EphA1 was
expressed, that was further increased upon activation with the ligand (Fig. 6.6B).
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Figure 6.5. Cx32 Y243E increases GJIC.
A) Immunostaining of Cx32 WT, Y243F, and Y243E transiently (top) and stable (bottom) expressed
in HeLa cells. Green: Cx32; Blue: DAPI. White arrow shows gap junction plaques. Scale bar is 20 µm.
(B) Western blot of Cx32 expression in stable Cx32 WT, Y243F, and Y243E HeLa cells. C) GJIC of
Cx32 WT, Y243F, Y243E were investigated using the scraping loading dye transfer assay. Cells
grown on glass coverslips were scrape loaded with Lucifer Yellow (LY, green) and Texas Redconjugated dextran (red). Nuclei were stained by DAPI to show the confluence of cells. Scale bar is
100 μm. **P<0.01 (T-Test). Modified from Trease et al., (2018).
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Since our work to this stage was completed using exogenous expression systems we
sought to determine if phosphorylation would occur under endogenous expression conditions. We
screened a number of cell lines (colon cancer, cholangiocyte, and cholangiocarcinoma lines) at our
disposal for expression of Cx32 and EphA1 (Fig. 6.6C). We determined that Caco2 cells (human
colon cancer line) expressed reasonable levels of Cx32 and EphA1 and thus tested whether EphA1
could phosphorylate Cx32 (Fig. 6.6D). We observed a significant increase in Cx32 Tyr
phosphorylation when the Caco2 cells were treated with the soluble ephrin-A1-Fc, confirming the
results we obtained from the overexpression system (Fig. 6.6D).
Having observed a significant increase in GJIC in our Cx32 Y243E expressing HeLa cells
(Fig. 6.5), suggesting that phosphorylation of Y243 enhanced the dye transfer we predicted that
activation of EphA1 in Caco2 cells would have a similar result. We therefore treated Caco2 cells
with ephrin-A1-Fc and used scrape loading to determine if GJIC was increased subsequent to
receptor activation. Our results indicate that similar to the phosphomimetic Cx32 Y243E mutant,
activation of EphA1 enhanced GJIC in Caco2 cells (29 vs. 12 cells receiving dye; Fig. 6.6E). Finally,
we were curious if the expression of EphA1, EphB1, and Cx32 was specific to the cancer state of
the Caco2 cells, so we compared the levels of expression in Caco2 cells to their normal counterpart
fetal human colon (FHC) cells by Western blot (Fig. 6.6F). To our surprise compared to Caco2 cell
FHC cells expressed EphA1 and Cx32, but not EphB1, while the FHC only expressed EphB1. This
may suggest a developmental role for EphB1 in colon, or oncogenic conditioning in the cancer
cells, however, further investigation is needed. The data taken together suggest a role for Eph
receptors in regulating Cx32 mediated cell coupling, and further reinforce the validity of using
phosphomimetic mutants to ascertain the function of specific phosphorylation sites.
23.6 Phosphorylation at Y243 has little-to-no effect on the Cx32CT interaction with
calmodulin or synapse-associated protein 97
A number of mechanisms by which phosphorylation affects the function of Cxs have been
described in the literature, including: altering trafficking and assembly, accretion, open probability,
channel gating, or modulation of protein partner binding (e.g., [204, 378]). Having demonstrated
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Figure 6.6. EphA1 phosphorylation of Cx32 increases gap junction intercellular
communication in vitro and in cyto.
A) Cx32CT was used as a substrate for a number of different Eph receptor isoforms. EphB1 and Yes were
used as positive and negative control, respectively. The amount of Cx32CT phosphorylation was compared
with a positive control peptide for each kinase (% of control signal). The dashed line highlights the 50% of the
control signal. B) HeLa cells stably expressing Cx32 were transfected with EphA1. EphrinA1-Fc was used to
activate EphA1 receptor. Cx32 was captured by IP and the tyrosine phosphorylation level detected by Western
blot. **P<0.01 (one-way ANOVA). Black arrows indicate IgG light chain. C) Western blot analysis of several
cell lines screening for endogenous expression of Cx32 and EphA1. D) Cx32 was enriched by IP from Caco2
cells stimulated with EphrinA1-Fc and probed for tyrosine phosphorylation by Western blot. E) Caco2 cells
cultured on glass coverslips were stimulated with EphrinA1-Fc and scrape loaded with Lucifer Yellow (LY,
green) and Texas Red-conjugated dextran (red). Nuclei were stained by DAPI to show the confluence of cells.
Scale bar is 100 μm. ***P<0.0001 (T-Test). F) Western blot analysis comparing endogenous expression levels
of EphA1, EphB1, and Cx32 in fetal human colon (FHC) and Caco2 cells. Modified from Trease et al., (2018).
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that phosphorylation of Cx32 Y243 enhances GJIC we were curious what the mechanism behind
this may be. Previously our laboratory reported direct interactions between either CaM or SAP97,
and the Cx32CT in a region which includes Y243 (CaM: C217-S266; SAP97: C217-Q245) [248].
We hypothesized that phosphorylation of Y243 may modulate the association of these proteins with
the Cx32CT. To test this, we used NMR
S266, pY243;

15N-CaM;

Fig. 6.7) or

15N-HSQC

15N-Cx32CT

titrations with either unlabeled Cx32 (C217-

Y243E (unlabeled SAP97701-924; Fig. 6.8). Little-

to-no difference was observed in the NMR spectra in the experiments between the non- and
phosphorylated (or phosphomimetic) Cx32, indicating phosphorylation of Y243 alone does not
significantly affect the interaction of Cx32CT with CaM or SAP97.
Although our results show that phosphorylation of Y243 alone do not modulate the binding
of either CaM nor SAP97 to the Cx32CT, it is possible that a requirement for multiple
phosphorylations exists. There are three Ser residues in close proximity to Y243 that have been
detected as phosphorylated (e.g., all in vitro: S229, PKC; S233, PKA and PKC; and Ser240, PKC)
[274, 478]. It may be that cooperativity between phosphorylation at Y243 and one (or more) of the
Ser residues may alter the binding of CaM and SAP97. An additional possibility is that
phosphorylation of Y243 may not alter protein partner binding at all, but rather alter channel
properties such as gating, open probability, or permselectivity. Interestingly, the presence of CaM
was shown to reduce the degree of Cx32 phosphorylation by EGFR and may represent a
mechanism by which CaM mediates or maintains the closure of Cx32 channels by negating the
effect of Y243 phosphorylation or preventing it altogether [239, 240, 298].
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Figure 6.7. Phosphorylation of Cx32 Y243 has little-to-no effect on the interaction with CaM.
15N-HSQC

spectra of purified 15N-CaM (30 µM) titrated with either (A) Cx32CT217-266 nop (no phosphorylation)
or (B) Cx32CT217-266 pY243 peptides at various molar ratios. The KD for each interaction was estimated by
fitting the change in chemical shift. Represented are a subset of the CaM residues used to calculate the KD.
Reprinted from Trease et al., (2018).
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Figure 6.8. Phosphorylation of Cx32 Y243 has no effect on the interaction with SAP97.
15N-HSQC

spectra of purified 15N-Cx32CT WT (left) or Y243E (right) (50 µM) in the presence (red) or absence
(black) of the SAP97 GUK domain (residues 701-924). For easier comparison, the main peaks affected by the
SAP97-GUK701-924 domain for both constructs have been boxed and linked. Reprinted from Trease et al.,
(2018).
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24. Discussion
Although our report of the regulation of Cx32 GJIC by Eph receptors is novel, others have
reported links between Cxs (Cx43 and Cx36) and Eph receptors. Notably, when GJIC was
measured, the studies all reported an impairment of communication. In one such study examining
the relationship of Cx43 and the EphB4 receptor, Cx43 was shown to co-IP the EphB4 receptor.
Additionally, when the receptor was activated in primary cardiomyocytes GJ coupling was impaired
[567]. A second study demonstrated co-IP of ephrin-B1(high affinity ligand of EphB2) and Cx43
[366]. The same study also showed that when ephrin-B1 was bound by EphB2 in NIH3T3 cells
Cx43 was internalized and consequently GJIC was disrupted [366]. Another study examining the
formation and function of GJs in zebra fish cap cells demonstrated that both unidirectional
(activation of either Eph receptor or ephrin) and bidirectional Ephrin signaling (activation of both
Eph receptor and ephrin) completely blocked transfer of LY dye at the boundary of two cell
populations [566]. Although the authors did not directly measure GJIC, a fourth study,
demonstrated Cx36 expression was required for EphA receptor mediated insulin secretion in
pancreatic β cells [574]. In the study, siRNA mediated knock-down of Cx36 reduced insulin
secretion to that of control levels (inactive EphA5), however, supplementing the cells with cDNA to
Cx36 cDNA rescued insulin secretion [574].
In the current study, we have shown that Cx32 Y243 is phosphorylated by EphB1 and
EphA1. Use of phosphomimetic Cx32 (Y243E) suggested phosphorylation of this site increased
GJIC in HeLa cells and did so through mechanisms that did not apparently affect number of size of
the GJ plaques. A result that was reproducible by activation of the EphA1 receptor in an
endogenous expression system (Caco2 cells). Interestingly, in hepatocytes, phosphorylation of
Cx32 S233 was also shown to correlate with increased GJIC [478]. We have additionally
demonstrated that the phosphatase TC-PTP dephosphorylates Cx32CT residue pY243 both in vitro
and in the context of cells, and based on our scrape loading assays would reduce Cx32 GJIC. This
contrasts with reports for Cx43, where Tyr phosphorylation (specifically Y247, Y265, and Y313)
decreases GJIC by disrupting cytoskeletal anchoring and thereby GJ stability [323, 325, 328, 575577]. These and our studies contained herein, therefore suggest that Cx phosphorylation by the
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same kinase can have largely diverse effects of the regulation of different Cx family members. The
number of reports of differences in response to activation of the same kinase is increasing. A good
example of this is differential regulation of Cx43 and Cx45, where activation of PKA was shown to
reduce Cx45 gj while that of Cx43 was increased [306, 454]. Another example is PKG activation
seemingly has no effect on Cx45 channels while it reduced Cx43 gj [306, 454]. Response to PKC
activation similarly has been shown to be divergent between Cx43 and both Cx45 and Cx37, where
Cx43 channel function (gj and dye coupling) is inhibited by PKC while one study showed Cx45 gj
increased, and a second showed although Cx45 gj had a mild decrease, its ability to couple NB
was unaffected [86]. For Cx37, PKC activation was shown to increase GJIC, again highlighting an
opposite effect than what has been observed for Cx43 GJ channels [446].
Although our study has demonstrated phosphorylation of Cx32 by Eph receptors positively
regulates GJIC, the relevance to human physiology remains to be determined. Using data curated
within the Human Protein Atlas, expression of Cx32 is primarily found in the foregut and lower
portion of the digestive tract (appendix, liver, gallbladder, gastrointestinal tract), renal (kidney), and
reproductive systems (both male and female) ([578]; www.proteinatlas.org). Importantly, the EphA1
receptor is also expressed in all of these systems, suggesting that this mechanism of Cx32
regulation is likely common in these systems. EphB1 expression, however, is more restricted and
relatively low. In the testes, however, EphB1 expression is relatively high and is therefore likely to
contribute to the regulation of Cx32 GJIC there. Although alternate mechanisms of Eph receptor
activation have been described (e.g., soluble ephrin-A1 secretion in HeLa cells [579, 580]),
canonical activation of EphA1 and EphB1 by their respective ephrin ligands [581] is dependent on
cell-cell contact. A similarity to this is the requirement of cell-cell contact for GJs to assemble. It is
therefore likely in cells and tissues that express either EphA1 or EphB1 and Cx32, that this contact
would result in the increased Cx32 phosphorylation and subsequent increases in GJIC.
Furthermore, any pathological dysregulation in the expression of either the receptors, ligands, or
Cx32, or aberrant cell interactions (e.g., implantation of metastatic cancer cell at site of metastasis)
could lead to aberrant Cx32/Eph signaling [565, 582, 583]. While our work demonstrates
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phosphorylation of Cx32 Y243 (independent of the kinase) enhances GJIC, future studies should
determine what physio- and pathological conditions Cx32/Eph signaling is relevant to.
Current research on Cx phosphorylation utilizing diverse techniques and systems have
demonstrated that Cx regulation by phosphorylation can traced to similarly diverse mechanisms
including changes in Cx structure, localization, trafficking/assembly, protein partner binding,
turnover, and channel gating (reviewed in [328, 338]). The identification of stimuli and signal
transductions which lead to phosphorylation of Cxs have greatly improved our understanding of the
regulation of Cxs by kinase programs (reviewed in [328]) and are of potential clinical significance.
However, comprehensive understanding of the regulation of Cxs phosphorylation will require
identification of all kinases that phosphorylate Cxs and characterization of the effect(s) of the sites
phosphorylated. This study is important because it demonstrates phosphorylation of a specific
Cx32 residue (Y243) modulates GJIC, and further supports the notion that the effect of Cx
phosphorylation by a given kinase is dictated by the Cx family member rather than the kinase, and
therefore investigation of the effects on other Cx family members is essential.
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CHAPTER SEVEN

Conclusions and Future
Directions
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25. Summary and Conclusions
GJs are critical mediators of juxtacrine signaling through the direct transfer of cytosolic
constituents from one cell to the next, thereby regulating processes essential to tissue and organ
homeostasis and function, including electrical and metabolic continuity, among others. Regulation
of GJ proteins is diverse and complex, relying on the coordination of many hierarchical mechanisms
ranging from gene expression to PTM. The importance of GJ function to many essential
physiological processes (organ development, contraction in the heart, insulin release in the
pancreas, neuronal plasticity, vision, hearing, etc.) makes them attractive therapeutic targets.
However, to develop therapeutic approaches for the modulation of GJ function a clear
understanding of mechanisms which: 1) differentiate one family member from another, 2) regulate
channel function, 3) block or restore coupling, and 4) are associated with disease, is essential. In
the previous Chapters, we have described the current state of GJ knowledge with a primary focus
on 2 out of the 21 human family members (Cx43 and Cx45), as well as presented studies
contributing to the advancement of that knowledge specifically on Cx45. Our studies focused on
highlighting the regulation of Cx45 by both structural and post-translational (phosphorylation)
features and described a regulatory landscape that is both similar and dissimilar to Cx43,
reinforcing the need to fully characterize each Cx protein individually in order to design novel
therapeutics. Our additional study on the regulation of Cx32 by phosphorylation further supports
this notion.
The intimate relationship that exists between the structure and function of proteins is not a
new concept and holds true for the regulation of Cxs as well. Our laboratory has historically made
its primary focus delineating this relationship by investigating the CT domain of several Cxs [231,
247, 248, 284, 287, 312]. While the CT domain is primarily unstructured for most Cxs, they easily
adopt structure from the influence other proteins or phosphorylation (for examples see [248, 312,
377]). The CT domain of one unique Cx, Cx45, was reported previously by our laboratory to contain
a static α-helical domain that led to high-affinity (KD ~141nM) dimerization of the recombinant CT
domain when in solution [247]. In the work presented in Chapters Two and Three, we followed up
on this to investigate the functional implications of Cx45CT dimerization with the hypothesis that at
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least in part, CT dimerization contributes to the uniquely (at least among cardiac Cxs) restrictive
channel properties elicited by Cx45 channels [424]. While the CT domains of other Cxs adopt
helical structure when tethered to their 4th TM domain, in the presence of protein partners, or when
phosphorylated, Cx45 is, to our knowledge, the only described to date with a static α-helix in the
absence of protein partners, phosphorylation or tethering to the 4th TM domain [247, 248, 284, 312,
377]. Notably, the region of the Cx45CT domain when compared to all proteins in the human
proteome by BLAST is unique [424]. Since Cx45 expression in the ventricles has been linked to
arrhythmias, the existence of this unique domain (and structure) would make an attractive target
for therapeutics if modulation of the dimerization interaction alters channel function in any way. By
inhibiting dimerization of the Cx45CT domain of full-length Cx45 through homologous mutants (6E,
DDSc, 40MD, 43MD, and ΔDD), and heterologous mutants (GCN4LZ, BsubVD, and BsubAA) we were
able to link the presence of dimerization to tightly regulated forward trafficking and proper plaque
formation, while the absence of dimerization uniformly increased the plasma membrane
expression, hemichannel activity, and detergent solubility. Importantly, the dimerization of Cx45
appears to influence Cx45 channel function in a manner that is directly opposite that of Cx43.
Dimerization of Cx43CT domains in a pH dependent manner serves to close the channel in
ischemic conditions, perhaps a mechanism that prevents the spread of necrotic factors from the
cells in the infarct the healthy cells outside the epicardial border zone [72, 84, 222, 224, 473]. It is
also probable, that since dimerization of Cx45CT domains influence the function of Cx45
homomeric channels, that it is also a contributing factor to the dominant negative phenotype Cx45
exerts on Cx43 in heteromeric channels [86, 87]. Since we observed Cx45CT dimerization
preceding oligomerization of connexons in the TGN, this is almost certainly a factor that controls
both stoichiometry and subunit arrangement in heteromeric channels. Two factors that are likely to
influence channel function in unique ways. Supporting this are studies done on the glutamate based
NMDA receptor, which are composed of two subunits each of GluN1/GluN2a that adopt an
alternating arrangement such that the two GluN1 subunits and the two GluN2a subunits are
diagonal to each other in the tetrad forming the receptor and pore [584]. How subunit arrangement
affects Cx function remains to be determined. Future efforts to investigate the structural regulation

232

of Cx45 should delineate the atomic structure of the dimer interface. By accomplishing this it may
be possible under certain circumstances (such as conditions that would phosphorylate Y356,
thereby reducing dimer affinity) to design small molecules capable of disrupting a weakened dimer,
consequently modulating Cx45 GJIC. Additionally, the role of dimerization should be addressed in
the context of heteromeric channels. Determining how heteromeric Cx43/Cx45 channels form in
terms of stoichiometry and subunit arrangement may offer unique insights into how dimerization
alters pore structure or channel permeability. It would be reasonable to predict that two Cx45
protomers side-by-side would likely have a smaller influence than two positions across from each
other. Although no results have been published, a study using atomic force microscopy is currently
underway investigating the allowed subunit arrangement and stoichiometries of two β-Cxs (Cx26
and Cx32; Jorge Contreras, personal communication). Finally, studies should focus on idenitfying
unique protein partners that preferentially bind on Cx45CT over the dimerization domain, as this
may offer alternate therapeutic targets that may be specific to Cx45 without needing to overcome
the high energetic costs required to disrupt the dimerization.
In addition to the regulation by a static structural feature another notable difference in the
regulation of different Cx family members is the response to phosphorylation. Cx43, the canonical
Cx family member, has been thoroughly (albeit not exhaustively) characterized with respect to
regulation by kinases and phosphorylation [524]. Since every aspect of the Cx43 life cycle is
regulated by phosphorylation it is highly likely, phosphorylation is a general mechanism of Cx
regulation. Indeed, this is supported by studies identifying phosphorylation of multiple family
members and reporting functional effects of kinase activating conditions in vitro and in vivo [86,
158, 159, 189, 283, 294, 301, 306, 307, 311, 324, 325, 344, 351, 356, 363, 385, 446, 464, 478,
543]. We characterized the regulation of Cx45 by kinases downstream of the AT1R that would be
active in hypertension and in failing hearts [491, 492, 498, 499, 504, 509]. Our results are the first
to show definitive evidence of direct phosphorylation of Cx45 by Src, Pyk2, and PKCα.
Previous studies have implicated PKC (non-specifically) in the regulation of Cx45 but direct
evidence of phosphorylation was lacking [86, 189]. Conversely, CaMKII has been shown to
phosphorylate Cx45 in vitro, notably four of the seven Ser residues phosphorylated by CaMKII
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(S381,381,384,385) are also phosphorylated in our samples by PKCα, suggesting the two kinases
may serve overlapping or compensatory roles in the regulation of Cx45 in different cell types or
under different physiological or pathophysiological states [83]. Additionally, a subset of the Ser
phosphorylated by CaMKII were also phosphorylated in vitro by CK1, two of those (plus one
additional not phosphorylated by CaMKII) were also phosphorylated in our study by PKCα (five of
seven for CaMKII; S326,382,384 for PKCα) [83]. Whether all of these residues are actually
phosphorylated in cyto or in vivo remains to be determined. Regardless of the kinase, based on
the work of Hertlein et al. phosphorylation of Ser residues in the last 26 amino acids of Cx45 would
likely contribute to GJ stability, similar to what we observed in MDCK cells stimulated with PMA
[189]. A noteworthy difference between Cx43 and Cx45, is the redistribution of Cx43 from the
plasma membrane following addition of PMA [585]. Speculatively, the enhancement of association
with cytoskeletal partners following PMA could explain increased stability of Cx45 vs. Cx43. To
address this more directly, validation of the residues phosphorylated by PKCα is essential, as well
as determining biophysically how phosphorylation affects the association with specific protein
partners. It is unclear if in the heart (if the same phenomenon occurs) whether this would be
protective or pathological. Since PKCα attenuation offers a cardioprotective effect, it is likely that
the its phosphorylation and subsequence stabilization of Cx45 would be conversely pathological
[518].
Currently, the effect of PKC (via activation with PMA) on Cx45 is controversial, two
separate studies highlighted opposing effects, in one the g j was increased while in the other it
decreased while NB transfer was unaffected [86, 306]. Our results do little to settle the controversy,
as we report a decrease in NB transfer upon treatment with PMA. It is unclear if this is a result of
parallel pathway activation from PMA treatment such as we observed in MDCK and HeLa cells,
differences in timescale or concentration used, or a combination thereof. The use of selective
inhibitors of PKC, MAPK, and Src would prove effective in teasing this out. It is interesting that we
observed an increase in both total Cx45 and Cx45 Tyr phosphorylation when PKC is activated.
Although we did not determine the exact residues phosphorylated, the activation of Pyk2 and Src
downstream of PKC may suggest they have phosphorylated Cx45 under these conditions, leading
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to a more complex effect than that of phosphorylation by PKC alone. Certainly, PMA is resulting in
either direct or transactivation of both of these pathways as we detected increased ratios of active
to total Pyk2 (MDCK and HeLa) and Src (HeLa). Future studies should focus on teasing out the
exact contributions of each of these kinases downstream of PKC, as well as validate the
phosphorylated residues with cellular and in vivo models. Subsequently, it would be important to
use phosphomimetic mutants to begin to tease out the functional importance of each individual
phosphorylation site as well as in combination.
The role of Src in regulating Cx43 has been well described by several studies [296, 325,
375, 376, 484]. Activation of Src leads to increased phosphorylation of several Tyr and Ser residues
of Cx43 and relies on the convergence of a number of signaling pathways mediated by Src activity
[325, 484]. Most notably Src activation leads to the recruitment and activation of MAPK which
phosphorylates Cx43 on S255,279,282 [325]. A unified theme of Src activation for Cx43 regardless
of the initial stimulus (EGF, PMA, v-Src transfection, etc.) leads to channel closure and
internalization accomplished by the direct and indirect displacement of cytoskeletal anchoring
proteins and recruitment of turnover/internalization machinery [286, 295, 328, 378]. When we
treated MDCK and HeLa cells with PMA we observed activation of Src (in HeLa) and Pyk2 (HeLa
and MDCK) that correlated with increased Tyr phosphorylation and increased association with
Drebrin, ZO-1, ZO-2, and β-Tubulin. This suggests that the molecular mechanisms that mediate
the association of Cx45 with these proteins differ from that of Cx43. Despite this difference we
observed Src mediated loss of GJIC, under conditions in which Src was chronically active (transient
transfection of constitutively active v-Src, or Src permissive temperatures in LA-25). This was
starkly contrasted by acute activation of Src through stimulation of the EGFR, which resulted in
upregulation of GJIC. Therefore, with respect to Src kinase, it seems Cx45 (and thus perhaps other
Cxs) has a bimodal response. Interestingly, several kinases have been reported to lead to different
(and many times opposite) effects when acutely vs. chronically active (reviewed in [586-590]). For
example, acute activation of p38 MAPK has prohypertrophic effects, while chronic activation seems
to abrogate cardiac hypertrophy [590]. Another example is Protein Kinase D 1 (PKD1) in the heart,
which acutely functions to mediate cardiomyocyte metabolism by the stimulation of glucose uptake,
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however, when chronically activated (in conjunction with PKD3) PKD1 mediated gene transcription
that promotes the development of hypertrophy [591]. Src kinase itself is a good example of the
dichotomous effects of acute vs. chronic kinase activation, acutely Src functions to regulate
angiogenic factors and vascular permeability, however, chronic activation leads to cellular
transformation [592-594].
Subsequent studies should focus on clarifying the differences observed between acute vs.
chronic activation of Src as well as examine the effects of inhibiting Src in cyto and in vivo with the
goal of determining how pathways parallel to Src may contribute. Furthermore, it would be
advantageous to explore the potential that other Src family kinases also regulate Cx45.
Biophysically, studies could investigate how activation by PMA leads to increased Tyr
phosphorylation and why this does not affect the binding of cytoskeletal protein partners. Finally,
an intimate relationship exists between Src and Pyk2, it should be investigated exactly what
contribution each of these kinases make to the regulation of Cx45.
Although the initial goal of Chapter Four was to investigate the regulation of Cx45 by three
kinases downstream of the AT1R, investigating the role of Pyk2 was not directly achievable beyond
our in vitro work and co-IP. We were able to demonstrate that Pyk2 phosphorylates Cx45 on
residues similar (albeit not identical) to Src. Work currently ongoing in our laboratory studying the
phosphorylation of Cx43 by Pyk2 has revealed a similar effect, with Pyk2 phosphorylating Cx43
residues that are also phosphorylated by Src (Sorgen Laboratory, unpublished data). A challenge
in investigating the direct phosphorylation of Pyk2 is the requirement of Src for “enhanced”
activation of Pyk2, as well as the lack of selective inhibitors that do not also target focal adhesion
kinase [505]. Additionally, Src and Pyk2 (when active) are physically linked via the scaffolding
protein Paxillin [541]. In addition to demonstrating Pyk2 phosphorylates the Cx45CT domain, we
were able to show that Pyk2 can complex with Cx45 using co-IP from Cx45 expressing HeLa cells,
to this end the interaction and resultant regulation of Cx45 warrants further investigation. Notably,
our study did not explore the involvement of upstream effectors including the AT1R, however,
collaboratively our laboratory has tested the effects of prolonged exposure to AngII in a mouse
model and consistent with the study of Yamada et al. demonstrated that Cx45 expression in the

236

ventricles is increased as a function of hypertrophic remodeling (Sorgen and Beuve Collaboration,
unpublished data; [82]). Our in vitro and in cyto data, in combination with the collaborative animal
model, numerous studies illustrating the importance of the AT1R in activation of the Src-Pyk2PKCα axis in heart failure, and differences observed between Cx43 and Cx45, strongly suggests
that expression and function of Cx45 is regulated in end-stage heart failure differently than Cx43
by the same kinase programming [72, 286, 295, 323, 378, 424, 488, 491-499, 504, 515, 530, 595,
596]. Future studies should primarily focus on the establishing the AT1R-Src-Pyk2-PKCα axis and
how it relates to Cx45 function specifically in cardiac derived primary cells or cell lines. With the
plethora of identified phosphorylation sites on Cx45 from this dissertation it would be beneficial to
develop the first phosphorylation site specific antibodies against Cx45, this would be invaluable in
terms of better understanding molecular mechanisms and temporal regulation of phosphorylation.
Furthermore, as mentioned above for PKCα, it would be useful to employ phosphomimetic mutants
to better understand the importance of individual sites of phosphorylation, and how those may alter
the binding of protein partners or modulate channel properties directly.
Another aspect of Cx regulation that we explored herein, is the potential for crossregulation between family members. Several studies describe altered channel properties or plaque
formation when more than one heterocompatible Cx family member is expressed in the same cell
type (for examples see [86-88, 476]). In our study we demonstrated co-expression of Cx45 with
Cx43 in LA-25 cells was able to protect Cx43 from Src mediated turnover, while it did not prevent
Src mediated channel closure as measured by NB transfer. Interestingly, though GJIC was reduced
Cx43 maintained at the GJ plaque was not marked by phosphorylation for channel closure nor
primed for ubiquitination and internalization. The implications of these observations are complex.
In terms of turnover and channel closure the co-expression of Cx45 has greatly altered how Cx43
would normally respond [325]. However, the lack of GJIC when Cx43 is not marked for channel
closure suggest that Cx45 is either marked for closure (exerting dominant negative effect on Cx43),
or permselectivity of the heteromeric channels has been altered by phosphorylation. Without
explicit knowledge of the specific Cx45 residues phosphorylated and their functional importance,
the first possibility is difficult to explore. The possibility that permselectivity is altered, is supported
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by a recent study of Cx43 describing altered permselectivity in CK1 site nonphospho- and
phosphomimetic mutants [597]. Whether this is a potential mechanism leading to the loss of GJIC
in our system remains to be determined. The significance of this set of experiments is the idea that
if this occurs in the heart it may be a causal factor leading to arrhythmia. Loss of Cx43 alone in the
heart is generally well tolerated, even to expression levels as low as 50% of normal, however, even
modest expression of Cx45 in these conditions promotes the development of lethal arrhythmias
[432, 437, 598]. In the case of reduced Cx43 expression, channel conductance properties are
maintained, however, the inclusion of Cx45 in the ensuing heteromeric channels greatly alters the
conductive properties and consequently impulse propagation [86, 87]. It therefore stands that any
mechanism which promotes the formation of Cx43/Cx45 heteromeric channels may therefore be
pathological. Additionally, this suggests that regulation of Cxs when intermixed is not always
predictable from regulation of the individual family members. Based on our findings future studies
should focus on characterizing the regulation of Cx43/Cx45 heteromeric channels in vivo, putting
an emphasis on the response to kinase activation. Similarly, as previously suggested, it would be
important to determine what degree of connexon incorporation (i.e. stoichiometry) is required for
Cx45 to exert its dominant negative effect. Finally, if the regulation of heteromeric channels is
unique in comparison to either homomeric channel, it is possible that this may similarly present as
a unique therapeutic target, thus the therapeutic potential of modulating the function of heteromeric
channel should be explored.
Finally, we explored the regulation of Cx32 a β-subtype Cx, by Eph receptors EphA1 and
EphB1, and the phosphatase TC-PTP. Our results indicate that EphA1 and EphB1 both
phosphorylate Cx32, on residue Y243 in the CT domain. In cells this is reversed by TC-PTP. A
unifying theme of this dissertation has been highlighting differences in the regulation of the Cx
family members studied, as compared to Cx43. The goal of which, has been to substantiate the
importance of thoroughly characterizing each family member with respect to protein interactions
and phosphorylation, two critical mediators of GJ function. Notably, comparing Cx43 and Cx32,
phosphorylation by Eph family receptors has opposite effects. For Cx43 activation of EphB4 in
cardiomyocytes disrupted GJIC [366]. Similarly, activation EphB2 by the ligand ephrin-B1 in
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NIH3T3 cells also resulted in loss of Cx43 mediated coupling [567]. Additional examples of
differences between Cx43 and exist between Cx45 and Cx43 as presented in the Chapters
contained herein, as well as in response to activation of PKA, PKC, and PKG [86, 306, 454].
Another example is differential responses of Cx37 and Cx43 to PKC [364]. These reports and our
studies in Chapters Two through Six clearly define a heterogeneous response of different Cx family
members to the same stimulus and therefore warrant direct investigation of each Cx family member
with respect to the same stimulus.
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